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Chapter I. General Introduction 
 
The administration of vaccines is a huge success story in modern medicine. Since the first 
vaccination attempts of Jenner in 1796, the administrat on of vaccine formulations to prevent 
spreading of infectious diseases has become routine, at least in the developed world. The 
occurrence of some infectious diseases has been reduced due to widespread vaccination 
programmes in many countries [1-3].  
 
However, one of the major drawbacks of most vaccine formulations is the need for 
administration by injection. Needle-stick injuries and transmission of blood-borne diseases 
due to re-use of disposable needles are a major issue n particular in developing countries. In 
addition, many commercially available vaccines require cold-chain transport and carefully 
controlled storage conditions due to the instability of vaccine antigens [4]. The conditions 
mentioned above may not be feasible in developing countries where supplies and costs are 
limiting factors. 
 
Combating these limitations in vaccine formulation requires expertise in pharmaceutical 
technology to develop novel dry vaccine formulations that can be applied using alternative 
routes of administration. 
 
Human skin is a target site for drug and vaccine delivery that is attracting more and more 
attention from researchers around the world. The epidermis of the skin, composed of live 
keratinocytes and immune cells, is a sensitive immune organ and a practical site for vaccine 
delivery. In addition, the epidermis lacks nerve endings and blood vessels which make this 
site of needle-free administration even more attractive [5]. Therefore, global health 
organisations are pushing for vaccination via the skin. As shown in Figure I-1, there are 
several needle-free methods for transcutaneous vaccine delivery, including liquid-jet injection, 
epidermal powder immunisation and topical applications [6]. These techniques are under 
development now and not yet applicable for replacing eedle injection vaccination. 
Researchers are putting a lot of efforts into this field to investigate the feasibility of 
vaccination without needles, but more work still needs to be done.   
 
2  I. General Introduction 
 
Figure I-1. Vaccine delivery to skin by transcutaneous routes. (A) Liquid-jet injection; (B) 
Epidermal powder immunization; (C) Topical applications of vaccines, including 
immunization through hair follicles, thermal or radio-wave-mediated vaccine penetration by 
creating micropore, colloidal carriers facilitation, low-frequency ultrasound mediated vaccine 
delivery, shallow microneedles assistance, etc. For all the routes, vaccines are delivered to the 
epidermis, and Langerhans cells will process and present the vaccines. Figure adopted from 
Ref. [6]. 
 
There are some important advantages for the epiderms as the target for immunisation. First, 
the epidermis contains a larger number of bone marrow-derived dendritic cells called 
Langerhans cells (LCs). Although LCs account for only about 1% - 3% of the epidermal cells, 
they cover about 25% of the entire surface of the skin [7]. About 500 - 1000 Langerhans cells 
exist in a square millimeter in most areas of the human skin, except the areas of sole and palm 
[8]. Langerhans cells are efficient antigen presenting cells (APCs) which can present antigen 
directly to the immune system when transfected by DNA or protein vaccines. The mechanism 
of presenting antigens introduced by the skin route is depicted in Figure I-2. Antigens 
penetrating into the epidermal layer are recognised and processed by LCs. The LCs carrying 
antigenic signals migrate to the draining lymph nodes under the stimulation of TNFα and IL-
1β. And then the LCs present the processed antigens to aïve T cell, resulting in either Th1 or 
Th2 types immune responses [8]; second, epidermal vaccine delivery is expected to decrease 
pain and suffering, as there are no nerves in the epidermal layer of skin. Compared to needle 
vaccination, needle-free vaccination is more comfortable for the patient; third, it is safer to 
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use a needle-free method for epidermal powder immunisation compared to needle vaccination 
because needle break and potential infection of blood-borne diseases may be harmful to the 
patient. Especially in developing countries, the reuse of disposable needles for vaccination 
may result the transmission of blood-borne diseases; fourth, use of powders make the storage 
easy and improve the stability of vaccine. The “cold chain” for the transportation of vaccines 
may be not necessary which could reduce the cost and increase the convenience for extensive 
use. However, there are some disadvantages of the pres nt devices for powder injection, such 
as the high cost of devices, occasional bleeding and limited clinical history [4]. The 
controllability of powder injection devices needs to be improved and the efficiency of 
vaccination should be evaluated systematically.    
 
 
Figure I-2. A schematic diagram of antigen processing and presenting by Langerhans cells. 
The antigens penetrate through skin and are recognized by LCs in the epidermis. LCs with 
antigens migrate to the draining lymph nodes under th  influence of TNFα and IL-1β. And 
then LCs induce either Th1 or Th2 types immune respon es by presenting processed antigen 
to naïve T cells. Figure adopted from Ref. [8]. 
 
Due to the skin barrier function, especially the protection of the stratum corneum of the most 
superficial layer of epidermis, it is not easy to delivery drugs or vaccines into epidermis or 
dermis. Efforts to improve the efficiency of drug or vaccine delivery into skin by needle-free 
methods have been made. So far, common needle-free techniques to achieve penetration of 
antigens into the skin are tape-stripping and electroporation. Researchers try to design the 
formulations which can penetrate through the skin barrier by encapsulating vaccines into 
colloidal carriers such as microemulsions and transfersomes. However, these techniques are 
time-consuming, elaborate, and may not result in an increase in patient compliance. Micro-
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needle mediated penetration is another option which proves to be a possible minimal invasive 
method [9].  
 
Another option is to deliver vaccine antigen either in liquid or solid form into the skin by 
exhibiting large acceleration forces on either liquid or the solid vaccine formulation. These 
techniques are called liquid jet injection and epidrmal powder immunisation, respectively [6]. 
The liquid injection device uses the kinetic energy of a high-velocity jet, whereas powdered 
vaccine devices usually contain helium gas cartridges that accelerate the powder particles to 
the required high speed [10]. The helium-related device is been used to administer DNA HIV 
vaccine (Phase I) and Herpes simplex type 2 (HSV2, Phase I) and DNA cancer vaccine 
(Phase I) by ballistic microparticle injection [11]. The use of helium results in an increase in 
costs per immunisation and thus limits the applicability of this approach in developing 
countries. Epidermal powder immunisation (EPI) is a promising method for delivery of 
vaccines by transcutaneous route [12, 13], but a more economic, elegant and effective device 
without helium is required.  
 
A novel device for EPI is being developed by our collaborator. A skin model for the 
evaluation of the device and vaccine powders/microparticles for EPI is needed. In this 
circumstance, the project was proposed to address these problems. Several areas such as the 
skin properties, skin models, vaccine particles for epidermal immunisation and detection of 
delivered vaccines are involved in this project andwill be introduced further.  
1. Structure and function of human skin 
The skin is the largest organ in the human body. For the average adult human, the skin has a 
surface area of about 1.8 m2, most of it is between 1 - 2 mm thick and the averg  thickness is 
1.2 mm. The average square inch (6.5 cm2) of skin holds 650 sweat glands, 20 blood vessels, 
60,000 melanocytes, and more than a thousand nerve endings [14]. The general skin structure 
is constituted of the stratum corneum (about 0.02 mm thickness), the viable epidermis (about 
0.1 mm thickness), the dermis (about 1.1 mm thickness) and hypodermis (0.1 to several 
centimetres) [14]. 
1.1 Epidermis 
The epidermis is the outer layer of the skin, composed of stratum corneum and viable 
epidermis with a total average thickness of about 0.12 mm [14]. It is the body's major 
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biological barrier against an inhospitable environme t or viruses. The epidermis is avascular 
and composed of four types of cells, i.e. keratinocytes, melanocytes, Langerhans cells, and the 
Merkel cells. Keratinocytes are the major constituen , constituting 95% of the epidermis. The 
epidermis is composed of 4 - 5 layers depending on the region of skin considered.  
 
The stratum corneum with a thickness between 10 and 40 µm is the outermost layer of the 
epidermis, composed of large, flat, polyhedral, plate- ike envelopes (15 - 20 layers of dead 
cells) filled with keratin. Keratin keeps the skin to stay hydrated by preventing water 
evaporation. These dead cells can also absorb water, further aiding in hydration. This is why 
humans and other animals experience wrinkling of the skin on the fingers and toes when 
immersed in water for prolonged periods. The mechani al properties of skin are decreased 
when hydrated.  
 
The viable epidermis with an average thickness of 60 µm is the target for drug or vaccine 
delivery by transcutaneous routes. The professional a tigen presenting cells, Langerhans cells, 
are uniquely present in the viable epidermis of skin. The density of LCs in most areas of 
human skin with the exception of sole and palm is approximately 500 - 1000 cells/mm2 [15]. 
LCs take up epicutaneous antigens, emigrate into the regional skin-draining lymph nodes and 
present the processed antigens to the T cells. In all, LCs initiate, maintain, and regulate 
adaptive immunities in the skin.      
1.2 Dermis 
The dermis is the layer of skin beneath the epidermis that consists of connective tissue and 
cushions the body from stress and strain. The dermis is t ghtly connected to the epidermis by 
a basement membrane. It also harbours many mechanoreceptor and nerve endings that 
provide the sense of touch and heat. It contains the hair follicles, sweat glands, sebaceous 
glands, apocrine glands, lymphatic vessels and blood vessels. The blood vessels in the dermis 
provide nourishment and waste removal from its own cells as well as from the stratum basale 
of the epidermis. 
1.3 Hypodermis 
The hypodermis is not part of the skin, and lies below the dermis. Its purpose is to attach the 
skin to underlying bone and muscle as well as supplying it with blood vessels and nerves. It 
consists of loose connective tissue and elastin. The main cell types are fibroblasts, 
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macrophages and adipocytes (the hypodermis contains 50% of body fat). Fat serves as 
padding and insulation for the body. 
2. Mechanical properties of human skin 
Mechanical properties of human skin are important for its function such as protecting tissues 
under the skin and forming the structure of organs. To measure the biomechanical properties 
of human skin is necessary to develop drug delivery methods through skin. It is difficult to 
describe the mechanical properties of skin due to the anisotropic properties and layered 
structures. In fact, different results of mechanical properties will be obtained when the same 
skin is measured by different methods. Furthermore, th  skin in vivo and that in vitro display 
different mechanical properties. Therefore, one should be careful to use the skin i vitro to 
evaluate the cutaneous drug delivery and administration.  
 
There are some kinds of methods for measuring the mechanical properties of soft materials 
including tissues. For transdermal delivery of drugs by a physical method, it is necessary to 
know the mechanical properties, i.e. storage modulus, Young’s modulus, shear modulus, 
tensile strength. The measurement methods include mainly suction, indentation, torque and 
extension. 
(1) Suction 
The suction method is one of the most extensively used ways to measure skin mechanical 
properties. The principle of the suction method is the measurement of skin elevation caused 
by application of a partial vacuum (usually in the range of 5 - 50 kPa or 50 - 500 mbar) via a 
circular aperture in a measuring probe. The deformation is measured with an ultrasound 
system (dermis) or optical coherence tomography (OCT) (epidermis and dermis) [16, 17]. 
Two different instruments are commercially available: Dermaflex (Cortex, Denmark) and 
Cutometer (Courage & hazaka Electronic GmbH, Germany).  
 
Hendriks et al. [18] studied the contributions of different skin layers to the mechanical 
behaviour of human skin i  vivo using suction methods. They assumed that the measurement 
was based on the hypothesis that experiments with different length scales represent the 
mechanical behaviour of different skin layers (epidrmis and papillar dermis, reticular dermis). 
For example, the upper layer is measured when the small ized (0.3 mm in diameter) aperture 
is used. Attention should be paid to that they justconsidered the skin with two layers: one is 
the upper layer including epidermis and papillar dermis, the other is the reticular dermis. The 
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mechanical properties of single epidermis have not been achieved by the present settings due 
to the limited resolution of the imaging systems, but may be obtained by measuring the skin 
using even smaller aperture sizes [18].     
(2) Indentation 
A rigid indenter is used to apply a known force or deformation to the skin in indentation 
experiments, and then the relation between the penetration depths and normal load is obtained, 
which could give the information of elastic mechanic l properties. Zahouani et al. [19] used a 
device for indentation experiments named bio-tribometer (Figure I-3) to characterize the 
mechanical properties of a dermal equivalent and human skin. The conical probe can be 
changed into spherical probe if necessary [19].        
 
 
Figure I-3. Skin tribometer device: (a) schematic diagram of the indentation device; (b) 
indentation system and positioning of the subject’s arm. The tests were performed on the 
inner forearm. Figure adopted from Ref. [19]. 
 
The nano-indenter® XP (MTS Nano Instruments, 1001 Larson Drive, Oak Ridge, TN, USA) 
can also be used for indentation experiments of skin, applying the continuous stiffness 
measurement (CSM) technique. By decreasing the diameter of the probe, the mechanical 
properties of the skin epidermis can be obtained [20]. Kendall et al. [20] used custom 
tungsten probes fabricated with nominally 5 and 2 µm diameters with nano-scale tips to 
measure the mechanical properties by penetrating throug  the intact stratum corneum and 
viable epidermis (Figure I-4). In the theory of viscoelastic properties, the elasticity of elastic 
solids and the viscosity of viscous fluid are combined to describe the characteristics of 
mechanical properties of viscoelastic materials [21]. The elastic portion is described by the 
storage modulus and the viscous portion is described by the loss modulus. Loss tangent 
describes the phase angle between the storage modulus and the loss modulus. Young’s 
modulus can be calculated from the storage modulus and the probe properties [20]. They 
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obtained the storage modulus, Young’s modulus, loss modulus and loss tangent for the viable 
epidermis of murine ear skin for the first time (Table I-1).  
 
 
Figure I-4. The schematic diagram of the skin epidermis structu e under micro-projections 
for gene and drug delivery [20]. (A) A single 2 µm micro-particle was accelerated to a speed 
of ~600 m·s-1 before penetrating into the epidermis, while simplfied profiles of 2 µm and 5 
µm probes will be gradually inserted into the skin with a speed lower than <1m s-1; (B) The 
respective positions of the ballistically delivered micro-particle and the two probes following 
insertion. Figure adopted from Ref. [20].  
 
Table I-1 Murine ear skin viable epidermis mechanical properties [20] 
Probe diameter (µm) 5 2 
Parameters Average S.D. Average S.D. 
Young’s modulus (MPa) 2.9 NA 11.1 NA 
Storage modulus (MPa) 3.587 2.35 13.974 2.49 
Loss modulus (MPa) 0.263 0.81 2.452 9.2 
Loss tangent 1.206 0.49 0.834 0.11 
 
The texture analyzer (TA) can be applied to measure the mechanical properties of skin and 
skin model materials. Jachowicz et al. [22] utilized the model TA-XT2 from Texture 
Technologies Corp. (Scarsdale, NY, USA) which was equipped with smooth stainless-steel 
spherical indenters characterized by diameters of 5/16, 5/8, 5/4 inch to obtain indentation 
curves (force vs penetration depth). They interpreted the experimental data with the Hertz 
theory of contact mechanics that describes the deformation of contacting solids and calculated 
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the fundamental parameters such as the modulus of elasticity [22]. The schematic represent is 
shown in Figure I-5, the equivalent Young’s modulus (E*) of elasticity between the bodies is 
defined as 
2
2
2
1
2
1 11
*
1
E
v
E
v
E
−+−=                                                 (1) 
where E1, E2 and ν1, ν2 are modulus and Poisson´ Ratios of the spherical probe and the 
spherical object, respectively. The load of compression P can be expressed as a function of 
indentation depth σ
5.15.0*
3
4 δREP =                                                  (2)
By fitting the experimental data of indentation force with penetration depth, the mechanical 
parameters can be obtained. 
 
 
Figure I-5. A scheme of the indentation of a spherical probe with a diameter R1 (Young’s 
modulus E1 and Poisson´s Ratio ν1) into a spherical object with a diameter R2 (Young’ 
modulus E2 and Poisson´s Ratio ν2). An a denotes the indentation diameter and σ is the 
indentation depth. Figure adopted from Ref. [22]. 
(3) Torsion  
In torsion tests a guard ring and an intermediary disc are attached to the skin. A constant 
torque or rotation is applied by the disc. According to Escoffier et al. [23], this method has 
two advantages: 1) hypodermis and underlying tissues do not affect the measurements and 2) 
the anisotropic character of the skin is minimized. However, it is difficult to differentiate the 
mechanical properties of epidermis and dermis, no such work has been reported yet.  
 
Agache et al. [24] studied skin stiffness using a torsional apparatus [25]. Application of a 
torque of 28.6×10-3 N·m during 2 minutes to the dorsal forearm skin resulted in a rotation of 2 
- 6˚. The torsional moment was applied by a 25 mm diameter disc surrounded by a 35 mm 
diameter guard ring. Young’s moduli (E) were calculated for the linear part of the stress-strain 
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curve and were found to be E = 4.2×105 Pa for people aged less than 30 years old, and E = 
8.5×105 Pa for people over 30 years.  
(4) Extension 
In tensile testing the skin is mainly loaded parallel to its surface. Two tabs are attached to the 
skin and then pulled apart. The attachment of the tabs o the skin may significantly influence 
the results as many of the double-sided adhesive tap s exhibit creep deformation. Rapidly 
bonding cyanoacrylate adhesives can be used to avoid these effects. The simplest method by 
extension tests is the in vitro tensile testing, but the in vivo test is a challenge.  
 
A typical example of a uniaxial tensile test is described by Manschot and Brakkee [26, 27]. 
They performed uniaxial tensile tests on human calf, both across and along the tibial axis. 
Two square tabs (10 × 10 mm2) were attached to the skin with cyanoacrylate adhesive with a 
distance of 5 mm in between. A skin thickness of 1.2 mm was measured with ultrasound. 
Four sawtooth shaped loads (maximum 12 N) were applied with a loading and interval time 
of respectively 10 and 20 seconds. Preconditioning is left out of consideration by neglecting 
the response to the first load cycle. A clear non-linear stress-strain relationship was observed. 
Across the tibia axis a maximum strain of 0.32 and  maximum Young’s modulus of 4 MPa 
were found. Along the tibia axis the maximum observed strain and Young’s modulus were 0.3 
and 20 MPa, respectively.  
2.1 In vivo mechanical properties of human skin 
The mechanical properties of human skin in vivo are summarized in Table I-2, and the results 
by different studies vary distinctly. Basically, the mechanical properties of human skin are 
related to age, individuals, body sites, and enviromental factors such as relative humidity and 
temperature. Meanwhile, different methods always give distinct different results of Young’s 
moduli. In the literature, the Young’s modulus of the human skin in vivo varies between 0.05 
and 0.15 MPa for the suction tests [16, 25], 1 and 10 kPa for the indentation tests [19, 20], 4.6 
- 20 MPa for the extension tests [27], 0.42 and 0.85 MPa for the torsion tests [24]. Therefore, 
caution should be paid when comparing the data of mechanical properties of skin.  
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Table I-2 In vivo Young’s modulus of human skin 
Skin sample 
Young’s 
modulus 
Method Descriptions  Ref. 
Forearm outside 2.5 MPa Suction  [28] 
Forearm  18 - 57 MPa Suction  20 to 70 years old [29] 
Forearm (man) 0.14 MPa Suction  Before 25 years old [30] 
Forearm (woman) 0.16 MPa Suction Before 25 years old [30] 
Forearm (man) 0.11 MPa Suction  28.3 ± 6.2 years old [31] 
Forearm (woman) 0.12 MPa Suction 27.8 ± 8 years old [31] 
Forearm inside 
2.20 ± 4.48 MPa 
(average 3.52)  
Suction (dermaLab) 9 - 29 years old [31] 
Forearm  1.09 - 1.51 kPa Indentation  [32] 
Forearm  14.0 ± 5.0 kPa  Indentation Relaxation  [33] 
Forearm (man) 2.7 - 3.3 kPa Indentation 28 - 65 years old [22] 
Forearm (woman) 1.1 - 2.2 kPa Indentation  28 - 65 years old [22] 
Inner forearm (man) 4.5 - 8 kPa Indentation (tribometer) About 30 years old [19] 
Inner forearm (woman) 8.3 ± 2.1 kPa Indentation (tribometer) 55 - 77 years old [19] 
Forearm outside 0.42 - 0.85 MPa Torque 
0.42 MPa before 30, 
0.85 MPa after 30 
[23, 32, 
33] 
Forearm outside  23 - 107 kPa Torque  6 - 61 years old  [34] 
Forearm  1.1 - 1.32 MPa Torque  [23] 
Human skin 4.6 - 20 MPa Extention  [27] 
Human skin 28.42 MPa Extension 7 months to 3 years [35] 
Human skin 65.66 MPa Extension 15 – 30 years old [35] 
Human skin 79.38 MPa  Extension 30 – 50 years old [35] 
Human skin 107.80 MPa Extension 50 – 80 years old [35] 
Human skin 0.5 MPa Extension  [36] 
Human skin 0.42 - 0.75 MPa Extension  [37] 
Forearm  457.8 kPa   Extension strain 40% [38] 
 
2.2 In vitro measurement of skin mechanical properties 
The removal of the skin samples from the body is involved in the in vitro measurement 
methods of mechanical properties. The skin in vitro could be considered to be a viscoelastic 
material. Due to the distinct effect of environments on the mechanical properties, the 
conditions for measurements of skin mechanical properties should be well controlled. 
Edwards and Marks summarized the measurements of biomechanical properties of human 
skin and discussed the in vitro methods with some considerations about the comparison in 
vitro with in vivo measurements [39]. Tensile testing is commonly used, including uniaxial 
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and biaxial tests. Typical stress versus stain relationships under uniaxial and biaxial tension 
are shown in Figure I-6, respectively [40]. Three obviously different regions can be observed 
for uniaxial tests as follows: (1) small strain stage (0 - 30%), the stress increases slowly with 
the strain increasing. It is caused by the gradual str ightening of an increasing fraction of the 
wavy collagen fibers and the stretching of elastic fibers; (2) middle strain stage (30% - 60%), 
the stress changes linearly with the increase of strain. It is attributed to the stretching and 
slippage of collagen molecules within crosslinked collagen fibers and collagen fibril slippage; 
(3) large strain stage (>60%), the final yield region, which is attributed to the loss of fibrillar 
structure resulting from the defibrillation of collagen fibrils. Compared with uniaxial stretch, 
the stress–strain curve is shifted left in biaxial stretch due to the two-directional stretch of 
collagen fibers, as shown in Figure I-6B. Table I-3 summarizes some of the in vitro Young’s 
modulus of human skin. Apparently, the skin in vitro is different from the status of the skin in 
vivo.     
 
Figure I-6. Schematic diagrams of skin mechanical behavior under (a) uniaxial and (b) 
biaxial tension. Figure adopted from Ref. [40]. 
 
Table I-3 In vitro Young’s modulus of human skin 
Skin sample Young’s modulus Method Description Ref. 
Human skin 2.16 kPa  Uniaxial stretch 0% strain [41] 
Human skin 26.5 kPa Uniaxial stretch 50% strain [41] 
Human skin 5.0 kPa Uniaxial stretch NA [42] 
Human skin 0.1 MPa Extension  47 - 86 years old [43] 
Human skin 0.3 MPa Extension  NA [44] 
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3. Powder and particle-mediated epidermal immunisation   
Epidermal powder immunisation (EPI), also known as a ballistic method, is carried out by 
delivering antigen-loaded particles or powders intothe upper layer of the skin and depositing 
in the epidermis or the superficial layer of the dermis [6]. The delivered antigens can be 
processed by LCs and then presented to naïve T cells, l ading to the immune responses [6]. 
Dean et al. [45] have reviewed powder and particle-mediated approaches for delivery of DNA 
and protein vaccines into the epidermis. They differentiate the intracellular and extracellular 
particle delivery (Figure I-7) as the mechanisms of epidermal powder immunisation.  
 
 
Figure I-7. A schematic represent of immunisation by transcutaneous routes. 1) Intracellular 
particle delivery depicts that 1 - 3 µm gold particles penetrate through the stratum corneum 
and directly transfect both Langerhans cells and keratinocytes of the viable epidermis; 2) 
Extracellular particle delivery depicts that dense particles of 20 - 70 µm in diameter 
containing protein antigens penetrate the stratum corneum and are deposited in the 
intracellular spaces of the viable epidermis. Figure adopted from Ref. [45]. 
 
The PowderJect® delivery system (Figure I-8) was developed especially for powder and 
particle injection into epidermis [45]. The device is a metal instrument that accelerates 
particles or powders at a high speed by regulating a burst of helium with an electrical solenoid. 
The particles or powders with DNA or proteins are contained in a cartridge [45]. The 
cartridge is inserted into a disposable nozzle linked to the device by a snap lock. When the 
compressed helium is released by activating the trigge , the gas bursts into the cartridge with 
vaccines and accelerates the particles or powders to a high velocity. Particles or powders are 
then ejected from the nozzle and injected into the epidermis of the skin.  
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Figure I-8. Particle-mediated delivery system for epidermal immunisation: (A) the prototype 
delivery device used for particle-mediated DNA vaccination and epidermal powder 
immunization; (B) cross-sectional view of the rechargeable PowderJect ND device used for 
epidermal powder immunization of 20 - 70 µm protein powders. Figure adopted from Ref. 
[45]. 
 
The PowderJect Centre for Gene and Drug Delivery Research at University of Oxford has 
investigated PowderJect® device or similar devices [45]. Kendall et al. [13] found the effects 
of relative humidity and ambient temperature on the ballistic delivery of microparticles into 
excised porcine skin are distinct, and calculated the theoretical penetration depths based on 
the properties of stratum corneum and viable epidermis and particles. Kendall et al. [12] 
revealed that the particle penetration depth in the excised human skin strongly depends on the 
particle density and impact velocity. Chen t al. [46] have proven the efficiency of the 
PowderJect device for epidermal immunisation by studying the immunogenicity of influenza 
vaccine and protection in mice. Drape et al. [47] described a phase I clinical trial to evaluate  
monovalent influenza DNA vaccine by particle-mediated epidermal delivery using the 
PowderJect device. In the mean time, different devices for powder injection have been 
developed. Roberts et al. evaluated the clinical safety and efficacy of a powdered Hepatitis B 
nucleic acid vaccine delivered to the epidermis by using the XR-1 clinical research and the 
commercial prototype ND5.5 devices [48]. When vaccine particles are delivered into the 
epidermis with the powder injection device, the damage to targeted cells by microparticles 
may influence transfection efficiencies, which was studied by Raju et al. [49]. In fact, the 
ballistic delivery of microparticles to the viable epidermis can result in localised cell death to 
some degree. It is a compromise of microparticle payload and cell death for optimizing the 
transfection by epidermal immunisation [49]. The work about the epidermal immunisation 
I. General Introduction  15 
with ballistic delivery and the device is still ongoing [50, 51], and much more work needs to 
be done on the development of the application of epidermal vaccination.  
3.1 Theoretical modelling of particle penetration into skin 
Based on the unified theory of penetration [52], the relationship between the theoretical 
penetration depth in skin and the properties of the particle, skin and the particle velocity has 
been proposed [12, 13, 53]. The mechanisms of particle impact were explored with a 
theoretical model attributing the particle resistive force (D) to plastic deformation and target 
inertia [12, 13, 53] 
yt AAvD σρ 32
1 2 +=                                                   (3) 
where ρt and σy are the density and yield stress of the target, A is the particle cross-sectional 
area, and v is the particle velocity. The yield strength or yield point of a material is defined in 
engineering and material science as the stress at which a material begins to deform plastically. 
Integration of expression (3) produces the theoretical penetration depth (d): [12] 
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Kendall et al. [13] proposed a two-layer model using expression (3) shown in Figure I-9. 
There are two kinds of penetration denoted A and B in Figure I-9. Penetration case A denotes 
particle delivery into the stratum corneum (dsc), whereas in case B the stratum corneum is 
fully breached (tsc) and the final particle location is within the viable epidermis (dve). The 
impact velocity is vi and the input velocity for the viable epidermis is vi,ve.  
 
Case A: particle delivery only to stratum corneum 
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Case B: particle delivery to viable epidermis 
The velocity of the particle at the SC-viable epidermis boundary (vi,ve) can be calculated from 
expression (5) 
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And then dve can be obtained. The total particle penetration depth (dt) is thus 
veSCt dtd +=                                                         (7) 
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However, the calculated depths in excised porcine skin are distinctly larger than the 
experimental results [13], which may be due to the deviations of the parameters and assigned 
values used in the theoretical calculations of the particle penetration depths.  
 
  
A B 
Figure I-9. Schematic diagrams of the epidermal structure of human skin (A) and the 
description of the corresponding bilayer approximaton of the epidermis in the theoretical 
penetration model (B). Figure adopted from Ref. [13]. 
 
It is a challenge to deliver particles to specific skin layers due to the complicated mechanical 
properties of the skin. From the above theoretical modelling, we can predict the particle 
penetration depth with the mechanical properties of skin and parameters of device and particle 
properties. Therefore, it is necessary to know the structure and properties of the skin for the 
powder injection into skin. In fact, the studies of the penetration into skin model materials 
with stable mechanical properties will help the evaluation of vaccine formulations and powder 
injection devices. 
4. Building of skin models for studying ballistic delivery of drugs and vaccines   
Skin models or artificial skins are useful for adhesion-to-skin testing [54], studying 
modification by cosmetic treatment [55], wound healing [55] and evaluation of needle-free 
transcutaneous delivery of drugs and vaccines [56]. According to the composition and 
structure of natural skin, the best way to build a skin model is to establish a structure 
mimicking the function of real skin. Biomacromolecules such as gelatin, collagen, alginate, 
etc. have been used to make artificial skin [57]. Collagen fibrils are the main components in 
dermis responding to the mechanical properties. Lir et al. [54] synthesized a film modelling 
human skin considering skin composition, structure, functions, mechanical properties and 
surface properties. They used collagen-derived skin protein gelatin to provide skin mechanical 
integrity, glycerol as a plasticizer to increase thfilm flexibility, hydroxyethylcellulose as 
polysaccharide component to tailor film mechanical properties, formaldehyde as cross-linking 
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agent to regulate film hydrolytic stability and lipid to create film hydrophobic surface [54]. 
Due to the layered structure including epidermis, dermis and hypodermis of natural skin, 
multilayer membrane composed of different layers wadeveloped by Yannas et al. [58]. Skin 
tissue engineering is another way to obtain skin equivalents [59]. Usually, single- and multi-
layer skin models can be used with different intentions.  
(1) Single-layer skin model 
Skin has a layered and anisotropic structure. A single-layer skin model will not produce an 
exact model, but still can be used if the intention is to mimic the average properties. Skin is a 
typical soft tissue and soft tissue modelling is applied extensively. Dermis is the main 
contribution of mechanical properties of skin, thus single-layer skin models may just simulate 
the properties of dermis in skin. The development of all diagnostic imaging system and most 
physical therapeutic interventions has required the us  of tissue-simulating objects to mimic 
the properties of tissues. Pogue and Patterson review d tissue simulating “phantoms” for 
optical spectroscopy, imaging and dosimetry [60]. Matrix materials typically used for 
phantom include gelatin, agar, polyester or epoxy and polyurethane resin, room-temperature 
vulcanizing (RTV) silicone, polyvinyl alcohol gels and so on.   
 
Gelatin is one of the most commonly used materials for kin modelling. Lir et al. synthesized 
a gelatin-based film with thickness of 100 ± 10 µm as a substrate for adhesion-to-skin testing 
[54]. They also imitated the topography of a real skin with the silicone replica technique 
employed. Figure I-10 shows the surface topographies. Polyacrylamide gels can be used as a 
model system for the investigation of jet injection mechanics into skin [56, 61, 62]. The best 
advantage of polyacrylamide gels is the transparency, making it possible to imaging the 
evolution of jet penetration (Figure I-11). RTV silicone-based materials may be a good 
choice for preparing skin models. The material is prepared by mixing the RTV with its 
hardener that initiates a chemical process which solidifies the compound. Heat and gas 
generation during the process requires pumping the material under vacuum. Mansy et al. 
evaluated the elastic properties of silicone-based materials for soft tissue modelling [63]. 
Polyvinyl chloride (PVC) phantoms can be used for tissue model in the investigation of 
needle insertion [64]. PVC gels with Young’s modulus ranging from 10 kPa to well over 100 
kPa could be prepared by varying the amount of plasticizer, a phthalate ester added to the 
PVC.    
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Figure I-10. Surface topographies of the model material (A) and real human skin (B) from 
the forearm zone (optical images, ×60). Figure adopted from Ref. [54]. 
 
 
Figure I-11. Imaging of jet penetration with different injection time during the injection into 
20% acrylamide gels. The jet enters the gel at the black/white interface. The black parts in the 
middle of the gels are the jets. Figure adopted from Ref. [56].  
(2) Multi-layer skin model 
Due to the layered structures of skin, multilayer membranes may be a good option for 
building a skin model. Yannas et al. [58] patented the method to prepare multilayer 
membranes, as shown in Figure I-12. The first layer, mimicking the dermis, is insoluble in 
the presence of body fluids, and nondegradable in the presence of body enzymes. According 
to the composition of dermis, preferred materials for the first layer are crosslinked collagen-
mucopolysaccharide composites, which are synthesized by intimately contacting collagen 
with a mucopolysacchride and subsequently crosslinking the resultant product [58]. For the 
simple double-layer skin model, the outmost layer mimicking the epidermis is a moisture 
transmission control layer which is adherently bonded to the first layer. Suitable materials for 
this layer include synthetic polymers such as silicone resins, polyacrylate or polymethacrylate 
esters or their copolymers, and polyurethanes [58].One of the polymeric materials is silicone 
polymer, such as Silastic® Medical Adhesive (Dow Corning), a mixture of a hydroxyl 
terminated silicone polymer and methyl triethoxy silane which cures into a flexible, tough 
layer that adheres very well to the first layer materi ls such as crosslinked collagen-
mucopolysaccharide composites. For example, a double layer skin model proposed in the 
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literature is composed of a 381 µm thick layer of collage-mucopolysaccharides and a 127 µm 
thick silicone film [58]. Multilayer membrane can be prepared by using a moisturecured 
silicone elastomer as the agent bonding the collagen-mucopolysaccharide layer to another 
material layer. The materials for the added layer include synthetic polymers such as the 
segmented polyurethanes, hydroxyethyl methacrylate and other hydrogels, polyethylene 
terephthalate and polytetafluoroethylene or modifie natural polymers such as cellulose 
acetate or natural polymers such as elastin [58].         
 
 
Figure I-12. Schematic represent of multilayer membrane as a skin model [58]. Layer 12 is 
the outmost layer controlling the moisture, while th layer 10 is the layer mimicking dermis in 
skin. Multilayer membrane can be made by using silicone adhesive as the agent bonding layer 
10 to layer 12. Figure adopted from Ref. [58].  
5. Applications of confocal laser scanning microscopy for the investigations of intra- and 
transdermal drug/vaccine delivery  
Confocal laser scanning microscopy (CLSM) is a technique for obtaining high-resolution 
optical images with depth selectivity [65]. The key feature of confocal microscope is its 
ability to acquire in-focus imagess from selected depths by a process known as optical 
sectioning. Images are acquired point-by-point and reconstructed with a computer, allowing 
three-dimensional reconstructions of topologically-complex objects. For opaque specimens, 
this is useful for surface profiling, while for transparent specimens, interior structures can be 
imaged. For interior imaging, the quality of the image is greatly enhanced over simple 
microscope because image information from multiple d pths in the specimen is not 
superimposed. A conventional microscope sees as far into the specimen as the light can 
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penetrate, while a confocal microscope only images one depth level at a time. In effect, the 
CLSM achieves a controlled and highly limited depth of focus.  
 
Human skin is a good target for drug and vaccine delivery and has been attracting 
considerable interest in recent years. CLSM is an appropriate method to visualize skin 
structure and determine the mechanisms of diverse skin penetration enhancement strategies 
[66]. CLSM is a no-invasive method both in vitro and in vivo conditions and can obtain the 
visualization of images parallel to the surface of the sample, at multiple depths, without 
mechanical sectioning. Figure I-13 shows the confocal optical sectioning of porcine skin. The 
structures of different depth in skin are visualized clearly.  
 
 
Figure I-13. Confocal optical sectioning. (A) A schematic of a z-series (sequential xy 
sections as a function of depth (z)), and (B) confocal images of sequential xy sections of a z-
series through porcine skin, the depth is 0, 2, 4, 6, 8, 10, 12, 14, 16, 18 µm, respectively. 
Figure adopted from Ref. [66]. 
 
The distribution of a fluorophore in hair follicles has been determined by CLSM, and the 
relative accumulation in the SC, epidermis, dermis, outer root sheath, inner root sheath, 
cuticular area and hair shaft in non-fixed fresh human scalp skin was determined semi-
quantitatively [67]. CLSM was used to visualize the distribution of calcein, a charged (-4), 
hydrophilic dye, and nile red, a lipophilic, neutral compound in hairless mouse skin, and the 
permeation of nile red was greatly enhanced by the application of iontophoresis [68]. Tuner t 
al. studied the extent and distribution of a series of m del peptides (poly-L-lysine, PLL) 
coupled to the fluorescent probe FTIC under iontophoretic skin penetration [69]. CLSM 
images revealed that iontophoresis increased transport via follicular pathways only slightly 
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more than that through non-follicular regions for the 4 and 7 kDa FTIC-PLL [69]. 
Pharmaceutical applications of confocal laser scanning microscopy have been summarised by 
Pygall et al. [70].  
 
Brus et al. [71] studied florescence-labelled polyethylenimine oligodeoxynucleotide 
(PEI/ODN) complexes in human skin after iontophoretic delivery using confocal scanning 
laser microscopy and visualized and quantified the penetration properties of double labelled 
PEI/ODN complexes across full thickness human skin. Figure I-14 shows the CLSM results 
of human skin after treatment with different substances.   
 
 
Figure I-14. The effect of anodal iontophoresis on the penetration of TAMRA-ODN and 
Oregon Green-PEI complexes. The human skins were trated with TAMRA-labelled ODN 
(red) and Oregon Green-labelled PEI (green) complexes. Upper panel shows the distribution 
of complexes in the skin layers after anodal iontophoresis for 1) 1 h, 2) 4 h, 3) 10 h, and 4) 24 
h, and lower panel shows the results for passive diffusion for 5) 1 h, 6) 4 h, 7) 10 h, and 8) 24 
h. The scale bar is 10 µm. Figure adopted from Ref. [71]. 
 
CLSM has successfully been applied on the visualization of skin and the distribution of drugs 
or vaccines across skin. CLSM provides a possible way to track the drug delivery into skin. 
Compared to normal wide field microscopy, CLSM enhances the resolution distinctly. 
Meanwhile, selecting a suitable fluorescence probe is important for the investigation of the 
distribution and flow of particles and/or drugs.  
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6. Nanoparticles and microparticles as vaccine delivery systems 
The applications of nano- and microparticles used for vaccine and drug delivery are well 
documented [72-77]. Particulate delivery systems have the advantages of controlled and 
targeted delivery, and can act as vaccine adjuvants [78-80]. Polymeric particles, inorganic 
nanoparticles and hybrid particles are the main research focus for such vaccine/drug delivery 
systems. Various nanoparticles have been designed ad functionalized for delivering 
antigens/drugs with different purposes. Reddy et al. used Pluronic-stabilized polypropylene 
sulphide (PPS) nanoparticles conjugated to ovalbumin to exploit lymphatic transport and 
complement activation [81]. Ultra-small PPS nanoparticles (25 nm) have been reported to 
show stronger immune response than 100-nm PPS nanoparticles because the former can be 
efficiently taken up by lymphatic vessels and then tra sported to the draining lymph node [81]. 
Bourquin et al. studied gelatin nanoparticles for delivering immunostimulatory RNA 
oligonucleotides in mouse tumor models, successfully triggering an efficient antitumoral 
immune response [82]. Poly(lactic acid) (PLA) nanoparticles modified with polyvinyl alcohol 
(PVA), alginate (ALG) and glycolchitosan (GCS) were prepared and investigated as 
Streptococcus equi antigen carriers [83]. Trimethyl chitosan-hyaluronic acid nanoparticles 
loaded with ovalbumin showed enhanced immunogenicity after nasal and intradermal 
vaccination [84]. Biodegradable poly(γ-glutamicacid) nanoparticles loaded with ovalbumin 
effectively induced innate and adaptive immunity, suggesting antigen carrier capacity and 
potential adjuvant function. Some inorganic nanoparticles have also been considered for 
vaccine/drug delivery. Gold nanoparticles for loading DNA antigens are often used for 
particle-mediated epidermal delivery [85-87]. Calcium phosphate nanoparticles have been 
reported as a promising vaccine delivery system and adjuvant [88].     
6.1 Silica nanoparticles as a drug/vaccine delivery system 
Mesoporous silica nanoparticles are potential useful drug delivery systems attracting a lot of 
interests for many biomedical applications (Figure I-15) [75, 89, 90]. The development of the 
technology for the synthesis has greatly improved the controllability of the properties of 
mesoporous silica nanoparticles with different mesostructures and pore sizes [91]. The 
porosity of silica nanoparticles and surface modifications enable the possibility of drug 
loading and release under a controlled manner [92, 93]. Stimuli-responsive mesoporous silica 
nanoparticles can be obtained by surface modification using some macromolecules. Park et al. 
prepared pH-sensitive silica nanoparticles by coating he surface with PEI and cyclodextrin, 
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which can release guest molecules at an acidic pH (5.5) [94]. Hybrid chitosan modified silica 
nanospheres also show very good pH-controlled releas  of loaded model proteins [95].  
 
A  B  
C  
Figure I-15. Mesoporous silica nanoparticles as a drug delivery system. (A) Functional 
groups (a) at the external surface, (b) at the pore entrances and (c) within the walls; (B) 
Counterpart charge modification for loading different drugs: negative surface for loading 
positively-charged drugs and positive surface for lading negatively-charged drugs; (C) 
Intracellular delivery by penetrating cell membrane: (a) plasmid DNA is release in cells and 
(b) release of activator β-estradiol stimulated by a reducing agent. Figure adopted from Ref. 
[89, 90]. 
 
However, silica nanoparticles have not received sufficient attention as a vaccine delivery 
system. In fact, silica showed an adjuvant effect in the immunological response of the guinea 
pig [96]. Vallhov et al. studied the effects of mesoporous silica particles (270 nm and 2.5 µm) 
on human monocyte-derived dendritic cells (MDDC) and found good cellular uptake of both 
particles and low-toxicity profiles on MDDC [97]. Recently, Vallhov et al. suggested that 
mesoporous silica particles have adjuvant properties of tuning effect T cell development 
according to cell culture experiments [98]. Furthermo e, mesoporous silica nanoparticles can 
enhance mucosal and systemic immune responses when applied by oral immunisations in 
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mouse models [99]. Although silica nanoparticles show potential as a vaccine delivery system, 
there is no study investigating their applications for epidermal powder immunisation.     
6.2 Particles targeting Langerhans cells 
Langerhans cells (LCs) in the epidermal layer covering about 25% of the entire surface of 
human skin [7] are responsible for the antigen presenting process. Particles carrying antigens 
can be accelerated into the epidermal layer to targe  LCs, subsequently inducing immune 
responses. Ginsberg et al. showed that particle-mediated epidermal delivery (PMED) of 
melanosomal antigens (Xenogeneic gp100 DNA) adsorbed on gold particles in melanoma 
patients produced similar immune response compared to intramuscular delivery, even though 
a significant smaller dose of DNA was used for PMED injection [100]. A phase I clinic trial 
of PMED for delivering Hantaan virus and Puumala virus M-segment DNA showed positive 
results in humans having hemorrhagic fever with renal syndrome [86]. Gold particles are well 
suitable for DNA vaccines, but gold is a high-cost and non-biodegradable material.  
 
Chitosan particles loaded with DNA vaccines was shown to be efficacious in mice using 
transdermal immunisation [101]. Skin Langerhans cells were promoted to migrate to lymph 
node and then to spleen after being bombarded with chi osan/DNA particles, confirming the 
function of LCs as antigen presenting cells [101]. The migration of Langerhans cells 
challenged by vaccines was better using core-shell polymeric nanoparticles by Lee’s work 
[102]. Targeting of antigens delivered by the intradermal route to skin dendritic cells makes it 
possible to enhance vaccine efficacy, even better than with the conventional subcutaneous or 
intramuscular route [103, 104]. Mesoporous silica nanoparticles as a drug delivery system 
have never been used as a vaccine delivery system for epidermal powder immunisation. The 
pores of silica particles provide a controlled space for loading adjuvants, peptide antigens, and 
protein antigens if silica particles with large pores are used. Therefore, we hope we can 
contribute to this point and open the door to apply si ica or silica-based nanoparticles for 
better epidermal immunisation.  
 
Silica nanoparticles cannot be delivered into epidermal layer of human skin by direct powder 
injection because smaller particles require higher v locity [12], which is limited by the 
particle-accelerating device. Kendall et al. proposed a relation between the particle 
penetration depth and the particle impact parameters (ρν ) that are determined by particle 
density (ρ), velocity (ν) and radius (r) [12]. As indicated from the penetration of gold particles 
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into human skin, ρνr should be 7 - 12 kg/m·s for delivering them into the viable epidermal 
layer [12]. Therefore, it is necessary to formulate silica nanoparticles and antigens into 
microparticles that meet the requirements of powder inj ction. Meanwhile, formulation of the 
nanoparticles into microparticles can improve the long-term stability of nanoparticles and 
protein antigens.    
6.3 Microparticles for epidermal powder immunisation 
The methods for epidermal powder immunisation include intracellular particle delivery of 
small particles such as 1 - 3 µm gold particles and extracellular particle delivery for micro-
scale particles (20 - 70 µm) [10, 45]. Sugar-based microparticles prepared by spray-freeze-
drying (SFD) were used for epidermal powder immunisation against influenza, resulting 
humoral immune responses in humans [105]. The formulations of sugar-based microparticles 
were optimized for better particle morphology and higher density that are required for powder 
injection [106-108]. Insulin as a polypeptide commonly used for treating diabetes is required 
to be injected regularly. Schiffter et al. developed insulin-encapsulated microparticles 
consisting of trehalose, mannitol and dextran for needle-free ballistic powder injection [109]. 
There are some other methods to prepare microparticles that may be useful as delivery 
systems for powder injection, for example, PLGA microparticles [110] and gelatin-
hydroxyethyl cellulose microspheres [111].  
 
The idea to encapsulate nanoparticles in microparticles for epidermal powder immunisation is 
novel, even though some composite microparticles were developed for other purposes. 
PLGA-mesoporous silica microspheres were prepared for DNA prime-protein boost 
vaccination [112]. Inorganic nanocrystals were encapsulated into PLGA microsphere to study 
their intracellular localisation in dendritic cells by transmission electron microscopy and 
confocal laser scanning microscopy [113]. However, nanoparticles encapsulated in the 
biocompatible sugar-based microparticles have not yet been investigated.  
7. Objectives of the project 
A locally based company is dedicated to establish a useful accelerating device by Dr. Peter 
Lell (Pyroglobe GmbH, Hettenshausen, Germany). Dr. Lell patented a needleless injection 
device with pyrotechnic drive [114], which can be modified for injection particles into a body 
tissue such as skin [115]. As shown in Figure I-16, the gas-generating material (19) was 
ignited to produce a high pressure; the pressure is directly or indirectly transmitted to the 
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membrane (9) and the pulse is transferred to the substance particles (3); the particles detached 
from the membrane are accelerated to a high speed and then penetrate into the tissue such as 
skin. The penetration depth can be controlled by adjusting the energy produced from the gas-
generating material. Active ingredients can be formulated in the particles for powder injection 
into skin using this device.     
 
Figure I-16. Representative diagram of the device for needle-fre  powder injection [115]. A 
longitudinal section of a reusable apparatus with a separate gas generator (33) and a sliding 
piston (49) for generating pulses are shown. The accelerated piston can transfer the energy to 
the membrane (9), accelerating the particle on the membrane to a high speed. The particles 
can penetrate into a body tissue through the window (53).  
 
With their expertise in extremely simple and cheap novel actuators it is thought to improve 
the delivery device by a small actuator device unit that is not dependent on helium gas. 
Experiments to formulate suitable powdered formulations that can be loaded into a surrogate 
device mimicking the later envisioned vaccine delivery device can be carried out. In order to 
achieve successful vaccination using powdered vaccines, it is inevitable to determine the 
penetration depths of particles. This can be determined and analysed using different skin 
models, ranging from simple gel-based skin surrogates to animal cadaver skin. Formulation of 
vaccines into microparticles with a suitable size and density is also very important for the 
subsequent animal experiments and clinical investigations.   
 
The aim of the research project is to develop suitable skin models which can be utilised to 
determine penetration of particles or powders of vaccines delivered by epidermal powder 
injection (EPI) and to create an antigen-loaded delivery system which can be used for 
epidermal powder immunisation.  
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Skin models simulating the mechanical properties of human skin will be studied for the 
purpose of evaluating the device for powder injection which is developed by a local company. 
The simple and cheap novel actuator used here is not dependent on helium gas, and is thought 
to improve the epidermal delivery. The skin models will be used to determine the parameters 
of the device for the experiments on living animals nd clinic studied in the future. The 
acceleration force necessary for the delivery of model particles into a certain depth in the skin 
will be correlated with the mechanical properties of skin and the characteristics of particles. 
The determination of particles delivered into skin models or skins will be studied. Confocal 
laser scanning microscopy will be used for the detection and imaging of fluorescently-labelled 
particles in skin models or skins.  
 
Particles carrying antigens for epidermal powder immunisation will be investigated. 
Considering the requirements of particle size, density and robustness for EPI delivery [12], 
the optimisation of the formulation containing antigens is necessary. The particles with sizes 
of 20 - 70 µm in diameter [10, 45] are preferably delivered into skin by epidermal powder 
injection. Sugar-based matrices including trehalose, mannitol and dextran will be incorporated 
to prepare water-soluble microparticles loaded with antigens. Nanoparticles have shown some 
advantages as good vaccine delivery systems [116-119], but nanoparticles are too small to be 
directly used for epidermal powder immunisation. Therefore, a nanoparticles-in-
microparticles (nano-in-micro) system is proposed to take advantage of nanoparticles for 
vaccine delivery and simultaneously meet the requirments for effective epidermal powder 
injection. Nanoparticles for loading antigens will be used in the formulations of the sugar-
based microparticles. Mesoporous silica nanoparticles (MSNP) and poly(lactic-co-glycolic 
acid) (PLGA) nanoparticles will be used for loading ovalbumin (OVA) and OVA peptide. 
MSNP nanoparticles will also be used for loading influenza vaccine H1N1 hemagglutinin. 
The encapsulation of antigen-loaded nanoparticles into the sugar-based microparticles will be 
achieved by spray-freeze-drying.   
 
Finally, the nano-in-micro particles carrying antigens will be applied on the skin models and 
porcine skin by powder injection using the novel devic . The depths and distribution of 
injected particles will be studies by CLSM. 
 
 
Chapter II. Preparation and Validation of a Skin Model for the 
Evaluation of Intradermal Powder Injection Devices 
 
1. Objectives 
Epidermal powder immunisation is a promising needle-fre  method for vaccination [6]. It can 
overcome the risk of needle-stick injuries and transmission of blood-borne diseases resulting 
from re-use of disposable needles [6]. A novel intradermal powder injection device has been 
developed by our collaborating partner. It is necessary to evaluate the new device on 
human/animal skin or skin models before it can be applied in animal studies. Human skin is 
preferred for the evaluation, but human skin in vivo has complex mechanical properties, e.g. 
sex and site-dependent variation and ageing effects [17, 31, 120]. Moreover, human skin i  
vitro is not easy to obtain and also requires careful handling because it cannot be stored for a 
long period of time after it has been removed from the human body. Animal skin, for example 
pig skin, can be obtained more easily but faces similar problems as regards storage and 
handling. In addition, animal skin may display very different mechanical properties 
depending on the animal species. Skin models mimickng the mechanical properties of real 
skin are needed. The mechanical properties of human skin in vivo or in vitro are considered 
the gold standard for developing model skin for the purpose of the evaluation of intradermal 
powder injection devices. Therefore, a skin model mimicking the mechanical properties of 
human skin needs to be developed that will be an appropriate option for evaluating powder 
injection devices and particles for injection.   
 
The most appropriate way to build a skin model is to establish a structure mimicking the 
function of real skin. Biomacromolecules such as gelatin, collagen, or alginate have been used 
to prepare artificial skin [57]. In the study of Condliffe et al., a 3% (w/w) agar gel was used as 
a model skin for evaluating the particle size distribution following powder injection [109], but 
this agar gel cannot be used as the evaluation base for injection of soluble microparticles in 
our study because of its high water content. Skin tissue engineering is another possibility to 
obtain skin equivalents [59]. A dermal equivalent built by tissue engineering displays 
identical mechanical properties as the skin in vivo from 20 subjects ranging 55 to 77 years old 
[121], but that such extremely costly skin for graft is not an option for our purpose. 
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Gelatin with a random coil conformation containing 3000 - 4000 amino acids residues is an 
irreversibly hydrolysed form of collagen that has a triple-helix structure [55, 122]. Gelatin 
based films have also been used for food and drug packaging due to a melting point close to 
the body temperature [123]. The mechanical properties of gelatin film can be tailored by 
adding plasticisers such as glycerol, polyethylene glycols (PEG), or mannitol [124, 125]. 
However, only a few publications about gel films used as a skin model for the purpose of the 
evaluation of powder injection devices can be found in the literature [109, 126, 127]. 
 
The aim of this study was to prepare and compare films made of different materials and 
investigate their potential to be used as a skin model for ballistic powder immunisation. 
Furthermore, storage stability of the prepared films was analysed. In addition, the localisation 
of particles in the skin gel models was determined by confocal laser scanning microscope 
(CLSM). The typical method for particle depths determination is cryo-sectioning of skin 
samples [72]. One of the drawbacks of this method is the time-consuming preparation 
procedure for each sample. Meanwhile, there is always the risk of creating artefacts simply 
due to the fact that the blade of the instrument ca move particles in the gel/skin. Also, cryo-
sections must be cut very thin to allow for an observation under the microscope. If the particle 
size is larger than the maximum thickness of the cryo-section, particles must be cut and 
artefacts can be produced. Moreover, the determination depth of fluorescent particles in real 
skin by CLSM is limited to 50 µm for high resolved observation [66]. Therefore, there is a 
need to develop a novel, simple and easy-to-use technique to determine particle distribution in 
the skin models within a range of large depth (up to 150 µm) and visualise them. 
2. Materials and Methods 
2.1 Materials 
GELITA Pharmaceutical Gelatin made from pig skin with a strength of 180 Bloom was 
purchased from DGF STOESS AG (Eberbach, Germany). 1,2,3-Propantriol (Glycerol) (purity, 
99%) was obtained from AppliChem GmbH (Darmstadt; Germany). Agar was purchased 
from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Elastosil® RT 604 A and 
Elastosil® RT 604 B were provided by Wacker Chemie AG (Munich, Germany) as a gift. 
Acrylamide solution (40(w/v)%) (29:1 ratio of mono- and bis-acrylamide) was purchased 
from Carl Roth GmbH (Karlsruhe, Germany). 10% ammonium persulfate (APS) and 
N,N,N’,N’-tetramethylethylenediamine (TEMED) were purchased from SERVA 
Electrophoresis GmbH (Heidelberg, Germany). Moisture barrier bags (aluminium bags) 
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including a static dissipative nylon outer layer and a static dissipative polyethylene inner layer 
with a centre layer of aluminium foil were obtained from Advantek, Inc. (Freiburg, Germany). 
Fluorescein isothiocyanate (FITC) labeled poly(methyl methacrylate) (PMMA) spheres were 
kindly provided by microParticles GmbH (Berlin, Germany). Tetramethyl rhodamine B 
isothiocyanate-Dextran (TRITC-Dextran) (average molecu ar wt. ~70 kDa) was obtained 
from Sigma-Aldrich (Steinheim, Germany). Petri dishe  of µ-Dish 35mm high ibiTreat were 
obtained from ibidi GmbH (Munich, Germany). 
2.2 Methods 
2.2.1 Preparation of human skin and pig skin  
Human skin samples were obtained from the Plastic Surgery Department of a renowned clinic 
after patient's consent and in line with the regulations of the German law on transplantation 
("Gesetz über die Spende, Entnahme und Übertragung von Organen und Geweben 
(Transplantationsgesetz - TPG"). The skin sample was obtained from the abdomen of an 
individual (37 years old). The working instructions for handling human skin were followed 
according to the appropriate regulations. The skin was stored in a sealed aluminium bag at -
80°C. It was thawed at room temperature for 4 hours before use. The measurements of 
mechanical properties were carried out after removing the subcutaneous fat of the skin.   
  
Piglet skin was provided by the Veterinary Faculty, Ludwig-Maximilians-University, Munich, 
Germany. After excision from the dead animal, full abdominal skin and ear skin were placed 
on ice. The subcutaneous fatty tissue was removed with a scalpel. The piglet skin without fat 
was covered with aluminium foil and stored in a sealed plastic bag in a -80 °C freezer until 
use. All samples were used within 6 months. Before measuring the mechanical properties, a 
part of the skin was cut out from the frozen skin and placed in a desiccator with a relative 
humidity of 43% for about 3 hours. The thickness of pig ear and abdominal skin was 750 ± 50 
µm and1050 ± 50 µm, respectively, according to the observations by adigital microscope.  
2.2.2 Preparation of gelatin based films 
Gelatin was dissolved in hot deionized water (~55°C), and a gelatin aqueous solution was 
obtained. Ten percent (by mass) gelatin aqueous soltion was used for the preparation of all 
films. A specific amount of glycerol (as outlined in Table II-1) was added into 10% (w/w) 
gelatin solution, and mixed together by stirring and degassed by ultrasound for 5 min. 45 g of 
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each mixture was cast in plastic Petri dishes having a diameter of 8.6 cm. The gelatin-based 
films formed after drying in a chemical hood for thee days at ambient condition. The films 
were peeled from the Petri dishes, turned over and placed in the chemical hood for one more 
day. The films were stored at a relative humidity (RH) of 43% for one week. At last, one film 
was cut into five pieces (discs) with each film having a diameter of 3.0 cm as shown in 
Figure II-1 . The small discs were stored in a sealed plastic bag at 4 ºC. Gelatin films with 
gelatin/glycerol (gel/gly) weight ratios of 5/5, 4.5/5.5, 4/6 and 3.5/6.5 were prepared (Table 
II-1 ). The thicknesses of all the films were between 1.1 - 1.4 mm as measured by an 
electronic micrometer IP54 from Messmittelonline (Kloster-Lehnin, Germany). 
 
Table II-1 Gelatin films with different contents of glycerol as skin models 
Gelatin/glycerol (gel/gly) gel1 gel2 gel3 gel4 
Weight ratio 5/5 4.5/5.5 4/6 3.5/6.5 
 
2.2.3 Preparation of silicone films 
36.0 g Elastosil RT 604 A and 4.0 g Elastosil RT 604 B were mixed together under gentle 
stirring. After 5 min, the mixture was poured into a plastic Petri dish with a diameter of 8.6 
cm, and then the dish was placed in a vacuum dryer with a vacuum pressure of 11 mbar and a 
temperature of 30 °C for 24 h. The silicone film was punched into small pieces with a 
diameter of 3.0 cm as shown in Figure II-1 , and a thickness of around 1.3 mm. 
2.2.4 Preparation of agar gel 
Three percent agar gel was prepared according to [109]. 0.44 g agar was dissolved in 14.8 g 
deionised water under gentle stirring in a water bath at 80 °C. After 20 min, the stirring was 
stopped and the agar solution was stored at 80 °C for another 10 min. After that, the solution 
was poured into Petri dishes with a diameter of 3.4 cm. The Petri dish with agar gel was 
sealed with parafilm and stored at 4 °C for at least 24 hours to ensure formation of the gel. For 
measurements by texture analyser, the agar gel was removed from the Petri dish and cut into a 
film with a diameter of 3.0 cm as shown in Figure II-1 .  
2.2.5 Preparation of polyacrylamide gels 
Polyacrylamide gels were prepared according to the work of Schramm-Baxter et al. [56]. 
Briefly, four kinds of gels ((w/v)% acrylamide: 10 - 40) were created with 10% ammonium 
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persulfate (APS) and N,N,N’,N’-tetramethylethylenediamine (TEMED) as initiators. 10 - 30% 
acrylamide solutions were obtained by dilution with DI water from 40% acrylamide solution. 
For polymerization, 30, 60, 45, and 24 µl of APS solution, and 6, 12, 12, and 6 µl of TEMED 
solution were added into the 10%, 20%, 30%, and 40% acrylamide solution, respectively. 
Cylindrical tubes with a diameter of 13 mm were used as the moulds for the gels. 1 ml 
mixtures were added into the tubes respectively. The tubes with gels were sealed with 
parafilm and stored at 4 °C for about 24 h before measurements.    
 
 
Figure II-1.  Photograph of gelatin films, silicone film and agar gel. From left to right, (1) 
gel/gly = 5/5, (2) gel/gly = 4.5/5.5, (3) gel/gly = 4/6, (4) gel/gly = 3.5/6.5, (5) silicone film 
and (6) agar gel. 
2.2.6 Measurements of the mechanical properties of gelatin based films, silicone films, 
agar gel, polyacrylamide gels, human skin and pig skin 
A texture analyser TA.XTplus from EXPONENT Stable Micro Systems Ltd. (Godalming, 
Surrey GU7 1YL, UK) was used to measure the force versus indentation distance curve. A 
custom-made conical probe with a cone angle of 60° (2α = π/3) was used for the measurement 
of indentation behaviour under a force of 0.08 N. The indentation speed for all the tests was 
set to 0.5 mm/s. The curve for each sample was obtained by calculating the average of three 
indentation results on different locations of the film surface (n = 3). A custom-made spherical 
probe consisting of a ball with a diameter of 0.98 mm attached to a cylinder with a diameter 
less than 0.98 mm was used to measure the puncture force of pig skin and skin models. The 
maximal force in the puncture tests was 20 N.   
2.2.7 Storage conditions 
The films were stored in the desiccator with a RH of 33 ± 3%, 43 ± 3% or 75 ± 3% at room 
temperature for one week after they had been dried in the chemical hood. Saturated salt 
solutions were used to control the relative humidity inside the desiccators [128]. Saturated 
potassium carbonate maintains an equilibrium relative humidity of 43% between 10 - 30 °C. 
(1) (2) (3) (4) (5) (6) 
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The desiccator with a RH of 43% was used to store the films for humidity controlling. After 7 
days of storage at RH 43%, the gelatin films were packaged in sealed plastic bags first, and 
then the bagged films were sealed in aluminium bags, nd finally placed in the freezer (-
80 °C) until use.  
2.2.8 Determination of the Young’s modulus  
The calculation was based on the Hertz theory of contact between a rigid conical indenter and 
an elastic solid [129]. The indentation distance (δ) and the contact radius (a) are related by 
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where E1, E2 are the elastic moduli and ν1, ν2 the Poisson's ratios of the rigid indenter and 
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Considering the relation between the rigid indenter and the elastic solid in equation (3), 
indentation force/distance curves were all simulated with  
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F0 was considered to reduce the systematic error and improve the simulation quality. Finally 
the Young’s modulus of the skin and skin models were obtained. All the correlation 
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coefficients (R2) are between 0.95 and 0.99. A Poisson’s ratio of 0.495 was used for all the 
skin and skin models as they could be assumed to approximate incompressible materials.  
2.2.9 Establishment of structural models and CLSM measurement  
Two layered structures were built as the models for the validation of a method to determine 
the depth of a particle in a skin sample using Confocal Laser Scanning Microscope (LSM 510 
META, Carl ZEISS, Germany). Two layered structural models were established as described 
in Figure II-2 . Glycerol was added to prepare gelatin films having a composition of 
gelatin/glycerol of 4/6 by mass which increases the adhesiveness of the films. For the first 
model structure, two species of thin gelatin films including unlabeled and fluorescently 
labeled ones were stacked in an alternating manner to obtain a layered composite with a total 
thickness of about 840 µm. For the second model, unlabeled films and FITC-PMMA particles 
were stacked in an alternating manner to simulate the location of particles at different depths, 
and one TRITC labeled gelatin film (TRITC-gel) layer was placed on the top for determining 
the surface. In order to make sure the layers hold together tightly, transparent adhesive tape 
(Tesa® film) was used to cover the entire layered models by wrapping from the top layer to 
the bottom layer. First of all, 20 ml of a 2.5% gelatin solution of the composition of gel/gly of 
4/6 (gel 3) was prepared and cast in the Petri dish w t  a diameter of 8.6 cm. After 3 days in 
the chemical hood, a dry flexible gelatin film was obtained with a thickness of 140 ± 20 µm. 
Second, in order to prepare a TRITC labeled gelatin film, 50 µl of a 4.0 mg/ml TRITC-
Dextran was added into 15 ml of a 2.5% gelatin solution of the composition of gel/gly of 2/1, 
and then 50 µl of a 18.0 wt% formaldehyde solution was added into the solution to crosslink 
the gelatin film. The mixture solution was cast in a Petri dish and a TRITC labeled gelatin 
film was obtained after drying of 3 days. The thickness of TRITC-gel was determined as 70 ± 
10 µm.  
 
Figure II-2.  Schematic of layered structural model A (left) and model B (right). The red part 
represents the TRITC-gel layer, while the grey partrepresents the unlabeled gelatin film with 
gel/gly of 4/6. The green circles represent PMMA particles. 
 
A B 
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A LSM 510 META Invert Laser Scan Microscope (Carl Zeiss, Germany) equipped with an 
Argon laser and a HeNe1 laser for excitation was used to observe the two structural models. 
The excitation and emission wavelengths for FITC-PMMA are 488 nm and 505 - 530 nm, 
while those for TRITC-Dextran labeled films are 543 nm and 560 - 615 nm, respectively. The 
objectives of Plan-Neofluar 10×/0.3 and LD-Achroplan 40×/0.6 corr were used to observe 
model A and model B, respectively. Z-stacking mode was used to obtain 3D images of the 
samples, orthogonal sections and galleries can be displayed with the Zeiss LSM Image 
Browser software. A specially designed Petri dish of µ-Dish was used as the sample holder 
(ibidi, Munich, Germany). The bottom is made of microscopic plastic with a thickness of 180 
µm, and the objective of the CLSM detects samples from the bottom of the Petri dish. The 
two structural models were placed inside the Petri dishes with the fluorescent surfaces facing 
the bottom.  
3. Results and Discussion 
3.1 Indentation behaviour of biological skin and films as candidates of skin models 
Measurements of the indentation behaviour of different skin models (Figure II-1 ) were taken 
in order to determine their mechanical properties and to assess their relative quality. Pig skin 
has been extensively used as a surrogate of human skin for the study of topical drug delivery 
and has been identified as one of the most appropriate in vitro and in vivo human skin 
models[130, 131]. Herein, pig skin is used as a mechani al model for comparison with human 
skin in vitro. Human abdominal skin samples were used as a referenc  criterion for 
mechanical properties in the development of skin models. For a skin model for powder 
injection, the mechanical properties are the main factors to be considered which will 
determine the penetration depth after powder injection. The in vivo properties, including 
immune reactions to vaccine delivery, have to be studied in vivo later, when the technical 
setup of the delivery device has been defined by means of the in vitro models. The indentation 
results of pig abdominal and ear skin are shown in Figure II-3  which indicates that pig 
abdominal skin is much softer than the ear skin. One of the most important factors affecting 
the mechanical properties of the skin is the water content in the skin which depends on the 
environmental relative humidity for storage.  
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Figure II-3.  Indentation curves of human skin, pig skin, agar gel, silicone film, and gelatin 
films using a conical probe. Gelatin films were stored at a relative humidity of 43%. Curve 
gel1 (gel/gly of 5/5) open diamonds, gel2 (gel/gly 4.5/5.5) open squares, gel3 (gel/gly 4/6) 
black squares, and gel4 (gel/gly 3.5/6.5) open circles. Curve human abd (black stars), pig 
ear (black triangles), pig abd (black circles), sili (black diamonds), agar (open triangles), and 
pg (open stars) correspond to human abdominal skin, pig ear skin, pig abdominal skin, 
silicone film, agar gel, and polyacrylamide gel (40% acrylamide), respectively. All the 
measurements were averaged by four measurements on different locations (n = 4). 
 
In the following, skin models were prepared, analysed and compared to the data obtained 
from the measurements of pig and human skin. All indentation results of skin and skin models 
are shown in Figure II-3  and the corresponding Young’s moduli (E) were obtained by the 
Hertz theory as shown in Table II-2. 
 
Table II-2 Mechanical parameters of skin and skin models 
Young’s 
Modulus 
human 
abd. 
pig 
abd. 
pig 
ear 
gel1 gel2 gel3 gel4 
silicone 
film 
polyacrylamide 
gel 
agar 
gel 
E (MPa) 0.7 0.6 6.8 8.6 2.8 1.4 0.8 2.5 1.6 1.2 
Human abd., pig abd. and pig ear are referred to human abdominal skin, pig abdominal skin 
and pig ear skin, respectively. 
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The silicone film is a good soft tissue mimicking material because of its elastic properties. In 
our study, a transparent silicone film was made from Elastosil® RT 604 by addition-curing of 
two-part silicone rubber that vulcanises at room tep rature. The Young’s modulus of the 
silicone is 2.5 MPa which is larger than that of human abdominal skin with an E of 0.7 MPa. 
Agar gels of a concentration of 3% were prepared as they had been reported in the literature 
as a base for powder injection [109, 132]. The indentation curve of 3% agar gel (E = 1.2 MPa) 
showing a distinct break point around the indentation distance of 0.3 mm is therefore very 
different from pig skin and gelatin films. Polyacrylamide gels have already been used as a 
base for jet injection [56] which leads us to also use this system for powder injection. 
Interestingly, 40% polyacrylamide gels (E = 1.6 MPa) show almost the same indentation 
curve under small indentation forces as gelatin film of the composition gel/gly 4/6 (E = 1.4 
MPa). However, 40% polyacrylamide gels are quite fragile and easily break into small pieces 
when removed from the mould.  
 
From the results in Table II-2 it can be concluded that gelatin films including gel2, gel3, and 
gel4 cover the range of mechanical properties of pig abdominal and ear skin. The Young’s 
modulus of human abdominal skin (E = 0.7 MPa) is close to those of pig abdominal skin (E = 
0.6 MPa) and gel4 (E = 0.8 MPa). Both gel4 and pig abdominal skin are good skin models for 
mimicking the mechanical properties of in vivo human abdominal skin. It is necessary to keep 
in mind that the properties of human skin in vitro may differ from the in vivo situation [40]. 
The human skin could be hydrated after excision which would reduce their strength. The 
gelatin film gel3 (E = 1.4 MPa) shows a larger Young’s modulus than that of human skin ex 
vivo (E = 0.7 MPa) used in the current study. Geerligs et al. used a similar in vitro indentation 
method to obtain the Young’s moduli of both the stratum corneum and epidermis varying 
between 1 and 2 MPa [133]. Papini et al. found an elastic modulus of 2.25 MPa for the 
consideration of penetration of high speed particles [127]. Some studies on i  vivo indentation 
tests reported Young’s moduli of human skin in the range of 7 - 33 MPa [19, 22, 121]. The 
Young’s modulus of human abdominal skin (E = 0.7 MPa) as we obtained is quite close to the 
one measured by Geerligs et al. [133], (approximately 1 MPa for both stratum corneum and 
viable epidermis). The Young’s modulus of skin can v ry much when measured by different 
methods such as indentation tests, torsion tests, ex ension tests, etc. [121]. Therefore, the 
mechanical properties of skin can be comparable only if the similar method for measurements 
is used. The difference of the reported Young’s moduli for skin may be attributed to the 
complexity and several heterogeneous layered structure of skin. The large indentation test 
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distance and the large size indenters could make the Young’s moduli come from the 
combination layer of epidermis and dermis, and even part of hypodermis. Actually, due to the 
variation of mechanical properties of human skin [31], three gelatin films having different 
mechanical properties with gel/gly of 4.5/5.5 (gel2), 4/6 (gel3) and 3.5/6.5 (gel4) were studied 
further as a series of skin models. The film with gel/ ly of 5/5 (gel1) was not considered 
further because it’s Young’s modulus (E = 8.6 MPa) is too far from that of human skin (E = 
0.7 MPa). The gelatin films can be obtained easily and are easy to store compared to human 
skin and animal skin. The transparency of gelatin films is another advantage for microscopic 
observation such as CLSM after powder injection. Though agar gels can be easily sliced into 
slices for microscopic observation with a normal scalpel at room temperature [109], they can 
be punctured too easily as there is a break point as shown in Figure II-3 . Three percent agar 
gel has a high viscosity and it is difficult to remove air bubbles inside. To improve the 
hardness of agar gel with a larger concentration is ot easy because of the high viscosity of 
agar solution at a concentration higher than 3%. Therefore, a series of gelatin films seem to be 
preferable skin models.  
 
Double-layer gelatin films were prepared as well by varying the composites of the two layers. 
The first layer (inside layer) was prepared using formaldehyde crosslinked gelatin, while the 
second layer (outside layer) of around 100 µm, which should be harder than the first one 
according to the composition, was added. However, th  indentation behaviour of the double-
layer film shows no much difference compared to the single layer gel. In the case of human 
skin, the stratum corneum has a higher Young’s modulus than dermis, but the thickness is not 
large enough to affect the global mechanical properties of skin [134]. Likewise, double-layer 
films are more difficult to handle and to control the mechanical properties. Thus all the gelatin 
films used further in this study have a single layered structure.   
The silicone film is hydrophobic and contains no water inside which suggests that relative 
humidity will not affect the properties of the silicone film. However, the silicone film is not 
flexible for preparing different mechanical properti s of skin models. As shown in Figure II-
3, the gelatin films with gel/gly of 5/5 (gel1), 4.5/5.5 (gel2), 4/6 (gel3) and 3.5/6.5 (gel4) 
display different mechanical properties when the glycerol content is varied. The more glycerol 
the film contains, the more flexible the film is. In fact, water residues in the gelatin films 
function as another plasticiser, which makes the mechanical properties of gelatin films 
sensitive to relative humidity which is further described in section 3.3.  
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Besides force/distance measurements, force relaxation behaviour is another relevant 
mechanical parameter as it describes the elastic properties of different materials. As shown in 
Figure II-4 , the visco-elasiticities of silicone and polyacrylamide gel are close to that of a 
perfect elastomer as the force holding a certain indentation does not decrease over time. 
Oppositely, the force relaxation of the agar gel is strong, which is consistent with its little 
elastic behaviour as indicated from its indentation curve in Figure II-3 . Human abdominal 
skin has a similar force relaxation as the agar gel, indicating the agar can simulate the visco-
elasticities of human skin very well. Pig ear and ab ominal skin have lower force relaxations 
compared to human abdominal skin and the agar gel. Human skin, pig skin, and gelatin films 
have much stronger force relaxations than silicone a d polyacrylamide gel. Gelatin films 
show different relaxation curves, where an inverse correlation between glycerol content and 
high/fast/relaxation exists. In a certain range, gelatin films can be adjusted to a relaxation 
according to different skin types. 
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Figure II-4.  Force relaxation of human skin, abdominal skin, ear skin, gelatin films, agar gel, 
silicone film, and polyacrylamide gel under constant penetration depths. Curve gel2 with 
gel/gly of 4.5/5.5, gel3 with 4/6 and gel4 with 3.5/6.5. Curve human abd, pig ear, pig abd, 
sili, agar, and pg correspond to human abdominal skin, pig ear skin, pig abdominal skin, 
silicone film, agar gel, and 40% polyacrylamide gels, respectively. All the measurements 
were repeated 3 or 4 times. 
3.2 Puncture of pig skin and candidates for skin models 
An indentation test using small forces of less than 0.08 N as described in our previous 
experiments is a non-invasive way which can be used to measure mechanical properties of 
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human skin in vivo [19]. The indentation curves obtained describe the diff rences for different 
skin model candidates. For powder injection, the true aim of the application mode is that 
particles will penetrate the stratum corneum and enter the epidermis of the skin. A puncture 
test with a ball-shaped probe may therefore well simulate the situation for particle penetration 
into skin or model skin. The custom-made spherical probe with a diameter of 980 µm was 
used for all the puncture tests. As shown in F gure II-5 , the turn points of the curves 
representing break points for gelatin films, silicone film, agar gel, pig ear skin, and abdominal 
skin can be identified by the maximal force before th y are punctured, while for human skin it 
is not easy to determine the break points. Human skin and pig skin can be punctured with the 
spherical probe at an indentation force of less than 5 N which was observed from the skin 
samples after testing. All break points are shown in Table II-3 and no exact break point for 
human skin was observed. The break point for agar under the spherical probe is too small to 
simulate the break point for pig skin, even though the agar gel has a force relaxation close to 
human skin. Gelatin films and silicone films have br ak points at the same order of magnitude, 
but the silicone films do not meet the force relaxation properties of human skin. The gelatin 
films with gel/gly of 4.5/5.5 (gel2), 4/6 (gel3) and 3.5/6.5 (gel4) have break points of 9.1 N, 
6.8 N and 4.6 N, respectively. The variations of gelatin films resulting from the glycerol 
content are useful to simulate real skin with a specific mechanical property. Therefore, the 
puncture properties of gelatin films provide another evidence to support them as skin models 
in powder injection delivery. 
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Figure II-5.  Results from puncture tests of human skin, pig ear skin, pig abdominal skin, and 
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skin models including gelatin films, silicone films, and agar gels. Curve gel2 (short dash), 
gel3 (short dot) and gel4 (solid) correspond to gelatin films with gel/gly of 5/5, 4.5/5.5, 4/6 
and 3:5/6.5, respectively. Curve human abd (bold solid), pig ear (dash), pig abd (dot), sili 
(short dash dot), and agar (dash dot) correspond to human abdominal skin, pig ear skin, pig 
abdominal skin, silicone film, and agar gel, respectiv ly. The inset shows the enlarged curve 
for agar gel. All the measurements were repeated 3 or 4 times. 
 
Table II-3 Break points of pig skin and candidates of skin model 
Sample human abd. pig ear pig abd. gel2 gel3 gel4 Silicone agar 
Break point (N) Less than 5 2.2 2.1 9.1 6.8 4.6 9.3 0.3 
Human abd., pig abd. and pig ear are referred to human abdominal skin, pig abdominal skin 
and pig ear skin, respectively. 
3.3 Effect of the environmental relative humidity (RH) on the mechanical properties of 
the gelatin films 
The relative humidity during measurements may have important implications on the results as 
the mechanical properties of the skin models may vary when a change in RH occurs. 
Therefore, the effect of the RH on the mechanical properties was investigated. Figure II-6  
shows the mechanical properties of the gelatin films with gelatin/glycerol ratios of 4.5/5.5, 4/6 
and 3.5/6.5 stored in a desiccator at a RH of 33%, 75%, and at ambient condition 
(35%<RH<45%). The data in Figure II-6  demonstrate that the mechanical properties can be 
varied and controlled as long as a control over RH during storage and experiment is in place. 
A RH of 43% for conditioning is used as this is close to typical conditions in our lab.    
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Figure II-6.  Effect of relative humidity (RH) on the mechanical properties of the gelatin films. 
The films were stored for 4 days in the desiccator t RHs of 33% (black squares) and 75% 
(open triangles), and ambient condition (open squares), espectively. 
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3.4 Effect of environmental temperature on the mechanical properties of the films 
Temperature is another factor affecting the mechanical properties of gelatin films besides 
relative humidity. Considering the films as model skin will be usually used under ambient 
conditions, the mechanical properties of gelatin films at 20 - 35 °C were measured. As shown 
in Figure II-7 , the higher the test temperature was, the weaker th  films became. The 
indentation force at the same indentation distance decreases a little when the test temperature 
increases between 20 and 30 °C. Above 30 °C, the ind ntation force at a certain indentation 
distance decreases more distinctly. Therefore, it is suggested to use the films as skin model at 
ambient conditions with 20 - 30 °C which is the normal room temperature range. Therefore, 
no special temperature control is needed when using the films at a typical condition of 22 ± 
2°C. 
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Figure II-7.  Temperature dependence of the mechanical properties of gelatin films with 
gel/gly of 4.5/5.5 (gel2), 4/6 (gel3), 3.5/6.5 (gel4). All the films were stored in the desiccator 
with RH of 43% for at least one week before measurement. The mechanical properties of the 
films at 20 (black squares), 25 (open squares), 30 (black triangles) and 35 °C (open triangles) 
were measured. 
3.5 Stability of gelatin films under long-term storage 
Freshly prepared gelatin films were stored in the desiccator with RH of 43% for 7 days, and 
then the films were placed in a sealed plastic bag and stored in the freezer at a temperature of 
-80 °C. After each week, the films were thawed in the desiccator with a RH of 43% for about 
4 hours, and then the mechanical properties were measur d. All the films measured were 
frozen and thawed once only. The results for the films with different storage times in -80 °C 
are shown in Figure II-8A . All the tests were carried out at ambient conditions, and the room 
temperature was between 20 - 30°C. The curves in Figure II-8A  are classified into three 
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groups corresponding to the results of gel2, gel3 and gel4, respectively. The different curves 
in one group are the results of the specified film at different storage times. The indentation 
forces of the gelatin films with gel/gly of 4.5/5.5 (gel2), 4/6 (gel3) and 3.5/6.5 (gel4) under 
indentation distances of 0.129 mm, 0.209 mm and 0.289 mm, respectively are used to track 
the change of gel strength of the films over the storage time as shown in Figure II-8B . The 
force for each film in Figure II-8B  varies within amplitude of only 0.01 N over time (12 
weeks). Figure II-8B  shows that 22 of 24 data points over 12 weeks storage show only very 
minor deviations from the starting value. Data for gel 2 after 6 and 8 weeks fall below the 
average but after 10 and 12 weeks gel strength of tis system reaches the starting level again. 
Considering the variation of test temperature, the films and those after frozen storage up to 12 
weeks have almost the same mechanical properties. Th refore, the gelatin films can be stored 
in the -80 °C for at least 12 weeks until use without bserving relevant changes in the 
properties of the films. For longer storage, they can be packed in sealed moisture barrier bags 
(Advantek®).       
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Figure II-8.  The stability of the gelatin films in a plastic bag stored at -80°C. Week 0 
represents the samples before storage in the freezer. Th  duration of storage is up to 12 weeks. 
(A) Indentation curves of gelatin films with gel/gly of 4.5/5.5 (gel2), 4/6 (gel3) and 3.5/6.5 
(gel4); (B) Indentation forces of gelatin films of gel2, gel3 and gel4 under indentation 
distances of 0.129 mm, 0.209 mm and 0.289 mm, respectively.  
3.6 Direct determination of particle deposition depths by CLSM in layered structural 
models  
Confocal laser scanning microscopy was used as a modern tool to investigate the presence of 
fluorescently labeled model particles in a layered skin model. This technique was used to 
validate the method in order to later use it for the determination of particle penetration depths 
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that have been injected into skin or skin models by epidermal powder immunisation. The 
layered model is depicted in Figure II-2  and the results of the investigations are shown in 
Figure II-9 . The four red lines in the cross section of model A in Figure II-9A correspond to 
the four red layers depicted in Figure II-2A . The first sub-photo which shows a red color in 
Figure II-9B  corresponds to the top red layer in Figure II-2B , while the yellow particles in 
different sub-photos in Figure II-9B  correspond to the particle layers as shown in Figure II-
2B. 
 
 
A B 
Figure II-9.  CLSM images of layered structural model A (left) and model B (right). The 
CLSM images of the established layered structural models confirm the validation of the depth 
measurement by the non-invasive CLSM method. The dye used for labelling gelatin film is 
Rhodamine B isothiocyanate-Dextran, while the PMMA particles were labeled with 
Fluorescein isothiocyanate. The brighter part is the area closer to the lens of CLSM. The scale 
bar of the left one is 100 µm, while that of the right one is 20 µm. For the CLSM 
measurement of model A structure, the pinhole of Ch3 (BP 560-615) is 164 µm. For the 
CLSM measurement of model B structure, the pinholes of Ch2 (BP 505-530) and Ch3 (BP: 
560-615) are 184 µm and 480 µm, respectively. 
Orthogonal sections of structural model A are shown. Four red layers of TRITC-gel films can 
be observed from the cross section. This result is in coherence with the composition of the 
model. It is worth noting that the deeper the layer, the weaker the intensity of fluorescence is. 
The laser intensity decreases with the increase of depth inside the gelatin films, especially 
when the laser passes through the upper-layer of TRITC-gel films before arriving at the 
deeper layer. That is to say that the fluorescence i tensity at different depths is not directly 
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related to the concentration of the fluorescent probe. The gallery image of structural model B 
is displayed in Figure II-9  (right). The first subset image showing red is thefluorescent 
surface of model B. It is a major advantage for measuring the depth of t e particles that the 
surface can be distinguished. The FITC-PMMA spheres at the specific layer can be excited by 
both excitations of 488 nm (green) and 543 nm (red). The merged photograph is shown in 
Figure II-9B  (right) and the yellow circles are the positions where the PMMA spheres reside. 
The depths of the particles can be determined in relation to the surface (z = 0). The depth of 
the first layer containing two PMMA particles is 120 µm. The second and the third layer are 
240 and 375 µm underneath the surface. The shape and size of the PMMA particles are the 
same as specified by the manufacturer. It means that the CLSM used here is a valid method to 
determine the depths of fluorescent particles inside model skin or real skin.     
 
CLSM has been extensively applied to visualise transdermal drug delivery into skin [66]. The 
penetration and distribution of polystyrene nanoparticles containing fluorescein 5-
isothiocyanate across porcine skin has been visualised using CLSM [135]. Even though the 
skin colour and auto-fluorescence can make it difficult to observe deeper layers inside, it is 
still attractive as a non-invasive method. Usually, the detecting depth of skin after topical drug 
delivery using CLSM is around 50 µm which is deep enough for evaluating whether drugs can 
penetrate the skin barrier stratum corneum or not [66]. The special morphology characteristic 
of stratum corneum surface can be used to define skin surface [135]. In the case of powder 
injection, we need to measure the depth under skin urface up to 120 µm or even deeper. 
From the results of the structural models established with gelatin films, the detection depth 
can be up to 400 µm. Gelatin films seems to be promising skin models for the visualisation of 
the penetration and distribution of particles delivred by powder injection devices.  
4. Conclusions 
Different skin models including gelatin films, silicone film and agar gel were analysed as skin 
models for powder injection delivery. The transparent silicone film may be a good candidate 
as model skin, but the mechanical properties of the silicone films are difficult to tailor, 
resulting in the difficulty to simulate different properties of the skin. Agar gels can be applied 
as model skin for powder delivery as proven by others, but the high water content in agar gel 
would make injected water-soluble microparticles disolve away quickly, and then result in 
ambiguous distribution of particles. A series of gelatin films seems to be good model skin 
according to our research. Gelatin films with gel/gly ratios of 4.5/5.5 (gel2), 4/6 (gel3) and 
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3.5/6.5 (gel4) which can be easily prepared at low cost could simulate the skin with different 
mechanical properties. Young’s modulus of the gelatin film with a gel/gly of 3.5/6.5 (gel4) (E 
= 0.8 MPa) is close to that of in vitro human abdominal skin (E = 0.7 MPa) making that this is 
favoured as a skin model. The reproducibility of the gelatin films can be controlled and the 
stability during storage is good. Furthermore, gelatin films are transparent for CLSM 
measurements, which is a major advantage for observing the penetration and distribution of 
fluorescent particles after powder injection. As seen from the CLSM image of the structural 
layered model B, the FITC-PMMA particles at a depth of 400 µm can be well visualised. In 
all, gelatin films will be simple and effective skin models for powder delivery research, which 
may facilitate the development of powder injection devices and the evaluation of powder or 
particles for injection. 
 
 
Chapter III. Nanoparticles-in-Microparticulate Syst ems for 
Epidermal Powder Injection 
 
1. Objectives  
As described in the first chapter, there are requirements for the particles to be used for 
epidermal powder injection (EPI), including the right size, sufficient density and good 
robustness. In fact, nanoparticles and microparticles have been extensively used as 
drug/vaccine delivery systems, but nanoparticles ar not suitable for EPI due to the limitation 
of size and density [12]. The definition of “nanoparticles” used in this thesis describes 
especially the particles in the size range of 100 nm to 1000 nm. Due to their small size and 
therefore low mass, it is necessary to formulate nanop rticles into microparticles in order to 
achieve a particle that can be delivered by EPI. The microparticles should optimally have 
sizes ranging from 20 µm to 70 µm that are best for EPI delivery [10, 45]. The particles lower 
than 20 µm may not penetrate into skin effectively if the density is not high enough, while the 
particles larger than 70 µm could induce blood bleeding and pain when impacted on human 
skin [10, 45].  
 
The idea of the work described in this chapter is to combine the advantages of nanoparticles 
for vaccine delivery and microparticles for EPI. The concept of nanoparticles-in-
microparticles (nano-in-mico) systems for EPI delivry is shown in Figure III-1 . Antigens 
are loaded in nanoparticles or on the surface of nanop rticles, and then these nanoparticles are 
formulated in microparticles by using spray-freeze-drying (SFD). The sugar-based 
microparticles are then delivered into the viable epid rmis layer or upper layer of dermis by 
EPI. The sugar and polysaccharide matrices are water-soluble and will subsequently be 
dissolved in the tissue, and then antigen-loaded nanop rticles are released. The Langerhans 
cells (LCs) distributed in skin can recognise and process the antigens, and then migrate to 
lymph nodes via lymphatic vessels to induce immune response [6, 136].  
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Figure III-1.  Schematic diagram of the concept of nano-in-micro particles for epidermal 
powder immunisation. The green circles represent the nanoparticles and red dots represent 
antigens. The antigens can be absorbed on the surface o  nanoparticles, or encapsulated inside 
nanoparticles. The antigen-loaded nanoparticles are then encapsulated in microparticles that 
can be delivered into skin by epidermal powder injection (EPI). The antigens and 
nanoparticles are released in the viable epidermis where the inherent Langerhans cells can 
recognise the antigens and process them. The Langerhans cells carrying the antigens migrate 
to the lymph node by the lymphatic vessels. Finally, a systemic immune response will be 
induced.  
 
The strategies for encapsulating nanoparticles in microparticles depend on the properties of 
the nanoparticles and microparticles, and also the applications. Poly(epsilon-caprolactone) 
(PCL) microparticles containing gelatin nanoparticles have been prepared by emulsification 
and investigated for oral delivery [137, 138]. Poly(e-caprolactone) (PCL) nanoparticles with 
loaded hydrocortisone acetate (HA) were incorporated in PLGA microparticles by a double 
emulsion method [139]. The PCL nanoparticles were trapped on the layer close to the surface 
of the microparticles resulting in a hollow core [139]. Microgels (microparticles) containing 
nanoparticles were fabricated by a new Michael addition during (water-in-oil) emulsion 
(MADE) method, and they are suitable for intracellular delivery into the deep lung [140]. 
PLGA microparticles containing mesoporous silica nanoparticles have been prepared for the 
use of DNA prime-protein boost vaccination [112]. Dexamethasone acetate-loaded PLGA 
nanoparticles were encapsulated into microparticles by spray-drying of the mixture of the 
nanoparticles, 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) and hyaluronic acid 
[141]. In our studies, spray-freeze-drying will be used to prepare nano-in-micro particles.  
 
To my knowledge, nano-in-micro particles have been used for oral and lung delivery [137, 
138, 140, 142, 143], but there are no reports on the application for EPI delivery. The particle 
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size for oral and lung delivery is usually smaller than 10 µm, which could be achieved by 
spray-drying. Spray-freeze-drying can produce larger sized particles around 10 - 50 µm as in 
our case here, even though the density may be reduced. In fact, the density can be improved 
by controlling the conditions for the freeze-drying step [132]. Furthermore, sugars could 
protect nanoparticles from aggregating during freeze-drying [144-147]. Sugar-based 
microparticles are suitably produced by spray-drying or SFD, while the SFD method is more 
suitable for formulating thermal-sensitive biological ingredients. The encapsulation of 
nanoparticles in sugar-based microparticles might be achieved by spraying the mixture of 
nanoparticles and the sugar-based matrix into a liquid nitrogen bath. The frozen 
microparticles encapsulating nanoparticles can be fre ze-dried, and then nano-in-micro 
particles would be obtained.  
 
The objectives of this chapter are to investigate the encapsulation of different nanoparticles in 
microparticulate formulations and to increase the density of microparticles by including dense 
materials in the formulation. Inorganic, polymeric and protein nanoparticles are going to be 
used, including mesoporous silica, poly(lactic-co-glycolic acid) (PLGA), recombinant silk, 
gelatin nanoparticles. Trehalose, mannitol, dextran (TMD) are used as the sugar-based matrix 
for microparticles. A spray-freeze-drying method will be used to manufacture the TMD 
microparticles encapsulating nanoparticles. The distribution of fluorescently labelled 
nanoparticles encapsulated in TMD microparticles will be observed by confocal laser 
scanning microscope (CLSM). To improve the density and robustness of TMD microparticles, 
dense inorganic materials have been added to the formulation.   
2. Materials and Methods 
2.1 Materials  
The copolymer poly(lactic-co-glycolic acid) (PLGA) (RESOMER RG 752S) was obtained 
from Evonik Industries AG (Darmstadt, Germany). Poly(vinyl alcohol) (PVA) (Mw 9000-
10000, 80% hydrolyzed), tetraethyl orthosilicate (reagent grade, 98%) (TEOS), (3-
aminopropyl)trimethoxysilane (97%) (APTMS), hexadecyltrimethylammonium bromide 
(BioUltra, ≥99%) (CTAB), fluorescein isothiocyanate (FITC), glutaraldehyde solution 
(25.0%), N-(3-dimethylaminopropyl)-N-ethylcarbodiimde hydrochloride (EDC), (2-
aminoethyl)trimethylammonium (Cholamin) chloride hydrochloride (99%), gelatin, Type A 
(175 Bloom), dextran from Leuconostoc mesenteroides (average mol wt 9 000-11 000), 
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dextran from Leuconostoc mesenteroides (average mol wt 100 000), dextran from 
Leuconostoc mesenteroides (average mol wt 150 000) were purchased from Sigma-Aldrich 
Chemie GmbH (Steinheim, Germany). D(+)-trehalose dehy rate (for biochemistry) was 
purchased from VWR International (Darmstadt, Germany). Mannitol was obtained from 
Boehringer Ingelheim (Ingelheim, Germany).  
 
Table III-1  Summary of the molecular structures of the sugar-based matrices 
 
 
 
Trehalose Mannitol Dextran 
 
Recombinant silk protein (eADF) was a gift from AMSilk GmbH (Munich, Germany). 
Fluorescent dye Alexa Fluor® 633 carboxylic acid, succinimidyl ester (ex.632/em.647) was 
purchased from Molecular Probes (Oregon, USA). Dimethyl sulfoxide (DMSO) was obtained 
from Gruessing GmbH (Wahrenholz, Germany). Monodisper ed polystyrene nanoparticles 
labelled with Rhodamine B (PS-RhB) with a diameter of 167 nm and a PDI of 0.08 (2.5 w/v% 
suspension in water) was purchased from Microparticles GmbH (Berlin, Germany). 
2.2 Methods 
2.2.1 Preparation of fluorescent PLGA nanoparticles 
Fluorescent dye was encapsulated into poly(lactic-co-glycolic acid) (PLGA) nanoparticles by 
a modified method from Sarti et al.[148]. 20 mg/ml of Rhodamine B isothiocyanate (RITC) in 
Dimethyl sulfoxide (DMSO) was prepared. 150 mg of PLGA (RESOMER RG 752S) was 
dissolved in 5.0 ml of dichloromethane (DCM). 50 µl of the 20 mg/ml RITC was added into 
the PLGA solution, and then the mixture was added to 20.0 ml of PVA solution (1.0% w/v). 
The mixture was emulsified by sonicating for 90 s at an amplitude of 40% using the probe 
type MS 73 (Sonopuls HD 2200, Bandelin electronic, Berlin, Germany). Finally, it was stirred 
overnight to remove DCM. The PLGA-RITC nanoparticles were obtained by centrifugation at 
12000 rpm for 10 min (Sigma 4K15 centrifuge, SIGMA Laboratory Centrifuges, Shropshire, 
UK) and washed three times with highly purified water (HPW). The suspension of 
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nanoparticles was obtained by resuspending them in 8.0 ml of HPW water. A microbalance 
(METTLER TOLEDO, Giessen, Germany) was used to determine the particle concentration. 
0.050 ml of the suspension was added to an aluminiu 100 DSC crucible (NETZSCH, Selb, 
Germany) and dried at 40 °C overnight. The dried weight of added suspension was calculated 
from the empty crucible weight and the weight of the crucible with dry particles.    
2.2.2 Preparation of fluorescent gelatin nanoparticles 
The method for preparing gelatin nanoparticles has been developed previously [149, 150]. 
1.25 g of gelatin (Type A) was dissolved in 23.75 g of sterile HPW water under stirring at 500 
rpm at 50 ºC. 25 ml of acetone was added quickly (within 1 min) to the gelatin solution. 20 s 
later, the supernatant was removed, and then the rest inside the 250-ml flask was weighed. 
Sterile HPW water was added to the flask until the total amount reached to 25.0 g. The gelatin 
inside the flask was dissolved again at 50 ºC under stirring. The pH was adjusted to 7.0-8.0 
using 1 M NaOH. 50 µl of Alexa Fluor® 633 was added into the solution and the mixture was 
stirred for 2h at room temperature (RT). After that, the gelatin solution was heated to 50 ºC 
under stirring, and then the pH was adjusted to 2.5 - 3 0. The gelatin solution was incubated at 
50 ºC for a while, and then 50-75 ml acetone was added slowly (3 - 5 ml/min) in while 
stirring at 500-700 rpm. After 15 min, 175 µl of glutaraldehyde (25.0%) was added to 
crosslink the nanoparticles. The suspension was stirred overnight to remove acetone.  
 
The obtained gelatin nanoparticles (GNP) suspension was transfer to a 15-ml falcon tube and 
centrifuged at 17,500×g for 15 min. The obtained particles were resuspended in 10 ml of 
sterile HPW by shaking or pipetting. The washing step was repeated three times. Finally, the 
particles were resuspended in 1-2 ml of sterile HPW to obtain the suspension of plain GNP 
nanoparticles. A microbalance (METTLER TOLEDO, Giess n, Germany) was used to 
determine the particle concentration. 0.050 ml of the suspension was added to an aluminium 
100 DSC crucible (NETZSCH, Selb, Germany) and dried at 40 °C overnight. The dried 
weight of added suspension was calculated from the empty crucible weight and the weight of 
the crucible with dry particles.    
 
In order to prepare cationic GNP nanoparticles, the dispersion of plain GNP particles was 
diluted with 20 ml of sterile HPW water. The pH was adjusted to 4.5-5.0 before adding 50 mg 
of cholamin under constant stirring. 50 mg of N-(3-dimethylaminopropyl)-N-
ethylcarbodiimide hydrochloride (EDC) was added when cholamin was totally dissolved. The 
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mixture was stirred at RT at 500 rpm for 30 min. The particles were obtained by using the 
same process as above. 1.0 ml of sterile HPW was added to resuspend the cationic GNP 
nanoparticles. The dispersion was filtered with a 1.2 µm syringer filter (Sartorius Stedim 
Biotech S.A., Aubagne, France) to obtain the final product of cationic GNP nanoparticles. A 
microbalance was used to determine the particle concentration. 
2.2.3 Preparation of fluorescent spider silk nanoparticles 
The recombinant spider silk protein eADF4 (C16) comprising 16 repeats of 
GSSAAAAAAAASGPGGYGPENQGPSGPGGYGPGGP (Mw = 47.7 kDa) was provided by 
Prof. Dr. Thomas Scheibel, University of Bayreuth. T e eADF4 powder was dissolved in 6 M 
guanidinium thiocyanate first and then the solution was dialysed in 
tris(hydroxymethyl)aminomethane/HEPES buffer (20 mM, pH 8.0) using tube membranes 
with a molecular weight cut-off of 6000-8000 Da (Spectrum Laboratories Inc., Rancho 
Dominguez, USA). 5 mg/ml of fluorescein isothiocyanate (FITC) in DMSO was prepared, 
653 µl of which was added into 10 ml of 2 mg/ml eADF4 in HEPES buffer (20 mM, pH 8.0). 
The solution was incubated for 1h at RT in the dark. FITC labelled eADF (eADF-FITC) in 
solution was obtained by dialysis against HEPES buffer at 4 ºC overnight to remove the 
excess FITC.  
 
The particle preparation was carried out using the method by Hofer et al. [151]. Briefly, 
eADF in Tris buffer and eADF-FITC in Hepes buffer were mixed together with a mass ratio 
of 3/1. A micromixing system (model 100 DX, Teledyne Isco Inc., USA) consisting of two 
channels was used to mix the silk protein solution and potassium phosphate buffer (2 M, pH 
8.0). The precipitated silk particles were collected by centrifugation (7500 g for 10 min and 
12 500 g for 15 min). The particles were washed three times with HPW. The dispersion of 
resuspended particles in HPW was sonicated for a maximum of 15 min (cycle 6, amplitude 
50%) using a probe sonifier (SonoPuls HD 2200, Badelin electronic, Berlin, Germany) and 
filtered using a 5 µm syringer filter (Sartorius Stedim Biotech S.A., Aubagne, France). A 
microbalance was used to determine the particle concentration.  
2.2.4 Preparation of fluorescent silica nanoparticles 
The synthesis method of mesoporous silica nanoparticles (MSNP) was modified from Xia et 
al. [152]. Briefly, 27.5 mg of FITC was dissolved in 18 ml of absolute ethanol and then 0.100 
ml of APTMS was added. The APTMS-FITC mixture was stirred for 24 h at room 
III. Nano-in-Micro Particulate Systems for Epidermal Powder Injection 53 
temperature in dark. 1.60 g of CTAB was dissolved in a mixture of 11.20 ml of 1 mol/l NaOH 
aqueous solution and 768 ml of deionised (DI) water under stirring. The temperature of the 
solution was increased to 80 ºC in 30 min. 8.00 ml of TEOS was added dropwise while 
stirring at 700 rpm, and then 8.0 ml of the prepared APTMS-FITC mixture was added. After 2 
h stirring, fluorescein 5(6)-isothiocyanate (FITC) labelled silica nanoparticles (FITC-MSNP) 
were obtained by centrifugation and washed with ethanol once. In order to remove CTAB, 
fresh prepared silica nanoparticles FITC-MSNP were r fluxed overnight in 160 ml of ethanol 
containing 8 ml of 37% (w/v) HCl aqueous solution and then washed with adequate water and 
ethanol. The surfactant extracting process was repeat d once. Finally, the nanoparticles were 
dried overnight at 20 ºC in a vacuum dryer.  
2.2.5 Preparation of microparticles encapsulating different nanoparticles 
Trehalose, mannitol, dextran (10 kDa) and dextran (100 kDa) or dextran (150kDa) (TMD) 
were mixed with a weight ratio of 3:3:3:1, and were th n dissolved in sodium phosphate 
buffer (PB) (10 mM, pH 7.4) under stirring to obtain 35 wt% sugar-based solutions. The 
TMD solution was filtered with a 0.2 µm syringe filter (VWR, Darmstadt, Germany) before 
use. Each kind of nanoparticles was added into the formulation of the TMD matrix according 
to Table III-2 . The mixtures were shaken occasionally by hand. The solid content of 
nanoparticles in microparticles is 3-4 µg/mg, which was calculated on the basis of the dry 
mass of sugar matrices.   
 
Table III-2  Formulations of microparticles encapsulating nanoprticles 
Sample TMD 35%(w/w) 
solution (g) 
Nanoparticle 
concentration (mg/ml) 
Nanoparticle 
volume (µl) 
Particle content 
(µg/mg) 
TMD/PS-Rhd 1.0 25 50 3.6 
TMD/PLGA-Rhd 1.0 15 100 4.3 
TMD/MSNP-FITC 2.0 50 50 3.6 
TMD/GNP-Alexa(-) 1.0 19 63 3.4 
TMD/GNP-Alexa(+) 1.0 18 66 3.4 
TMD/silk-FITC 2.0 15 168 3.6 
 
The prepared formulations of TMD and nanoparticles w re sprayed into liquid nitrogen by an 
ultrasonic atomizing nozzle (120 kHz, Sono-Tek, Milton, USA). The power for spraying was 
set to 4.0-4.5 watts and the flow rate of a peristalt c pump (IsmaTec IPC 78001-20, Wertheim, 
Germany) to 0.6 ml/min. The custom-made set-up for spray-freezing is shown in Figure III-2 . 
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The sprayed microparticles were collected in vials and transferred to a pre-cooled lyophilizer 
(Martin Christ EPSILON 2-6D, Harz, Germany). The freze-drying sequence was carried out 
by 24 h of primary drying at -10 ºC and 20 h of secondary drying at 25 ºC. The chamber 
pressure was kept at 0.12 mbar during the whole drying process. 
 
 
Figure III-2.  Set-up of a spray-freezing system. A peristaltic pum  is used to feed the 
solution for spraying. The vial for freeze-drying and the reversed big vial without bottom are 
connected by a Teflon tape and adhesive plastic film. Liquid nitrogen is filled into the white 
foam box and the vials. The ultrasonic nozzle (120 kHz) sprays the solution into the special 
vial. Atomized liquid drops are frozen quickly as they meet liquid nitrogen. The frozen 
particles are collected in the small vials. The upper art of the vial is removed and then the 
small vial containing frozen particles is freeze-drie  subsequently.     
2.2.6 Microscopic examination of microparticles 
Confocal Laser Scanning Microscopy (CLSM) 
A confocal Laser Scanning Microscope (LSM 510 META, Carl ZEISS, Germany) was used 
to observe the microparticles encapsulating fluorescent nanoparticles. Argon laser (488 nm) 
and HeNe laser (543 nm) were used as excitation wavelengths, corresponding the emissions 
of BP 505-530 nm and LP 560 nm, respectively. Different objectives were used, including 
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Plan-Neofluar 40×/1.3 Oil, Plan-Apochromal 63×/1.4 Oil DIC and Plan-Neofluar 100×/1.3 
Oil Ph3. Z-stacking mode was used to observe the distribution of nanoparticles in the 
microparticles. 
 
Scanning electron microscopy (SEM) 
Microparticles were placed on Leit adhesive carbon tabs (Plano GmbH, Wetzlar, Germany) 
and then coated with a thin layer of carbon before bserved under a JEOL JSM-6500F 
scanning electron microscope (SEM) (Joel Inc., Peabody, USA). Samples were viewed at a 
magnification of 300. 
2.2.7 Measurements of hydrodynamic diameter and zeta-potential 
The hydrodynamic diameter and zeta-potential of nanop rticles were determined using a 
Zetasizer Nano ZS (Malvern Intruments, Herrenberg, Germany). The reflective index (RI) of 
all nanoparticles used for the size measurement was 1.59. The dispersant phase is water with 
RI of 1.330 and viscosity of 0.8872 cP. The particle oncentration was kept around 0.05 
mg/ml for dynamic light scattering (DLS) measurements. 
2.2.8 Cellular uptake of nanoparticles by macrophage cells 
A macrophage cell line J774.A1 with a concentration of 7×105 cells/ml in Dulbecco’s 
modified eagle’s serum with 10% Fetal Bovine Serum (FBS) was used. 300 µl of the cell 
suspension was added to each well of 8-well ibidi µ-s ldes (ibidi, Martinsried, Germany) and 
incubated at 37 ºC for 4 hours prior to particle tra ment. 20 µl of a 0.25 mg/ml of 
nanoparticles suspension was added in duplicates, homogenized and incubated for 30 min in 
the dark. After that, the wells containing cells were carefully washed with PBS to remove the 
excessive particles. The cells were fixed by 4% paraformaldehyde and stained by 
bisBenzimide H 33342 trihydrochloride. The resultant samples were observed by Confocal 
Laser Scanning Microscope LSM 510 META (Carl ZEISS, Göttingen, Germany) as described 
above.     
2.2.9 Tap density of the microparticles 
Tap density was measured by using a small custom-made cylinder with a volume of 1.5 ml. 
About 0.5 g of powder was added into the cylinder, and then it was tapped for 1000 times 
using a Stampfvolumeter (JEL STAV, 2003 model, Engelsmann AG, Ludwigshafen, 
Germany). The volume after tapping and the mass were used to calculate tap density.    
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2.2.10 Measurements of the mechanical properties offreeze-dried matrix cakes by a 
texture analyser 
A texture analyser TA.XTPlus from EXPONENT Stable Micro Systems Ltd. (Godalming, 
Surrey GU7 1YL, UK) (Figure III-3 ) was used to measure the force versus indentation 
distance curve. A custom-made steel cylinder probe was used for the measurement of 
indentation behaviour. The indentation speed for all the tests was set to 0.5 mm/s. The 
maximal force in the puncture tests was about 60 N.  
 
 
Figure III-3.  The set-up of a texture analyser for the measurements of freeze-dried cakes.   
3. Results 
3.1 Encapsulation of nanoparticles in microparticles  
3.1.1 Nanoparticles for the encapsulation in the sugar-based microparticles 
Several kinds of nanoparticles (NPs) made of polystyrene (PS), poly(lactic-co-glycolic acid) 
(PLGA), gelatin (GNP), recombinant spider silk were pr pared. Table III-3  shows the sizes 
and surface properties of the nanoparticles measured by dynamic light scattering (DLS). The 
polymer nanoparticles have very narrow particle siz distributions as the PDI is low than 0.1. 
The zeta-potential of PS nanoparticles is -70.6 mv in PB (10 mM, pH 7.4), indicating a 
negatively charged surface. PLGA nanoparticles in the PB buffer shows a zeta-potential of -
1.8 mv. Gelatin nanoparticles with positive (ZP = 6.5 mv) and negative (ZP = -3.1 mv) 
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surfaces have a similar size of about 300 nm. As another protein particle, silk NPs have a Z-
average size (Z-Ave) of 334.9 and a PDI of 0.154. The negative ZP (-26 mv) indicates a 
negative surface of silk NPS in the PB buffer.   
 
Table III-3  Sizes and zeta-potentials (ZPs) of different nanoprticles  
Sample Chemical structure Z-Ave (d.nm) PDI ZP (mv) 
PLGA NPs 
 
216 0.072 -1.8 
PS NPs 
 
155 0.016 -70.6 
Cationic GNP protein 295 0.276 6.5 
Plain GNP protein 300 0.269 -3.1 
Silk NPs protein 335 0.154 -26.0 
The nanoparticles were suspended in PB (10 mM, pH 7.4) at a concentration of 0.1 - 0.2 
mg/ml. 
 
These nanoparticles made of different materials have a size range from 150 nm to 350 nm. 
The surface properties of the nanoparticles are diff rent. They were used as model particles 
for investigating the encapsulation of nanoparticles in the sugar-base microparticles by spray-
freeze-drying.  
3.1.2 Distribution of different nanoparticles in the sugar-based microparticles. 
These nanoparticles were used in the sugar-based microparticles to study the encapsulation of 
nano-sized particles into micro-sized particles (nano-in-micro). The nanoparticles in aqueous 
suspension were added to the TMD solution (35 wt%). The mixture was mixed thoroughly 
before spray-freeze-drying. In order to observe the nanoparticles in microparticles using 
CLSM, all nanoparticles were fluorescently labelled.  
 
TMD microparticles without nanoparticles inside were prepared as a control. FITC labelled 
dextran (Dextran-FITC) was used in the formulation at a content of 1 wt% of the solid 
microparticles. As shown in Figure III-4 , the microparticles can be well visualised by 
labelling the matrix. Figure III-4A shows a single scan of CLSM, while Z-stacking 
micrographs are shown as the 3D view in F gure III-4B  and gallery model in Figure III-4C . 
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One of the advantages of CLSM is the optical slicing by focusing on a specific layer. The 
green fluorescence is distinctly strong when the surface of the microparticles was illuminated. 
There are two particles in Figure III-4A  showing green circles and black centres. Dextran-
FITC could be on the surface or in the matrix.  
 
The different intensities on the single scan layer of one particle can be contributed to the 
point-by-point scanning of CLSM. The matrices of the microparticles are non-transparent 
materials which can decrease the intensity of fluorescence transmitting through them [153]. 
When the middle layer of microparticles is observed under CLSM, the edge is brighter 
because it is more close to surface and the centre shows less intensity because the light needs 
to pass the matrixes causing some loss of the intensity. This can explain the observation of 
microparticles with a green circle and black centre in Figure III-4A . Furthermore, the rough 
surface can also lead to heterogeneous appearance of an optical layer of CLSM observation.  
  
 
Figure III-4.  TMD/FITC-Dextran microparticles. (A) Single scan micrograph; (B) 3D 
micrograph produced from Z-stacking scan; (C) Gallery displaying Z-stacking micrographs.   
A B 
C 
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The microparticles containing PS nanoparticles have a size of 10-40 µm in diameter and a 
wrinkled surface as shown in the SEM micrograph (Figure III-5A ). PS-RhB nanoparticles 
(Figure III-5) were observed and the fluorescent microparticles indicate that the PS (167 nm 
in diameter) nanoparticles can be encapsulated verywell. With CLSM micrograph of 
microparticles containing only Dextran-FITC (Figure III-4 ), brighter edge of each particle 
was observed at both magnifications (40× and 63×). This does not mean that PS-RhB 
nanoparticles are just located on the layer close to surface. As explained above, this 
phenomenon results from the decrease of light after transmitting the middle part of the 
microparticle. The wrinkles on the surface of the microparticles are very bright in the 3D view 
of Z-stacking micrographs (Figure III-5D ), indicating a morphology consistent with the SEM 
micrograph.  
 
  
A B 
  
C D 
Figure III-5.  Sugar-based microparticles containing PS-RhB nanoprticles. (A) SEM 
micrograph; (B) CLSM micrograph with a magnification of 40×; (C) CLSM micrograph with 
a magnification of 63×; (D) 3D view produced from z-stacking micrographs.  
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PLGA nanoparticles (216 nm in diameter) are encapsul ted in the microparticles as shown in 
Figure III-6 . The surface of the microparticles containing PLGA-RITC nanoparticles is very 
bright. The PLGA nanoparticles are distributed in the whole particles as indicated by the 
homogeneous distribution of fluorescence.  
 
  
 
Figure III-6.  CLSM micrographs of TMD microparticles containing PLGA-RITC 
nanoparticles. (A) Single scan micrograph; (B) 3D micrograph produced from Z-stacking 
scan; (C) gallery displaying of Z-stacking micrographs. 
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In the case of silica nanoparticles (MSNP-FITC) with a size of ~130 nm, the distribution is 
not as homogeneous as for PS and PLGA. There are som  bright spots in the area of 
microparticles as shown in Figure III-7B . However, the silica nanoparticles are still 
distributed in the whole space as can be observed in Figure III-7C . The 3D view shows green 
spots everywhere in the microparticles. Therefore, silica nanoparticles can also be 
encapsulated in the TMD microparticles.  
 
  
A B 
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Figure III-7.  Sugar-based microparticles containing MSNP-FITC nanop rticles. (A) SEM 
micrograph; (B) CLSM micrograph with an objective of Plan-Apochromal 63×/1.4 Oil DIC; 
(C) CLSM micrograph with an objective of Plan-Neofluar 100×/1.3 Oil Ph3; (D) 3D view 
produced from z-stacking micrographs.  
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Until now, we have successfully encapsulated polymer and inorganic nanoparticles in the 
sugar-based microparticles. It is also interesting to investigate whether protein-based 
nanoparticles can be encapsulated in the microparticles using this method. Considering the 
availability in our group, gelatin nanoparticles and recombinant spider silk nanoparticles were 
used. Plain gelatin nanoparticles (GNP(-)) have a ngative surface, which can be cationized to 
a positively charged surface (GNP(+)). Both have been encapsulated in the TMD 
microparticles. As shown in Figure III-8 , GNP(-) are distributed evenly and the 3D view 
micrograph displays many wrinkles on the particle surface. The distribution of GNP(+) was 
not as good as that of GNP(-). Although red GNP(+) can be seen in the microparticles, the 
surface morphology is not well resolved as for GNP(-).   
 
  
  
Figure III-8.  SEM micrographs of microparticles containing gelatin nanoparticles. (A, B) 
Plain gelatin nanoparticles (negative surface); (C, D) Cationic gelatin nanoparticles (positive 
surface). A and C are single scan micrographs, while B and D are 3D micrographs produced 
from Z-stack scanning.   
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FITC-labelled recombinant spider silk nanoparticles were distributed in TMD microparticles 
as green fluorescence can be observed allover the microparticles. Micrographs with different 
magnifications (10×, 40×, 63×) were scanned (Figure III-9 ). The silk nanoparticles are 
obviously encapsulated in all microparticles. The 3D view was obtained by processing the Z-
stacking micrographs with projections, confirming the spatial distribution of the silk 
nanoparticles in microparticles.  
 
  
  
Figure III-9.  TMD microparticles silk-FITC at magnifications of 10× (A), 40× (B) and 63× 
(C). 3D view (D) was produced from Z-stacking scan.  
 
All the nanoparticles we have used in the formulations have been successfully encapsulated in 
microparticles fabricated by spray-freeze-drying. The mixing of the nanoparticles and sugar-
based matrix was done by occasional hand-shaking. Furthermore, labelled nanoparticles and 
labelled dextran were both added into the formulation, n order to distinguish the matrix and 
nanoparticles. As shown in Figure III-10 , nanoparticles (red) and matrix (green) appear 
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together and also overlap to each other to produce a y llow area. The 3D photos of the 
microparticles are vivid and a cave under the surface has been visualised (Figure III-10B ).  
 
  
Figure III-10.  TMD/FITC-Dextran/PS-Rhd microparticles. 3 µg/mg of FITC-Dextran and 3.6 
µg/mg of PS-Rhd nanoparticles in the microparticles. (A) Single scan micrograph; (B) 3D 
view was produced from Z-stacking scan. 
3.2 Stability of nanoparticles in TMD microparticles 
Size is an important parameter when nanoparticles are used in a drug formulation. It is 
necessary to investigate the colloidal stability of the nanoparticles encapsulated in the TMD 
formulation. 15 mg of the microparticles containing different kinds of nanoparticles were 
redissolved in 1 ml of PB (10 mM, pH 7.4). The size and zeta-potential were then measured.   
 
Table III-4.  Sizes and zeta-potentials of nanoparticles before and after being formulated in 
microparticles (n = 3) 
Before formulation After formulation in microparticles 
sample 
Z-Ave (d.nm) PDI ZP (mv) Z-Ave (d.nm) PDI ZP (mv) 
PLGA NPs 216 0.072 -1.8 263 0.269 -3.5 
PS NPs 155 0.016 -70.6 173 0.030 -45.1 
Cationized GNP 295 0.276 6.5 1162 0.818 -5.5 
Plain GNP 300 0.269 -3.1 687 0.718 -7.7 
Silk NPs 335 0.154 -26.0 550 0.423 -23.7 
A B 
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The sizes of the nanoparticles before being formulated in TMD matrix and those resuspended 
after formulated in TMD microparticles are shown in Table III-4 . The PS nanoparticles are 
the most stable ones, showing a size of 155 nm and PDI of 0.016 before formulating and a 
size of 173 nm and PDI of 0.030 after formulated in microparticles. PLGA nanoparticles have 
a size of 216 nm and PDI of 0.072, while the size increases to 262 nm and PDI to 0.269. Two 
kinds of dextran with molecular weight of about 10 kDa and 100 kDa are in the formulations. 
The dextran may increase the size in a small degree wh n adsorbed to the nanoparticles, as in 
the cases of PLGA and PS nanoparticles. Both plain GNP and cationized GNP have a size 
around 300 nm and PDI around 0.27 before added into the matrix, but the size and PDI 
increase distinctly in the resuspended suspension of microparticles. Recombinant silk 
nanoparticles are moderately stabilised in the micropa ticles as the size and PDI increases 
slightly, from 335 nm and 0.154 to 550 nm and 0.423, respectively. The zeta-potentials of all 
nanoparticles except cationic GNP were negative but a solute values changed at different 
levels.    
3.3 Cellular uptake of nanoparticles   
Cell penetration properties of nanoparticles determine the usability as a vaccine delivery 
system. As a general investigation, we applied the formulations containing PS-Rhd, PLGA-
RITC, MSNP-FITC, plain GNP and cationic GNP to macrophage cells. This is basically used 
to study the properties of the nanoparticles as systems for intracellular drug delivery. The 
fluorescently-labeled nanparticles can be observed near the nuclei area stained as blue if they 
are successfully delivered into cells. Strong fluorescence of nanoparticles observed in cells 
indicate good cellular uptake of the nanoparticles into the cells.    
 
Figure III-11  shows CLSM results of macrophages respectively treated with the labeled 
nanoparticles and sodium phosphate buffer as a negativ  control. The same settings for 
obtaining the micrographs were used to ensure that fluorescence intensity represents the 
concentration of delivered nanoparticle. PS-Rhd nanop rticles cannot penetrate into the 
macrophage cells within 30 min (Figure III-11A ), because the reddish background is similar 
to the negative control, indicating no sufficient amount of PS-RhD in the cells. On the 
contrary, PLGA-RITC nanoparticles penetrate very well (Figure III-11B ), as red dots 
(particles) were obviously observed in macrophages. The green color around the blue nuclei 
(Figure III-11C ) indicates that MSNP-FITC nanoparticles were taken up by the cells. Plain 
and cationic gelatin nanoparticles can also be delivered into the cells as some particles appear 
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around the blue cell nuclei (Figure III-11 D and E). More cationic gelatin nanoparticles were 
observed in macrophages than the plain gelatin nanoparticles. As a negative control, the 
phosphate buffer was added to the macrophage cells.Only blue cell nuclei can be observed 
for the negative control (Figure III-11F) .       
 
Figure III-11.  CLSM results of macrophage cells incubated in different substances. (A) PS-
Rhd (TMD matrix); (B) PLGA-Rhd nanoparticles (TMD matrix); (C) FITC-MSNP-NH2 
(TMD matrix); (D) plain gelatin nanoparticles (negatively charged) (TMD matrix); (E) 
cationic gelatin nanoparticles (TMD matrix); (F) negative control. The scale bar is 10 µm.  
3.4 Enhancement of the density of microparticles by dense materials. 
Normally, sugar-based particles prepared by spray-freeze-drying have a low density due to the 
high porosity. The density can be improved by increasing the solid content of the solution for 
spraying and controlling the shrinkage during the fr eze-drying step. 35 wt% of matrix 
solution was used in our experiments. It is limited by the solubility of sugar and 
polysaccharides and the viscosity increases. Another way to improve the density could be 
achieved by adding dense materials in the formulation. Considering the biocompatibility of 
calcium carbonate (CaCO3), it was used in the formulations of microparticles. Different 
amounts of CaCO3 were added as shown in Table III-5 . In the formulation of TMD (100 
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kDa), the tap density was increased from 670 to 831 kg/m3 when the weight ration of TMD 
and CaCO3 comes to 2.5/1. For the case of TMD (150 kDa), the tap density was increased 
from 618 to 770 kg/m3 when the weight ration of TMD and CaCO3 is 5/1. When TMD and 
CaCO3 are used at a weight ration of 1/1, the density of TMD (100 kDa) and TMD (150 kDa) 
increases to 850 (Figure III-12 ) kg/m3. Unfortunately, there are many aggregates for the 
formulation of TMD/CaCO3 = 1/1 (by mass) because the spraying is not working well.  
 
Table III-5  Tap density of sugar-based microparticles 
Sample  Dextran (100 kDa) 
Tap density (kg/m3) 
Dextran (150 kDa) 
Tap density (kg/m3) 
TMD (35%(w/w)) 670 618 
TMD/CaCO3 = 10/1 669 627 
TMD/CaCO3 = 5/1 671 765 
TMD/CaCO3 = 2.5/1 831 770 
TMD/CaCO3 = 1/1* 853 848 
*many aggregates 
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Figure III-12.  Effect of calcium carbonate particles on the tap density of the sugar-based 
microparticles. 
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3.5 Indentation measurements of TMD/CaCO3 composite by a texture analyser 
CaCO3 can not only enhance the density of TMD microparticles, but it could also increase the 
robustness which is very important for powder injection. It is very difficult to measure the 
force of breaking for one microparticle due to the small size and small force. Therefore, we 
prepared composites by freeze-drying the mixtures of TMD and CaCO3 at different weight 
ratios under the same conditions for SFD process. The freeze-dried composites were 
measured by a texture analyser using a custom-made steel cylinder probe. As shown in 
Figure III-13 , the force for indenting the pure TMD matrix increas s firstly and then 
decreases a little before increasing again. All the composites containing CaCO3 similarly 
show straight increase of force against increasing indentation distance. The indentation force 
on TMD stays at one level or even decreases a little bi  before increasing again, indicating the 
higher porosity of the pure TMD matrix. This is reasonable considering that CaCO3 can fill 
some gaps or pores in the TMD matrix. The difference between the different mass rations of 
TMD and CaCO3 can not be figured out because the curves of the samples with a 
TMD/CaCO3 mass ratio of 9/1 to 5/5 overlap. Even though the enhancement of TMD 
robustness by CaCO3 was just observed in freeze-dried composites, it also indicates that TMD 
microparticles containing CaCO3 could have higher robustness due to that the same freeze-
drying process was used for SFD. 
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Figure III-13.  Indentation results of the composites of TMD and CaCO3. Maximal force for 
indentation was limited to 65 N according to the spcifications of the texture analyser.  
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4. Discussion 
4.1 Nano-in-micro systems for drug delivery 
Different nanoparticles have been encapsulated into TMD microparticles fabricated by spray-
freeze-drying. CLSM observations of the nano-in-micro particles confirm the encapsulation 
and distribution of the nanoparticles in the microparticles. Most of the microparticles have a 
size range of 20 - 40 µm and a shrunken surface morphology, making them suitable for 
epidermal powder injection. There are some advantages of this nano-in-micro system for EPI. 
First, nanoparticles in microparticles can be delivered into the skin by epidermal powder 
injection. Second, labile substances such as proteins, peptides etc. could be formulated in the 
nanoparticles to protect them from the physical stress during SFD process. Third, two or even 
more kinds of nanoparticles providing different functions can be simultaneously encapsulated 
in the same microparticle, e.g. antigens loaded in one kind of nanoparticles and adjuvants 
loaded in another kind of nanoparticles may be formulated into the same microparticle for 
vaccination purpose. Fourth, formulations of nanoparticles in sugar-based microparticles may 
reduce the aggregation of some unstable nano-sized particles during long-term storage.  
 
Our aim is to develop microparticles applicable for EPI and also make use of nanoparticles as 
drug/vaccine delivery systems. As there are requirements of the particles concerning particle 
size (r), density (ρ) and velocity (ν) [12], more effort has been put on the preparation of 
optimal particles for EPI. As shown in Figure III-1 , nanoparticles in the microparticles made 
of water-soluble materials are accelerated into skin, and then the matrix is dissolved while the 
antigen-loaded nanoparticles are released to target Langerhans cells.   
 
The density can be improved for SFD microparticles by improving the solid concentration of 
the solution for SFD and inducing the shrinkage of the microparticles during the freeze-drying 
process. Furthermore, dense materials such as CaCO3 can be added to improve the density. 
Spray-freeze-drying has been favoured because the nanoparticles of PS, PLGA, silk and 
gelatin are evenly encapsulated in TMD microparticles.   
4.2 Colloidal stability of nanoparticles processed by freeze-drying or spray-freeze-drying 
Herein, stability of nanoparticles is understood as referring to the particle size. The freeze- 
drying of nanoparticles can lead to distinct increase of the particle hydrodynamic size if there 
is no matrix for protection [144]. Mannitol, sucrose or trehalose has been used to protect 
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PLGA nanoparticles from aggregation during freeze-drying or spray-drying process [144-
147]. The stability of colloid nanoparticles depends on the interaction forces including van der 
Waals attraction, electrostatic attraction and steric attraction [154]. In aqueous solution, the 
repulsive effect of the electrostatic barrier plays an important role on the stability. The 
absolute value of zeta-potential (ζ) determines the repulsive force. Normally if the |ζ| is larger, 
the dispersion is more stable. Steric effects can be used to improve the stability of dispersion 
by coating the nanoparticles with polymers. The polymer layer induces steric hindrance when 
two particles come close to each other [154]. The matrix used for protecting nanoparticles acts 
as a spacer between the nanoparticles to stop the agglomeration.   
 
In the formulation of TMD microparticles encapsulating nanoparticles, the matrix plays a role 
of protecting the nanoparticles from aggregation. The polymeric nanoparticles such as PS and 
PLGA are well protected because only small increase of particle sizes was observed. The 
gelatin nanoparticles have a distinct larger size in TMD microparticles. This probably results 
from the low absolute value of zeta-potentials. Gelatin nanoparticles in lactose microparticles 
prepared by spray-drying also show increased sizes [142]. The silk nanoparticles in the TMD 
matrix are more stable than GNP as the size increases t a moderate level. It seems that zeta-
potential is very important for the stability of protein-based nanoparticles.  
4.3 Properties of nanoparticles for intracellular delivery  
Though Langerhans cells could be the first choice for investigating the intracellular delivery 
of nanoparticles considered as vaccine delivery system  for EPI, it is rather complicated to 
culture Langerhans cells [155]. In fact, macrophage cells are also involved in the immune 
response. As macrophage cell lines are commercially vailable, we use it for initial 
experiments for intracellular delivery of different nanoparticles. Almost no PS-Rhd 
nanoparticles penetrated into microphage cells, while PLGA, silica nanoparticles and gelatin 
nanoparticles penetrated. The surface properties such as charge, hydrophobicity, coating, and 
particle size determine the uptake of them by cells. As the membrane of cells is negatively 
charged, the nanoparticles with low negative charge or positive charge on surface could be 
taken up more easily. This could explain that PS-Rhd nanoparticles (ζ = -45.1 mv) were not 
delivered into macrophage cells because of the highnegative charge on the particle surface. 
Cationisation is one popular method for coating particles used for intracellular delivery, e.g. 
cationic PLGA nanoparticles [148, 151].  
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4.4 Effect of dense excipients on the density of the microparticles 
It is rational to use dense materials to increase the density of TMD microparticles. The density 
of SFD microarticles depends very much on the solid concentration of the solution for SFD. 
35 wt% of TMD used in our experiments is too viscous to add more absolute amounts of any 
component. Solid CaCO3 powder with a size around 1 µm in diameter was added into the 
TMD solution to obtain a composite which can still be sprayed by the ultrasonic probe. The 
true density of CaCO3 (~2.7 g/cm
3) is much higher than the sugar-based matrix (~1.4 g/cm3) 
[156]. The density should increase as the amount of CaCO3 increases. This is consistent with 
that the tap density of TMD microparticles increased when efficient amount of CaCO3 was 
added. On the other hand, CaCO3 is insoluble in aqueous solution so that it can fill some 
small pores which may exist in the TMD microparticles. It can make the microparticles 
denser which is beneficial for EPI delivery.    
 
In the formulation of TMD, dextran as a polysaccharide is used to increase the robustness that 
is necessary for EPI delivery. The robustness of TMD matrix has been further enhanced by 
adding CaCO3 as proved here. The indentation force for each composite of TMD and CaCO3 
increases faster that that of pure TMD (Figure III-13 . The TMD/CaCO3 can stand a larger 
force at the same indentation distance compared to the pure TMD matrix.  
5. Conclusion 
Sugar-based microparticles consisting of trehalose, mannitol, dextran have been fabricated by 
spray-freeze-drying. The compact morphology ensures th  potential application for EPI 
delivery. Nanoparticles-in-microparticle systems have been investigated by formulating 
different kinds of nanoparticles in the TMD matrix. Each type of nanoparticles including PS, 
PLGA, gelatin, silica and silk has been encapsulated in TMD microparticles from the CLSM 
observation, but the stability of PS and PLGA can only be best preserved. Silica and PLGA 
nanoparticles for loading antigens will be investiga ed in the next chapters. PLGA, gelatin, 
silk, silica nanoparticles can be taken up by macrophages after redissolution from TMD 
microparticles, suggesting that they can be used for intracellular delivery. Addition of CaCO3 
in TMD microparticles can increase the tap density and enhance the robustness, which are 
positive for EPI delivery.  
 
 
Chapter IV. Encapsulation of Antigen-loaded Silica Nanoparticles into 
Microparticles for Intradermal Powder Injection 
 
1. Objectives 
Silica-based nanoparticles have been extensively used for drug delivery and biomedical 
applications [75, 93], but are not well investigated as a vaccine delivery system. In fact, silica 
showed an adjuvant effect in the immunological respon e in guinea pigs [96]. Vallhov et al. 
studied the effects of mesoporous silica particles (270 nm and 2.5 µm) on human monocyte-
derived dendritic cells (MDDC) and found good cellular uptake of both particles and low-
toxicity profiles on MDDC [97]. Recently, Vallhov et al. suggested that mesoporous silica 
particles have adjuvant properties of tuning effect T ell development according to cell culture 
experiments [98]. Furthermore, mesoporous silica nanop rticles can enhance mucosal and 
systemic immune responses when applied orally in mouse models [99]. Although silica 
nanoparticles show potential as a vaccine delivery system, there is no study investigating their 
applications for epidermal powder immunisation.     
 
The objective of this work was to prepare microparticles encapsulating antigen-loaded silica 
nanoparticles, i.e. nanoparticles-in-microparticles (nano-in-micro) system integrating the 
advantages of nanoparticles as vaccine delivery vehicles and microparticles for epidermal 
powder immunisation (EPI). Cationic mesoporous silica nanoparticles (MSNP-NH2) were 
prepared and used for loading a model antigen, ovalbumin (OVA). The surface of MSNP-
NH2 is positively charged in solution with near neutral pH, while ovalbumin is negatively 
charged at that pH. Thus the OVA protein can be absorbed on the surface of the silica 
nanoparticles driven mainly by electrostatic interactions.  
2. Materials and Methods 
2.1 Materials  
Tetraethyl orthosilicate (reagent grade, 98%) (TEOS), (3-Aminopropyl)trimethoxysilane 
(97%) (APTMS), hexadecyltrimethylammonium bromide (BioUltra, ≥99%) (CTAB), 
ovalbumin from chicken egg white (Grade V, lyophilized powder, ≥98%) (OVA), N,N'-
carbonyldiimidazole (CDI), Fluorescein isothiocyanate–dextran (FITC-dextran) (average mol 
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wt 70 000, FITC:Glucose = 1:250), Dextran (average mol wt 9 000-11 000) from Leuconostoc 
mesenteroides and Dextran (average mol wt 10 000) from Leuconostoc mesenteroides were 
purchased from Sigma-Aldrich (Steinheim, Germany). D(+)-Trehalose dehydrate (for 
biochemistry) was obtained from VWR (Darmstadt, Germany). Mannitol was obtained from 
Boehringer Ingelheim (Ingelheim, Germany). Rhodamine B isothiocyanate-labeled 
ovalbumin (RITC-OVA) were prepared by conjugation of Rhodamine B isothiocyanate 
(Sigmal-Aldrich, St. Louis, USA) and ovalbumin according to the instructions where the 
method is adapted from Larsson (www.piercenet.com/instructions/2162081.pdf ) [157].    
2.2 Methods 
2.2.1 Preparation of mesoporous silica nanoparticles  
The synthesis method of mesoporous silica nanoparticles (MSNP) was modified from Xia at 
al. [152]. Briefly, 1.60 g of CTAB was dissolved in a mixture of 11.20 ml of 1 mol/l NaOH 
aqueous solution and 768 ml of deionised (DI) water under stirring. The temperature of the 
solution was increased to 80 ºC within 30 min. For preparing plain MSNP nanoparticles with 
hydroxyl groups on the surface, 8.00 ml of TEOS wasadded dropwise while the solution was 
stirred at 700 rpm. After 2 hours of stirring, plain MSNP nanoparticles (MSNP-OH) were 
obtained by centrifugation and washed with ethanol o ce. For preparing MSNP nanoparticles 
with amine groups on the surface, 7.60 ml of TEOS and 0.40 ml of APTMS were mixed 
together and then added into the solution containing CTAB and NaOH at 80 ºC drop by drop 
while stirring at 700 rpm. After 15 min of stirring, 0.656 ml of APTMS was added dropwise, 
and then the complete suspension was stirred for anther 2 hours. MSNP nanoparticles with 
positive charges on the surface (MSNP-NH2) were obtained by centrifugation and washed 
with ethanol once. In order to remove CTAB, fresh prepared silica nanoparticles MSNP-OH 
and MSNP-NH2 were refluxed overnight in 160 ml of ethanol containing 8 ml of 37% (w/v) 
HCl aqueous solution and then washed with ethanol three times and water three times using 
120 ml for each time. The surfactant extracting process was repeated once. Finally, the 
nanoparticles were dried overnight at 20 ºC in a vacuum dryer. The fluorescently-labeled 
silica nanoparticles (FITC-MSNP-NH2) were prepared as described in Chapter III.  
2.2.2 Preparation of MSNP–ovalbumin conjugates 
Ovalbumin (OVA) was chemically conjugated to MSNP-OH according to a N,N'-
carbonyldiimidazole-mediated functionalization method [158]. 45 mg of MSNP-OH was 
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suspended in 3 ml of DI water under probe sonication (Bandelin UW 3200, Berlin, Germany). 
The nanoparticles were separated by centrifugation at 10000×g for 5 min, and then washed 
with anhydrous Tetrahydrofuran (THF) four times, 9 ml of THF each time. The MSNP-OH 
nanoparticles were resuspended in 9 ml of THF again under probe sonication. 450 mg of 
carbonyldiimiazole (CDI) was added into the particles suspension, and the mixture was stirred 
for 2 hours at 700 rpm at room temperature. The particles were washed with THF twice and 
subsequently with 20 ml each of ice-cold sodium phos ate buffer (PB) (100 mM, pH 8.5) 
three times within 40 min. The CDI-activated MSNP-OH was resuspended in 4.5 ml of PB 
(100 mM, pH 8.5), and then 45 mg of ovalbumin was added into the suspension. The mixture 
was stirred gently for 24 hours at 4 ºC. Finally, excess OVA was removed by washing three 
times with PB (100 mM, pH 8.5). MSNP-ovalbumin conjugates (MSNP-OVA) was obtained 
and stored at 4 ºC for subsequent use. Fourier transform infrared spectroscopy (FTIR) and 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) were used to 
characterise the conjugates.           
2.2.3 Ovalbumin loading and release from MSNP-NH2 nanoparticles 
The ovalbumin loading process was carried out as following: 50 mg/ml suspension of 
nanoparticles in sodium phosphate buffer (PB) (10 mM, pH 4.8 or 6.8) was prepared by probe 
sonicating (Bandelin UW 3200, Berlin, Germany) twice, each for 1 min (amplitude 30%, 
pulse 1s/1s). Ovalbumin was dissolved in PB (10 mM, pH 4.8 or 6.8) under occasional 
shaking. After centrifugation at 12000×g for 5 min, the supernatant was obtained as 
100 mg/ml ovalbumin stock solution. 0.5 ml of the particle suspension and specific volume of 
the stock OVA solution were mixed together. Specific volume of PB buffer (10 mM, pH 4.8 
or 6.8) was added if necessary to make the final volume for loading 1 ml in a 2-ml Eppendorf 
tube. The final ovalbumin concentrations for loading were 1, 2, 5, 10, 25 and 50 mg/ml, 
respectively while keeping the MSNP-NH2 concentration at 25 mg/ml. The 1 ml loading 
suspension in 2 ml EP tube was gently shaken at RT under 30 rpm for 4 hours. The tubes 
were centrifuged and the supernatants were removed. The particles were washed with PB 
(10 mM, pH 4.8 or 6.8) twice. The loaded amount was c lculated by subtracting the OVA 
concentration in supernatants from the original OVA concentration.  
 
The determination of ovalbumin release is described riefly here. 5 mg of MSNP-NH2 
nanoparticles loaded with OVA were resuspended in 1 ml ×PBS buffer (150 mM, pH 7.4) in 
2-ml EP tubes. After a specific release time, the tubes were centrifuged and 0.5 ml 
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supernatant was replaced with 0.5 ml of fresh PBS buffer. The process was repeated at each 
time point for release test. The supernatants were measured using a Nanodrop (Thermo 
Scientific, Wilmington, USA) to obtain OVA concentra ion. The amounts of accumulated 
released ovalbumin were calculated. The same process was used for all the release 
experiments in other buffers.  
2.2.4 Preparation of microparticles with nanoparticles encapsulated by spray-freeze-
drying 
50 mg/ml of MSNP-NH2 in sodium phosphate buffer (PB) (10 mM, pH 5.8) was prepared 
under probe sonication. 200 mg/ml of ovalbumin in the same PB buffer was obtained after 
removing the non-dissolvable part by centrifugation. Trehalose, mannitol, dextran (10 kDa) 
and dextran (100 kDa) (TMD) were mixed with a weight ratio of 3:3:3:1, and were then 
dissolved in sodium phosphate buffer (PB) (10 mM, pH 7.4) under stirring to obtain 35 wt% 
sugar-based solution. The TMD solution was filtered through a 0.2 µm syringe filter before 
use. TMD solution and OVA solution were mixed together by a short vortex-shaking 
(Heidolph, Schwabach, Germany) to prepare microparticles with 25 µg per 1 mg (25 µg/mg) 
of dry microparticles. MSNP-NH2 suspension and OVA solution were mixed together under 
gentle shaking for 1 hours at RT before mixed with TMD solution. MSNP-NH2/OVA mixture 
was then mixed with TMD solution by a short vortex-shaking. In the formulations, ovalbumin 
was kept at 25 µg/mg of dry sugar-based microparticles and the MSNP-NH2 amount was 
varied.  
 
The prepared formulations of TMD, OVA and MSNP-NH2 were sprayed into liquid nitrogen 
by an ultrasonic atomizing nozzle (120 kHz, Sono-Tek, Milton, USA). The power for 
spraying was set to 4.0 watts and the flow rate of peristaltic pump to 0.6 ml/min. The sprayed 
microparticles were collected in vials and transferred to a pre-cooled Christ lyophilizer 
(Martin Christ EPSILON 2-6D, Harz, Germany). The freze-drying sequence was carried out 
by 24 hours of primary drying at -10 ºC and 20 hours of secondary drying at 25 ºC. The 
chamber pressure was kept at 0.12 mbar during the whole drying process. 
2.2.5 Preparation of microparticles containing fluorescently-labeled ovalbumin by 
spray-freeze-drying 
10 mg of Rhodamine B isothiocyanate-labeled ovalbumin (RITC-OVA) and 30 mg of OVA 
were dissolved in 0.2 ml PB buffer (10mM, pH 5.8), resulting in OVA/RITC-OVA solution. 
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0.0438 ml of OVA/RITC-OVA solution and 0.0875 ml of 50 mg/ml MSNP-NH2 in PB buffer 
(10 mM, pH 5.8) were mixed. Then, 1.0 g of 35 wt% TMD solution was added into the 
mixture to prepare TMD microparticles containing MSNP-NH2 and protein with a mass ratio 
of 1/2 by the same SFD process as described previously. Similarly, TMD microparticles 
containing MSNP-NH2 and protein with a mass ratio of 1/4 were prepared.  
2.2.6 Characterisation of the nanoparticles and microparticles 
Measurements of hydrodynamic diameter and zeta-potential 
The hydrodynamic diameter and zeta-potential (ζ) were determined by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany). 
The reflective index (RI) of silica nanoparticles ued for the size measurement was 1.47 as 
suggested in the literature [159]. Before DLS measurements, the suspensions of MSNP 
nanoparticles sodium phosphate buffer were diluted to 0.25-0.5 mg/ml, which can produce 
effective signals. MSNP-NH2 loaded with OVA and MSNP-OVA conjugated were also 
measured using the same conditions.  
 
Scanning electron microscopy (SEM) 
Silica nanoparticles and sugar-based microparticles w re coated with a thin layer of carbon 
before observed using a JEOL JSM-6500F scanning electron microscopy (SEM) at 
magnifications of 18000-20000 for silica nanoparticles and 300 for microparticles. 
 
Pore size distribution and surface area 
Pore size distribution of MSNP-NH2 was determined from absorption and desorption of 
nitrogen gas using Autosorb-1 (Quantachrome, Odelzhausen, Germany). The sample was 
outgassed at 250 ºC for 36 hours before each measurement. The specific surface area and pore 
size distribution (PSD) was calculated by the Brunauer-Emmett-Teller (BET) and Barrett-
Joyner-Halenda (BJH), respectively, using the Autosorb-1 software.  
 
Measurements of particle size 
Microparticles obtained from spray-freeze-drying were suspended in Miglyol 812 (Sasol, 
Witten, Germany) under stirring. A Partica LA-950 (HORIBA, Kyoto, Japan) was used to 
measure the particle size distribution. The reflectiv  indexe (RI) of sugar-based microparticles 
is 1.530, which was approximated by the RI of the sugar (sucrose) as described in the ‘Sample 
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Dispersion & Refractive Index Guide’ from Malvern Istruments; the RI of Miglyol 812 is 
1.449 as described by the manufacturer.  
 
Confocal Laser Scanning Microscopy (CLSM) 
An invert Confocal Laser Scanning Microscope (LSM 510 META, Carl ZEISS, Germany) 
was used to observe the microparticles encapsulating fluorescent nanoparticles. Argon laser 
(488 nm) and HeNe laser (543 nm) were used as excitation wavelengths, corresponding to the 
emissions of BP 505-530 nm and LP 560 nm, respectively. Three different oil lenses were 
used, including Plan-Neofluar 40×/1.3 Oil, Plan-Apochromal 63×/1.4 Oil DIC and Plan-
Neofluar 100×/1.3 Oil Ph3. The Z-stacking mode was used to observe the distribution of 
nanoparticles in the microparticles. 3D view of Z-stacking micrographs was obtained by 
processed with projection under a Turning Axis of Y, First Angle of 180°, Number 
Projections of 16 and Difference Angle of 1°. 
 
TMD microparticles containing MSNP-NH2 and OVA/RITC-OVA were ballistically injected 
into a gelatin film and pig skin by a custom-made device. The distribution and depths of 
fluorescent microparticles in model skin and pig skin after injection were determined as 
follows. 4 mg/ml of FITC-dextran in PBS (150 mM, pH 7.4) was prepared and then glycerol 
was added into the solution to obtain 2 mg/ml FITC-dextran in solution, which was used to 
distinguish the surface of model skin or pig skin. 50% (v/v) of glycerol in the solution was 
used to increase the viscosity. A petri dish for imaging with a diameter of 35 mm and thin 
bottom (ibidi GmbH, Martinsried, Germany) was used. One drop of the FITC-dextran 
solution was added on the bottom of the petri dish, and then the model skin or pig skin was 
placed in by facing the layer with injected particles to bottom. The FITC-dextran solution fills 
the space between the bottom and the skin surface. This is particularly advantageous for 
determining rough surfaces, e.g. of biological skin samples.  
2.2.7 Ovalbumin concentration determination 
The application ‘‘Protein A280’’ of NanoDrop 2000 (Thermo Scientific, Wilmington, USA) 
was used for the determination of ovalbumin concentrations. The absorbance at 280 nm (A280) 
and OVA concentration has a very good linear correlation over a broad range between 0.02 
mg/ml and 200 mg/ml with an R2-value of 0.99993. In order to obtain a more precise 
determination of ovalbumin concentration, a standard curve between A280 and OVA 
concentration over the range of 0.5-50 mg/ml was measured to calculate the extinction 
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coefficient (E1%). E1% = 6.3 was obtained by linear fitting of the A280 and OVA concentration. 
Finally, OVA concentration (C, unit of mg/ml) was calculated as follows: 
%1
28010
E
A
C
×=        (1) 
Micro BCATM protein assay reagent kit (PIERCE, Thermo Scientific, Rockford, USA) was 
also used to confirm the results from NanoDrop and determine the amount of ovalbumin 
conjugated to MSNP-OH. Diluted albumin (BSA) standards were prepared with final BSA 
concentrations between 0.5 and 200 µg/ml. The standards and samples were measured at 562 
nm in a microplate well using a plate reader (Fluostar Omega, BMG LABTECH GmbH, 
Ortenberg, Germany). 
2.2.8 Characterisation of ovalbumin  
NuPAGE® 10% Bis-Tris precast gels (Life Technologies, Darmstadt, Germany) were used for 
SDS-PAGE. Non-reducing conditions were used and the proteins were stained with 
coomassie blue (Life Technologies, Darmstadt, Germany). Size-exclusion high-performance 
liquid chromatography (SEC-HPLC) was carried out to determine the molecular size of 
ovalbumin. A TSK-GEL® column (TOSOH BIOSCIENCE, Stuttgart, Germany) and Thermo 
Scientific System equipped with a UV1000 detector we e applied. The running buffer was 50 
mM sodium phosphate buffer (pH 7.2, 300 mM of NaCl). Data analysis was done using 
ChromQuestTM 4.1 (Thermo Scientific, Dreieich, Germany).   
2.2.9 Cellular uptake of nanoparticles by macrophages 
The cell experiments were carried out using the same method as described in Chapter III. 
Cellular uptakes of each sample were performed at 37 nd 0 ºC, respectively.   
3. Results 
3.1 Characterisation of mesoporous silica nanoparticles  
Mesoporous silica nanoparticles (MSNP) were synthesized using CTAB as the surfactant and 
NaOH as the catalyst. MSNP around 130 nm in diameter were obtained as shown by SEM 
micrographs in Figure IV-1. The plain MSNP (MSNP-OH) and cationic MSNP (MSNP-
NH2) have almost the same spherical shape and size that are close to the results by Xia et al. 
[152]. The mesopore size of MSNP-NH2 is 2.3 nm calcul ted from the BJH method, and the 
estimated specific surface area by the BET method is 1170.27 m2/g.  
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Figure IV-1. Results of mesoporous silica nanoparticle analysis. SEM micrographs of 
MSNP-OH (A), MSNP-NH2 (B) (the scale bar is 1 µm); Nitrogen physisorption isotherm (C) 
and corresponding pore size distribution of MSNP-NH2 (D). 
 
MSNP nanoparticles were dispersed in 15 mM PBS (pH 6.2) and DLS measurements were 
carried out. As shown in Table IV-1, MSNP-NH2 particles have a hydrodynamic size of 111
nm which is consistent with the results from the SEM observation. The cationic MSNP-NH2 
particles have a positive charge on the surface at pH 6.2, while plain MSNP-OH have a 
slightly negative surface. The Z-average size of MSNP-OH is much larger than that from the 
SEM micrograph, which indicates the aggregation due to the ζ-potential (-5.5 mV) which is 
close to neutrality. The positive surface of MSNP-NH2 enables the particles to be a possible 
delivery system for negatively charged drugs or antige  as absorption of negatively charged 
antigens may take place due to electrostatic interac ions. [152].   
Table IV-1 Size distribution of MSNP in 15 mM PBS (pH 6.2) buffer 
Silica nanoparticles Z-Ave (nm) PDI ζ-potential (mv) 
MSNP-NH2 111 0.244 30.8 
MSNP-OH 670 0.510 -5.5 
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3.2 Conjugation of mesoporous silica nanoparticles with ovalbumin 
Ovalbumin was considered to be conjugated to MSNP as this method has already been proved 
effective for vaccine delivery [81]. We used the same method for the conjugation of OVA 
onto inorganic nanoparticles as the one developed by Ho, et al. [158]. OVA was successfully 
conjugated to MSNP-OH as shown by SDS-PAGE and FTIR results (Figure IV-2). SDS-
PAGE was performed to determine if the conjugation of ovalbumin onto silica nanoparticles 
was successful or not. From lane 4 and lane 10 in Figure IV-2, there is no OVA band as 
obviously all OVA was chemically bound to MSNP, but a narrow blue band can be seen at 
the starting points. For physically absorbed OVA on silica, OVA bands (lane 6 and lane 12) 
are very clear. MSNP-OH was used as a control showing no protein bands. For FTIR 
measurements (Figure IV-2B), MSNP-OVA and MSNP-NH2 with physically adsorbed OVA 
(MSNP-NH2/OVA) were washed with sufficient DI water. As expected, physically adsorbed 
OVA has been washed away, and as a result no OVA signal  were detectable in Figure IV-
2B. The curve of MSNP-OVA shows distinct signals (as annotated with an arrow) resulted 
from OVA.  
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Figure IV-2. Conjugates of MSNP-ovalbumin. (A) SDS-PAGE of ovalbumin at different 
conditions. From right to left (lane 1-12), they are marker (lane 1), OVA control (lane 2), 
supernatant after conjugated onto silica nanoparticles (lane 3), conjugation of MSNP-OH and 
OVA (lane 4), MSNP-OH particles (lane 5), MSNP-NH2 with physically adsorbed OVA 
(lane 6), marker (lane 7), OVA control (lane 8), supernatant after conjugated onto silica 
nanoparticles (lane 9), conjugation of MSNP-OH and OVA (lane 10), MSNP-OH particles 
(lane 11) and MSNP-NH2 with physically adsorbed OVA (lane 12), respectively. (B) FT-IR 
spectra of (a) ovalbumin, (b) MSNP-ovalbumin conjugates, (c) pure MSNP-OH, (d) MSNP-
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OH absorbed with ovalbumin physically and washed with adequate buffer. (Transmission 
mode of FT-IR-microscope)  
3.3 Ovalbumin (OVA) loading on the silica nanoparticles and release tests 
BSA loading on silica nanoparticles and release behaviour have been investigated by Want et 
al. [99], aiming to use them as an oral vaccine adjuvant. It is necessary to study loading 
capacity of OVA on MSNP and release behaviour before this type of delivery system can be 
used in the formulation of microparticles. The effect of loading time was investigated from 
four hours to three days. No further increase in OVA loading was observed for loading times 
longer than 4 hours. Thus 4 hours was kept as the loading time. The effect of the pH on 
loading was studied as shown in Table IV-2. A larger amount of OVA can be loaded on 
MSNP-NH2 at PB loading buffer with a lower pH. The ydrodynamic sizes of silica 
nanoparticles and OVA-loaded ones are very dependent on the zeta-potentials. All protein 
loaded particles are aggregated except MSNP-NH2 at pH 6.8, which are already aggregated 
before loading. Thus, the loading was only achieved with aggregates.   
 
Table IV-2 The effect of pH on ovalbumin loading capacity 
 
OVA concentration is another important factor affecting loading amounts and loading 
efficiencies, as shown in Table IV-3 and Figure IV-3. The amount of OVA loaded on 
MSNP-NH2 increases with the increasing concentration of OVA for loading, while the 
efficiency decreases. As antigens for vaccination are usually expensive, it is necessary to 
balance loading amount and efficiency.  
 
Table IV-3 Ovalbumin loading on silica nanoparticles in different concentrations of OVA 
OVA Concentration (mg/ml) 1.0 2.0 5.0 10.0 25.0 
Loaded OVA (mg/mg) 0.028±0.002 0.057±0.003 0.117±0.002 0.168±0.006 0.218±0.037 
Loading efficiency (%) 71 71 58 41 22 
Before loading After loading 
Sample 
PB 
Buffer 
Z-Ave 
(nm) 
PDI Ζ (mv) 
Z-Ave 
(nm) 
PDI Ζ (mv) 
Loading capacity 
(mg/mg) 
MSNP-NH2 pH = 4.8 88 0.278 29.0 1129 0.273 -3.5 0.37±0.05 
MSNP-NH2 pH = 6.8 746 0.297 13.2 710 0.382 -14.4 0.30±0.01 
MSNP-OH pH = 4.8 181 0.345 -4.9 1856 0.429 -7.4 0.18±0.02 
MSNP-OH pH = 6.8 110 0.227 -17.7 249 0.305 -17.6 0.12±0.01 
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Figure IV-3. Effect of OVA concentration on the loading amount o  silica nanoparticles and 
loading efficiency.  
 
The release tests were carried out in PBS (150 mM, pH 7.4) which is a commonly used buffer 
simulating the physiological environment in humans. MSNP-NH2 particles loaded with OVA 
at 10 mg/ml were used for release tests in Figure IV-4A , while the same nanoparticles in 
Figure IV-4B were loaded at 25 mg/ml of OVA. All particles show a distinct burst effect 
during the first few hours of the release. Different frequencies for refreshing release buffer 
have been tested in order to study the effect of sampling time on the release. As we can see 
from Figure IV-4, fast release was observed when changing the release buffer at a shorter 
time span (2 hours compared 24 hours at the beginning stage). In other words, the speed of 
OVA release from MSNP-NH2 depends on the distribution of OVA in the liquid phase. The 
release tests were also carried out in different buffers such as 1×PBS (150 mM, pH 7.4), 
1×PBS (150 mM, pH 9.8), 10×PBS (1500 mM, pH 7.4) and 10×PBS (1500 mM, pH 9.8). It is 
not surprising that fast release of OVA in the release buffers with higher pH and higher ionic 
strength considering the main interaction force betwe n OVA and MSNP-NH2 is electrostatic 
attraction. Therefore, the OVA release is just controlled by the displacement from 
electrostatic bindings by salt and no sustained release was observed.  
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Figure IV-4. OVA release from the OVA-loaded silica particles. (A) OVA release in 1×PBS 
buffer (pH 7.4); (B) Effect of pH and ionic strength on OVA release behaviour. 
3.4 Sugar-based microparticles encapsulating model antigens and nanoparticles 
Before using the MSNP-NH2 in the formulation for pre aring microparticles, it is necessary 
to investigate the stability of MSNP-NH2 before and after loading with OVA in the sugar-
based matrix. Aggregation of silica nanoparticles is a major challenge for the application. 
Much effort was put to minimize the aggregation tend cy of MSNP-NH2 for OVA delivery. 
MSNP-NH2 particles dispersed in PB buffer (10 mM, pH 4.8) have no aggregation before 
loading OVA, but MSNP-NH2/OVA particles at pH 4.8 show big aggregates. Moreover, this 
pH (4.8) is too close to isoelectric point (pI = 4.5 or 4.9) as specified in the product 
information that may result in the tendency of OVA precipitation. At a pH 6.8, MSNP-NH2 
particles show aggregation before loading OVA, even though the size of OVA-loaded MSNP-
NH2 does not increase more. As a compromise, PB (10 mM, pH 5.8) was chosen. Different 
amounts of OVA were mixed with specific amounts of MSNP-NH2 in PB (10 mM, pH 5.8), 
and then DLS measurements were carried out after the samples were diluted with PB buffer 
(10 mM, pH 5.8). As depicted in Table IV-4, the hydrodynamic sizes increase when MSNP-
NH2 nanoparticles were mixed with OVA. The aggregation is very distinct for MSNP-
NH2/OVA mixtures with mass ratios of 4/1, 2/1 and 1/1. In the mixture of MSNP-NH2/OVA 
= 1/2 and 1/4, the sizes were increased from 116 nm to 472 nm and 187 nm, respectively, 
after mixing for 24 h. Therefore, the mass ratios of MSNP-NH2/OVA = 1/2 and 1/4 were 
used in the next formulation of TMD, OVA and MSNP-NH2. Higher stability of the mixtures 
MSNP/OVA = 1/2 and 1/4 was also observed from the optical images (data not shown). 
Similar results were obtained when TMD dissolved in PB (10 mM, pH 7.4) was added (data 
not shown). The formulations with MSNP-NH2/OVA = 1/2 and 1/4 were investigated further.  
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Table IV-4 Effect of OVA on the colloidal stability of MSNP-NH2 
Fresh mixture  Mixture after 24h Sample 
Z-Ave (nm) PDI ζ (mv) Z-Ave (nm) PDI ζ (mv) 
MSNP-NH2 116 0.259 22.8 128 0.290 19.2 
MSNP-NH2/OVA = 4/1 1800 0.352 -9.1 1007 0.303 -9.3 
MSNP-NH2/OVA = 2/1 1049 0.236 -9.4 870 0.386 -11.0 
MSNP-NH2/OVA = 1/1 772 0.208 -12.2 1180 0.279 -11.7 
MSNP-NH2/OVA = 1/2 243 0.344 -12.0 472 0.340 -12.0 
MSNP-NH2/OVA = 1/4 171 0.335 -11.6 187 0.374 -12.5 
The samples were diluted to about 0.2 mg/ml of particles with PB buffer (10 mM, pH 5.8) for 
DLS measurements.  
 
The effect of TMD on the size of MSNP-NH2/OVA particles was also studied. 5 mg/ml of 
silica nanoparticles and 20 mg/ml of ovalbumin in PB buffer (10 mM, 5.8) were used to 
prepare the mixture. Considering the situation for using MSNP-NH2/OVA in the TMD 
formulation, the mixtures of TMD, OVA and MSNP-NH2 were prepared by keeping constant 
OVA contents at 25 µg per 1 mg of absolute TMD mass. OVA can be loaded onto MSNP-
NH2 at pH 5.8 and the OVA-loaded particles are supposed to be used at a physiological pH 
(7.4). Thus each formulation was diluted in PB buffer (10 mM, pH 7.4) for DLS 
measurements (Table IV-5). MSNP-NH2 was mixed with OVA for 4 hours under gentle 
shaking, and then the MSNP-NH2/OVA was mixed with TMD solution. After a short vortex-
shaking, the formulations of TMD and MSNP-NH2/OVA were diluted in PB (10 mM, pH 
7.4) for DLS measurements. As shown in Table IV-5, the sizes of the MSNP-NH2/OVA do 
not change when the OVA loaded nanoparticles are mixed with TMD solution, while the 
PDIs increase. The zeta-potentials were maintained during the mixing of MSNP-NH2/OVA 
and TMD. Thus TMD matrices containing MSNP-NH2/OVA (1/2 and 1/4) are acceptable for 
preparing TMD-based nano-in-micro particles.   
 
Table IV-5 Effect of TMD solution on the the stability of MSNP-NH2 
Before TMD mixing After TMD mixing 
Sample 
Z-Ave (nm) PDI ζ (mv) Z-Ave (nm) PDI ζ (mv) 
MSNP-NH2 2194 0.242 8.5 1763 0.433 5.4 
OVA 21 0.534 -8.3 24 0.589 -8.1 
MSNP-NH2/OVA = 1/2 709 0.125 -13.3 529 0.332 -12.9 
MSNP-NH2/OVA = 1/4 448 0.211 -12.9 431 0.492 -15.5 
The samples were diluted to about 0.2 mg/ml of particles with PB buffer (10 mM, pH 7.4) for 
DLS measurements. 
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The colloidal stability of nanoparticles is limited by the properties of the nanoparticles and the 
media for suspension. To increase the long-term stability on storage is one of the reasons we 
incorporate the silica nanoparticles into formulations of dry microparticles. Spray-freeze-
drying (SFD) is a promising method for the preparation of microparticles for ballistic delivery 
[106-109]. The main concern of SFD methods is to obtain dense (non-porous) microparticles 
with strong mechanical stability for bombardment on skin. Several formulations (Table IV-6 ) 
were prepared. The SEM results are shown in Figure IV-5. Most of the microparticles were 
in the size range between 20 µm and 40 µm, and are well suitable for powder injection. Some 
parameters of the microparticles are shown in Table IV-6. The span of particle size 
determined by laser diffraction is close to 1.0, indicating a narrow size distribution. 
TMD/MSNP-NH2/OVA (S1), TMD/MSNP-NH2/OVA (S2) and TMD/OVA (S3) correspond 
to the TMD formulations containing MSNP-NH2/OVA (1/2), MSNP-NH2/OVA (1/4) and 
free OVA without nanoparticles (25 µg/mg), respectively. 
 
  
  
Figure IV-5. SEM micrographs of sugar-based microparticles by SFD. (A) TMD; (B) 
TMD/OVA (S3); (C) TMD/MSNP-NH2/OVA (S1); (D) TMD/MSNP-OVA. The scale bar is 
10 µm.  
 
A 
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D 
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Table IV-6 Results of microparticles prepared by spray-freeze-drying 
Formulation 
OVA 
(µg/mg) 
MSNP-NH2 
(µg/mg) 
Median Size 
(µm) 
Span 
Tap density 
(mg/ml) 
Residual 
water (%) 
TMD/MSNP-
NH2/OVA (S1) 
25 12.5 43.47 0.902 533±23 0.25±0.04 
TMD/MSNP-
NH2/OVA (S2) 
25 6.25 42.35 0.775 580±17 0.23±0.05 
TMD/OVA (S3) 25 0 43.92 0.87 583±80 0.26±0.07 
 
It is necessary to investigate the nanoparticle sizafter a resuspension of the microparticles. 
The SFD microparticles were dissolved in sodium phos ate buffer (10 mM, pH 7.4) before 
DLS measurements. The MSNP-NH2 physically coated with OVA in the TMD formulation 
before spray-freeze-drying process have hydrodynamic sizes of 681 nm (PDI = 0.204) and 
307 nm (PDI = 0.250) for MSNP-NH2/OVA = 1/2 and 1/4 (Table IV-7), respectively. After 
re-dissolution in the buffer, the apparent particle sizes decrease to 139 nm (PDI = 0.281) for 
MSNP-NH2/OVA = 1/2 and 118 nm (PDI = 0.258) for MSNP-NH2/OVA = 1/4. It indicates 
that SFD process seems to disaggregate MSNP-NH2/OVA nanoparticles. The MSNP-NH2 
particles in the re-suspensions of both TMD/MSNP-NH2/OVA microparticles have negative 
zeta-potentials, indicating that at least a major part of loaded OVA is still attached to the 
surface of the silica nanopartilces.  
 
Table IV-7 Stability of MSNP-NH2 in the sugar-based SFD microparticles 
Suspension before SFD Re-suspended after SFD 
Sample 
Z-Ave (nm) PDI ζ (mv) Z-Ave (nm) PDI ζ (mv) 
MSNP-NH2 1398 0.276 6.8 2550 1.000 0.5 
TMD/MSNP-NH2/OVA (S1) 681 0.204 -15.4 139 0.281 -17.2 
TMD/MSNP-NH2/OVA (S2) 307 0.250 -16.8 118 0.258 -15.5 
TMD/OVA (S3) 18 0.574 -7.7 21 0.548 -16.3 
Samples were resuspended in PB (10 mM, pH 7.4) for DLS measurements. 
 
The ovalbumin released from the dissolution of SFD microparticles was analysed using SDS-
PAGE and SEC-HPLC (Figure IV-7). The bands of the SDS-PAGE indicate that the 
recovered ovalbumin samples from SFD microparticles show no difference to the ovalbumin 
control. The major band locates between 36.5 kDa and 55.4 kDa, consistent with the 
specification (~43 kDa) of the producer. Another band located between 66.3 kDa and 97.4 
kDa represents the dimers of ovalbumin, which was confirmed by the SEC results (Figure 
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IV-6 ). There are no obvious bands for additional fragments or oligomers. As seen in Figure 
IV-7B , the ovalbumin monomer contents in different formulations are almost the same, 
indicating that there is no harmful stress during the SFD process in the formulations.    
 
 
Figure IV-6. SEC-HPLC spectrum of ovalbumin recovered from the TMD/MSNP-
NH2/OVA (S1) microparticles.  
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Figure IV-7. Characterisation of ovalbumin in the microparticles. (A) SDS-PAGE of the 
released ovalbumin formulated in TMD microparticles; (B) Monomer contents of ovalbumin 
obtained from SEC results. Lane 1 is the Mark12TM(Invitrogen); lanes (2, 5, 8) and lanes (3, 6, 
9) correspond to the ovalbumin in the formulation of TMD/MSNP-NH2/OVA (S1) and 
TMD/MSNP-NH2/OVA (S2), respectively; lane 11 represents formulation of MSNP-NH2 
and TMD; lane 12 represents ovalbumin as a control. Three repeats were carried out.    
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3.5 Epidermal powder injection of the microparticles on model skin and pig skin 
Rhodamine B isothiocyanate labeled ovalbumin (RITC-OVA) was added to the formulations 
of microparticles containing MSNP-NH2 to visualise the distribution of the added antigen. 
Both of the formulations containing MSNP-NH2 and without MSNP-NH2 were prepared. 
20% of the antigen of the formulations was replaced by RITC-OVA. The fluorescence is 
strong enough to allow observation of the particles. RITC-OVA is evenly dispersed in the 
TMD/MSNP-NH2/OVA formulation (Figure IV-8A ) and the 3D view shows the shrinking 
on the surface (Figure IV-8B). As for the formulation without MSNP-NH2, the distr bution 
of RITC-OVA is also very good and the surface of microparticles wrinkles as shown in 
Figure IV-8 (C, D). These microparticles were used for powder injection, enabling 
observation of depth and distribution by CLSM.    
 
  
  
Figure IV-8. CLSM micrographs of fluorescent microparticles. (A) Single scan of TMD 
microparticles containing MSNP-NH2/(OVA/RITC-OVA) (1/2); (B) Single scan of TMD 
microparticles containing OVA/RITC-OVA; (C) 3D view of Z-stacking micrographs of TMD 
microparticles containing MSNP-NH2/(OVA/RITC-OVA) (1/2); (D) 3D view of Z-stacking 
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micrographs of TMD microparticles containing OVA/RITC-OVA. The objective of Plan-
Apochromal 63×/1.4 Oil DIC was used. The scale bar is 20 µm.   
 
The injection of the microparticles into a gelatin f lm skin model (see Chapter II) with a 
gelatin/glycerol (gel/gly) mass ration of 4/6 and pig abdominal skin was carried out by using a 
custom-made device developed by Dr. Lell (Pyroglobe GmbH, Hettenshausen, Germany). 
The gelatin film or pig skin surface was labeled by putting a drop of FITC-dextran solution 
onto the surface showing green colour as seen in Figure IV-9. The position and depth of 
injected particles could then be simply determined as the position of the surface is defined by 
the FITC-dextran solution. The gelatin film has a smooth surface as the interface between 
green and black areas is linear. Parts of TMD micropa ticles have penetrated in the gelatin 
film, while the shape of the injected particles is preserved as spheres. As for the pig skin, the 
surface is very rough that can be told from the intrface of green and black parts in Figure 
IV-9B. The TMD microparticles dissolved, leaving the diffusion of OVA into the pig skin. 
The depths of injected TMD microparticles in the gelatin film and pig skin are quite similar. 
The penetration is not as deep as expected probably due to the too low velocity (about 250 
m/s) because model polystyrene (PS) microparticles (42 µm in diameter) did not penetrate 
better under the same conditions for delivery. More work on the optimization of the device 
was needed at that point of the device development.      
 
  
A B 
Figure IV-9. Orthogonal sections of Z-stacking micrographs of the microparticles injected 
into gelatin films (gel/gly = 4/6) (A) and pig abdominal skin (B). TMD microparticles 
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containing MSNP-NH2 and OVA/RITC-OVA were used. Red r prents RITC-OVA and green 
represents FITC-dextran.  
3.6 Cellular uptake of ovalbumin-loaded silica nanoparticles  
Cellular uptake of antigens is very important for the process of presentation of the antigen to 
induce immune response. As an initial test, ovalbumin-loaded silica nanoparticles in the TMD 
matrix were incubated together with macrophages to study particle uptake. The cell nuclei are 
stained by 4′,6-Diamidino-2-phenylindole (DAPI) showing blue fluorescence under excitation 
of 364 nm. The substance delivered into the cells should be close to the blue nuclei. The 
cellular uptake results of fluorescently-labeled OVA or silica nanoparticles (Table IV-8) by 
macrophages at 37 ºC are shown in F gure IV-10. For samples A, B and C, the solutions 
were obtained by redissolution of TMD microparticles in PB (10 mM, pH 7.4). For sample D,
RITC-OVA was loaded on MSNP-NH2 at a mass ratio of 1/10 firstly in HPW and the loaded 
particles were then added into TMD in PB (10 mM, pH 7.4). For sample E, it was prepared as 
sample D, but no TMD was used.  
 
Table IV-8 Summary of the samples for cellular uptake by macrophages 
Sample  Particle Con. RITC-OVA Con. 
A: resuspension of TMD/MSNP-NH2/OVA/RITC-OVA 1.0 mg/ml 1.0 mg/ml 
B: redissolution of TMD/OVA/RITC-OVA 0 1.0 mg/ml 
C: resuspension of TMD/FITC-MSNP-NH2 0.2 mg/ml 0 
D: suspension of MSNP-NH2/RITC-OVA (10/1) + TMD 1.2 mg/ml  0.12 mg/ml 
E: suspension of MSNP-NH2/RITC-OVA (10/1) without TMD 1.2 mg/ml 0.12 mg/ml 
10 µl of solution was added to macrophages and then incubated for one hour at 37 or 0 ºC. 
 
RITC-OVA loaded on MSNP-NH2 particles recovered from TMD microparticles was 
delivered into the cells (Figure IV-10A). On the contrary, RITC-OVA recovered from TMD 
microparticles was not sufficiently taken up by macrophages (Figure IV-10B). FITC-labeled 
MSNP-NH2 (FITC-MSNP-NH2) alone resuspended from TMD microparticles can penetrate 
into macrophages (Figure IV-10C). The MSNP-NH2/RITC-OVA (10/1) in TMD solution 
(Figure IV-10D) can be delivered into macrophages, but the amount of delivered RITC-OVA 
is low. Almost no RITC-OVA was observed in macrophages for MSNP-NH2/RITC-OVA 
(10/1) particles in solution without TMD (Figure IV-10E). The RITC-OVA amount in 
samples D and E is much lower than in sample A, which could explain much less RITC-OVA 
was found in macrophages treated with sample D and E compared to sample A. In a word, it 
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is reasonable to conclude that cellular uptake of OVA by macrophages can be enhanced by 
MSNP-NH2 nanoparticles.  
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Figure IV-10. Uptake of fluorescent substances by macrophage cells at 37 ºC. (A) incubated 
in resuspension of TMD microparticles containing MSNP-NH2/OVA/RITC-OVA; (B) 
incubated in redissolution (1 mg/ml of RITC) of TMD microparticles containing OVA/RITC-
OVA; (C) incubated in FITC-MSNP-NH2 nanoparticles resuspenion; (D) incubated in a 
mixed solution of MSNP-NH2/RITC-OVA (10/1) and TMD in HPW; (E) incubated in 
MSNP-NH2/RITC-OVA (10/1) solution without TMD; (F) incubated in PB (10 mM, pH 7.4) 
as a negative control. Green indicates FITC-MSNP, red indicates RITC-OVA and blue 
indicates cell nuclei. The scale bar is 10 µm.     
 
Each sample described in Table IV-8 was also used for macrophage uptake at 0 ºC (Figure 
IV-11). The RITC-OVA loaded on MSNP-NH2 in TMD particles was taken up by 
macrophages at 0 ºC (Figure IV-11A), while no RITC-OVA was found in the formulation 
without MSNP-NH2 (Figure IV-11B). Very weak signals were observed for MSNP-
NH2/RITC-OVA (10/1) in TMD solution (Figure IV-11D) and there are almost no signals 
for the MSNP-NH2/RITC-OVA (10/1) suspension without TMD (Figure IV-11E). No 
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signals were observed for the in PB (10 mM, pH 7.4) as a negative control. Less RITC-OVA 
was found in macrophages at 0 ºC than at 37 ºC (Figure IV-10A and Figure IV-11A). It 
indicates that OVA absorbed on silica nanoparticles are taken up by macrophages at passive 
and active modes. For FITC-MSNP-NH2 without protein, both passive and active modes 
were found for cellular uptake (Figure IV-10C and Figure IV-11C).   
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Figure IV-11. Uptake of fluorescent substances by macrophage cells at 0 ºC. (A) incubated in 
resuspension of TMD microparticles containing MSNP-H2/OVA/RITC-OVA; (B) 
incubated in redissolution of TMD microparticles containing OVA/RITC-OVA; (C) 
incubated in FITC-MSNP-NH2 nanoparticles resuspension; (D) incubated in a mixed solution 
of MSNP-NH2/RITC-OVA (10/1) and TMD in HPW; (E) incubated in MSNP-NH2/RITC-
OVA (10/1) solution without TMD; (F) incubated in PB (10 mM, pH 7.4) as a negative 
control. Green indicates MSNP-FITC, red indicates RITC-OVA and blue indicates cell nuclei. 
The scale bar is 10 µm.    
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4. Discussion 
4.1 Nanoparticles in microparticles (nano-in-micro) for epidermal powder immunisation 
Mesoporous silica nanoparticles with positively charged surface are coated by negatively 
charged ovalbumin, and then they are encapsulated in sugar-based microparticles. After 
powder injection into skin, the matrix of the microparticles is dissolved and nanoparticles and 
antigens are released. The released antigens can then be processed and presented by LCs.   
In a first experimental setup, rhodamine B labeled polystyrene (PS-RhB) nanoparticles as 
model nanoparticles were formulated into TMD microparticles by spray-freeze-drying. The 
PS nanoparticles were well formulated in the sugar-based matrix (Figure III-5  in Chapter III) 
by a simple mixing method. This method for preparation of nano-in-micro systems also works 
for silica nanoparticles. The small hydrodynamic size of MSNP-NH2/OVA in TMD 
microparticles after resuspended (Table IV-7) from the microparticles indicates that they are 
well dispersed in the sugar-based matrix.         
4.2 Silica nanoparticles for vaccine delivery 
Silica nanoparticles show positive results as a novel adjuvant [98, 99], promoting us to use it 
as an antigen delivery system. Considering that the model antigen we are using is negatively 
charged, the mesoporous silica nanoparticles with positively charged surface (130 nm, ζ = 
+22.8 mv at pH of 5.8) have been chosen. Ovalbumin is too large to enter into the pores, but it 
can be absorbed on the surface. The plain MSNP has a negatively charged surface and only 
adsorbed very small amounts of OVA. The loading capa ity of MSNP-NH2 is larger at pH of 
4.8 than that at pH of 6.8 because the zeta-potential at pH of 4.8 is more positive. More 
ovalbumin could be loaded onto MSNP-NH2 when higher concentration of OVA solution 
was used, while the loading efficiency decreased with the increasing of OVA concentration 
(Table IV-3). The release of ovalbumin is very fast due to that e main interaction force is 
electrostatic attraction. This is also the reason why the release is even faster at higher pH and 
higher concentration of PBS (Figure IV-4) because high pH would decrease the zeta-
potential of MSNP-NH2 and high ionic strength would shield the electrostatic interaction to 
some degree. As an alternative to silica nanoparticles with physically absorbed ovalbumin, 
ovalbumin was chemically conjugated to the silica nanoparticles by other authors. MSNP-
OVA may induce better immune response when processed by LCs as particulate systems 
could be more easily recognised as dangerous signal [81].    
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MSNP-NH2 has a positive zeta-potential (+22.8 mv) in PB (10 mM, pH 5.8) making a well 
dispersed suspension. The zeta-potential becomes close to neutral when more and more 
ovalbumin is adsorbed to the surface and thereby the aggregation propensity is increased. The 
aggregation is expectedly high when less ovalbumin is used, as in the case of MSNP-
NH2/OVA mixtures with mass ratios of 4/1 and 2/1 (Table IV-4). In this circumstance, 
ovalbumin may act like a glue to bind MSNP-NH2 together. The aggregation problem can be 
minimized by increasing the amount of OVA relative to MSNP-NH2, as in the case of 
MSNP-NH2/OVA mixtures with mass ratios of 1/2 and 1/4 (Table IV-4). On the other hand, 
a centrifugation process needs to be avoided not to increase amount of the aggregates further. 
That is why MSNP-NH2 and ovalbumin were mixed directly and formulated together into 
sugar-based microparticles without removing the free ovalbumin. Actually, the excessive 
amount of ovalbumin can ensure the particles are entirely surrounded by OVA. It may 
increase the stability of MSNP-NH2/OVA as a protection layer surrounding the particles is 
formed. The mixing of MSNP-NH2/OVA and TMD has no obvious effect on the size but 
increases the PDI (Table IV-5). Interestingly, the MSNP-NH2/OVA resuspended from the 
SFD microparticles have smaller sizes (~130 nm) (Table IV-7) than MSNP-NH2/OVA and 
TMD in solution before SFD (~450 nm) (Table IV-5). OVA is still absorbed on MSNP-NH2 
as the zeta-potential of the particles in redissolution of the TMD microparticles is negative (-
16 mv). It seems that spray-freeze-drying process can improve the stability of MSNP-
NH2/OVA in the formulation.  
4.3 Microparticles with encapsulated silica nanoparticles and ovalbumin meeting the 
requirements for epidermal powder immunisation 
The matrix of trehalose, mannitol and dextran is water soluble so that the microparticles can 
be dissolved after EPI delivery into skin. The ovalbumin and MSNP-NH2 can be released like 
‘‘sub-bullets’’ as shown in the schematic diagram (Figure III-1  in Chapter III). This matrix 
has already shown the ability of stabilizing protein structures and functions [106, 107, 109]. 
The same fact was observed in our formulations, as indicated from the SDS-PAGE and SEC 
results of recovered ovalbumin. Furthermore, the low water residue (around 0.25 wt%) in the 
formulations (Table IV-6) could increase the storage stability in a long-term period. As 
elucidated by the mechanisms of particle impact on ski using a theoretical model, particle 
impact parameter ρνr (unit in kg/m·s, ρ is the density of particles, ν is the particle impact 
velocity, r is the radius of particles) determines the penetration [12], estimated 7 kg/m·s as a 
threshold for breaching the stratum corneum. Most of the microparticles we prepared have 
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diameters around 40 µm and tap density around 580 mg/ml. ρνr can be calculated as 8.7 
kg/m·s assuming the speed of the microparticles is 750 m/s.  
 parameterImpact γυρ ××=     (2) 
The microparticles are expected to breach the stratum corneum of skin as the impact 
parameter (8.7 kg/m·s) is larger than the threshold (7 kg/m·s). Once the skin barrier is 
breached, the antigens and silica nanoparticles can be dissolved and diffuse into the viable 
epidermis.  
 
The shrinkage of the particles during drying as seen from the SEM micrographs is very 
important for increasing the density and mechanical robustness. In order to increase the 
density of microparticles, high concentration of TMD (35.0 wt%) was used to prepare the 
formulations for spray-freeze-drying. The cause of the shrinking was attributed to the plastic 
flow of the TMD phase when the shelf temperature (Ts = -10 ºC) for primary freeze-drying 
exceeds the glass transition temperature (Tg’) of the frozen SFD microparticles [132]. As seen 
in Figure IV-5, the TMD without ovalbumin shows more obvious shrinkage compared to the 
formulations containing ovalbumin, indicating that added ovalbumin could increase the Tg’. 
Increasing the temperature for primary freeze-drying can increase the degree of shrinkage, but 
may result in collapse of the product that is not good for the flowability of the microparticles.   
4.4 Antigen-loaded nano-in-micro particles for epidermal powder immunisation 
The encapsulation of ovalbumin and MSNP-NH2 nanoparticles in TMD microparticles is 
very efficient as proved by observing the formulations containing RITC-OVA. The 
fluorescence intensity of RITC-OVA is so strong that the surface of microparticles is clearly 
imaged.  
 
The TMD microparticles containing RITC-OVA have been accelerated to penetrate gelatin 
films and pig skin by our custom-made device, but the penetration depth is still too low. The 
same result has been obtained when using PS microparticles by the same device. Therefore, 
the insufficient penetration of TMD microparticles may result from the velocity of the 
accelerated particles, which is not high enough due to the limitation of the device at that 
moment. The optimisation of the device is still going on, and progress is expected in the short 
term. Due to the high water content in pig skin, the TMD microparticles were dissolved after 
injection. This is useful especially when the sudden p netration is not as deep as required. If 
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the stratum corneum (about 15 µm for human skin) could be penetrated, the ovalbumin ay 
diffuse deep itself because the main biological barrier has already been broken. 
 
Ovalbumin has been delivered into macrophage cells at 37 and 0 ºC with the assistance of 
MSNP-NH2 in one hour as indicated in Figure IV-10. More RITC-OVA in the TMD/MSNP-
NH2/OVA/RITC-OVA formulation was delivered into macrophages at 37 ºC than at 4 ºC, 
indicating that active uptake exists. On the other and, RITC-OVA was also taken up with 
MSNP-NH2 in the TMD matrix by macrophages at 0 ºC. It means that a passive mode is also 
the route for uptake by macrophages. For FITC-MSNP-NH2 nanoparticles without protein, 
they have also been taken up by macrophages at both passive and active modes. Therefore, 
silica nanoparticles play a major role in enhancing the cellular delivery of ovalbumin. In fact, 
silica nanoparticles helping to deliver macromolecus into cells was also found by others 
[152]. These results support the idea of using silica nanoparticles for vaccine delivery in the 
TMD microparticles for EPI.  
5. Conclusion 
Cationic mesoporous silica nanoparticles have been pr pared as a vaccine delivery system. 
Negatively charged antigens such as ovalbumin can be loaded on the surface through 
electrostatic interactions. The release of ovalbumin is mainly a displacement process from 
electrostatic bindings by salt, depending on the elimination speed of ovalbumin, the pH and 
ionic strength of solution. Ovalbumin and MSNP-NH2 have been formulated in sugar-based 
microparticles that are suitable for epidermal powder immunisation. The silica nanoparticles 
resuspended from the spray-freeze-dried (SFD) microparticles show a hydrodynamic size 
close to the actual size, indicating that the sugar matrix can stop the aggregation of 
nanoparticles when they are dried. In the redissolution of TMD microparticles containing 
MSNP-NH2/OVA, OVA is still coated on the surface of MSNP-NH2 as the zeta-potential is 
negative. The ovalbumin recovered from the microparticles maintains the integrity as well. 
Therefore, nanoparticles-in-microparticles (nano-in-micro) systems, combining the 
advantages of nanoparticles for vaccine delivery and the method of needle-free epidermal 
powder immunisation, can be prepared by spray-freeze-drying and used for EPI.  
 
In the present study, silica nanoparticles and TMD matrix were used to prepare the 
microparticles for epidermal powder immunisation. I fact, the nano-in-micro idea is not 
limited to the materials used in this study. Other nanoparticles for vaccine delivery and matrix 
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materials can be chosen to obtain the nano-in-micro microparticles which can release antigens 
in an appropriate timeline. In a word, this method gives the possibility to deliver 
nanoparticulate vaccine delivery systems and adjuvants via ballistic delivery into skin. 
 
Chapter V. Formulation of H1N1 Hemagglutinin and Silica 
Nanoparticles in Sugar-based Microparticles 
 
1. Objectives 
As described in Chapter IV, cationic mesoporous silica nanoparticles (MSNP-NH2) have 
been successfully used for a model antigen, ovalbumin (OVA), in the sugar-based 
microparticles made of trehalose, mannitol, dextan (9-10 kDa) and dextran (100 kDa) (TMD). 
The TMD microparticles encapsulating OVA and MSNP-NH2 particles have a size range of 
10-40 µm, mainly of 20-30 µm. They are suitable for epidermal powder immunisation (EPI). 
The stability of the nanoparticles and OVA in the formulation of microparticles has been 
proved to be good. Ovalbumin is a good model antige for studying the formulation and 
immune response, but it is more stable than some real protein antigens such as influenza 
hemagglutinin [160, 161]. The formulation stabilising OVA must not necessarily be 
applicable to some real antigens.  
 
Influenza vaccines are the most popular and extensiv ly used in the world. The occurrence of 
influenza is impossible to predict, thus a large amount of influenza vaccines needs to be 
formulated, produced, and reserved every year in case it happens. Until now, the influenza 
vaccines on the market are all liquid formulations, leading to some disadvantages such as 
cold-chain transportation and storage, short shelf lif , etc. [162-164]. For example, influenza 
subunit vaccine showed a strongly increased degradation rate of haemagglutinin when the 
storage temperature was increased from 5 ºC to 25 ºC [162]. Therefore, it is necessary to 
develop solid formulations of influenza vaccines that ave better stability during a long-term 
stability and economic distributions. Furthermore, influenza vaccines in a solid form of 
powder or microparticles give some chances for novel administration routes, i.e. nasal 
delivery, intradermal or epidermal delivery. 
 
Influenza hemagglutinin is an antigenic glycoprotein, found on the surface of the influenza 
viruses. The viruses bind to cells by the interaction of HA proteins and the sialic acid on the 
membranes [160]. Influenza virus or HA proteins separated from viruses have the ability to 
cause agglutination of erythrocytes (red blood cells). There are many subtypes of HA antigens 
depending on the species where the viruses were found, e.g. H1, H2 and H3 are found in 
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human influenza viruses. The monomers of HA have a molecular weight of about 62 kDa, 
dimers and trimers also exist as indicated from SDS-PAGE bands [165, 166]. HA monomers 
(HA0) can be cleaved into two smaller subunits of the HA1 and HA2, under reducing 
conditions of SDS-PAGE [165].  
 
A real vaccine was chosen to study the stability and biological activity of the antigens in 
TMD formulation. The Pandemrix® suspension as an influenza vaccine (H1N1) (split virion, 
inactivated, adjuvanted), produced by GlaxoSmithKline (GSK), has been used in Germany in 
2011. Pandemrix® was obtained from the Bavarian State Ministry of Environment and Public 
Health. The antigen suspension before mixing with an adjuvant contains 15 µg of 
hemagglutinin (HA) per 1.0 ml. This antigen suspensio  and the suggested adjuvant emulsion 
AS03 are mixed at a volume ratio of 1:1. 0.5 ml of the mixture is used as the dose for humans. 
The H1N1 HA has been used to study the formulation of microparticles for EPI due to its 
sensitivity and the availability of the vaccine. The main objective of this chapter is to 
encapsulate H1N1 HA and silica nanoparticles in TMD microparticles and to investigate the 
stability of H1N1 HA in the formulation. The interaction between H1N1 HA and MSNP-NH2 
was studied and the biological activity of HA in TMD microparticles was determined. 
2. Materials and Methods 
2.1 Materials 
Pandemic influenza vaccine, Influenza A/California/7/2009 (H1N1)v-like strain (X-179A), 
known as Pandemrix®, was produced by GlaxoSmithKline Biologicals s.a. (Rixensart, 
Belgium). One pack of Pandemrix® consists of one pack containing 50 vials of 2.5 ml 
suspension (antigen) (15 µg/ml HA) and two packs containing 25 vials of 2.5 ml emulsion 
(adjuvant). Pandemrix® requires mixing of the antigen suspension and adjuv nt emulsion with 
the same volume. A volume of 0.5 ml of Pandemrix® after mixing has been suggested for 
adults. The adjuvant of AS03 contains squalene, DL-a-tocopherol and polysorbate 80. The 
other ingredients in Pandemrix® are octoxynol 10, thiomersal, sodium chloride, diso um 
hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride, magnesium 
chloride, water. The antigen suspension (15 µg/ml HA) before mixing is used for our research 
herein.  
 
Micro BCATM Protein Assay Reagent Kit (PIERCE) was purchased from Thermo Fisher 
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Scientific (Rockford, IL Campus, USA). VivaSpin® 20 (5kDa cut-off) tubes were purchased 
from Sartorius Stedim Biotech GmbH (Goettingen, Germany). Polysorbate 80, TritonX-100 
and Tween 20 were obtained from Sigma-Aldrich (Steinh m, Germany). Phenomenex Jupiter 
300 (5 µm, C18) was purchased from Phenomenex (Aschaffenburg, Germany). NuPage 10% 
Bis-Tris-Gel and Nitrocellulose membranes were obtained from Invitrogen, Life 
Technologies Corporation (Carlsbad, USA). An Anti-ifluenza A H1N1 Hemagglutinin (HA) 
monoclonal antibody (MAb) was obtained from Sino Biological (Beijing, China). IRDye 
800CW conjugated goat Anti-Mouse IgG, was from LI-COR Biosciences (Lincoln, USA). 
Chicken erythrocytes (25% whole blood suspension in Alsever's buffer), also called red blood 
cells (RBCs), Dextrose-gelatin-veronal (DGV) buffer and Agglutest buffer (for 
haemagglutination inhibition tests) was purchased from LABOR DR.MERK & KOLLEGEN 
GmbH (Ochsenhausen, Germany).  
2.2 Methods 
2.2.1 Concentrating of H1N1 hemagglutinin by ultrafiltration 
The H1N1 HA protein has molecular weight above 50 kDa [165], thus VivaSpin 20 with a 
molecular cut-off of 5 kDa was used to concentrate the H1N1 HA protein. VivaSpin tubes 
containing about 20 ml of Pandemrix® vaccine for each were centrifuged for 2 hours under a 
swing-out mode at a speed of 5000×g (Sigma 4K15 centrifuge, SIGMA Laboratory 
Centrifuges, Shropshire, UK). More original vaccine solution was added after the previous 
concentrating process. 250 ml of original vaccine solution was concentrated to about 3 ml. 
Finally, the buffer was changed into a freshly prepar d KH2PO4-Na2HPO4-MgCl2-polysorbate 
80-tritonX-100 (KNaMgPT) buffer (pH 7.0), which was prepared by dissolving 0.694 g of 
KH2PO4, 1.0705 g of Na2HPO4·2H2O, 0.025 g of MgCl2·6H2O, 0.4 g of polysorbate 80 and 
0.2 g tritonX-100 in 1L of high-purified water (HPW) and filtering with 0.2 µm membrane 
(Sartorius Stedim Biotech GmbH, Goettingen, Germany). The concentrated H1N1 HA in 
KNaMgPT buffer was stored at 4 ºC for subsequent use.  
2.2.2 Determination of H1N1 HA concentration 
2.2.2.1 Bicinchoninic acid assay (BCA) assay 
2.0 mg/ml BSA was used to prepare the standards for BCA assay, including BSA 
concentrations of 180, 90, 22.4, 11.2, 5.6, 2.8, 1.4 and 0 µg/ml. The concentrated HA was 
diluted 10 fold before used for BCA assay. The micro BCA working reagent (WR) was 
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prepared according the instructions of the assay kit. 150 µl of each standard and sample was 
added to the 96-well plate and then 150 µl of WR was added into the wells. The 96-well plate 
was shaken at 600 rpm (Thermo Scientific Sorvall ST 16R, Dreieich, Germany) for about 30 s 
before incubated at 37 ºC (UL 50, Memmert, Schwabach, Germany) for 2 hours. After that, 
the plate was cooled at room temperature and centrifuged at 1000×g in case some air bubbles 
were observed. The absorbance at 562 nm of each well was measured using a plate reader 
(Fluostar Omega, BMG LABTECH GmbH, Ortenberg, Germany).  
2.2.2.2 Reversed phase high-performance liquid chromatography (RP-HPLC) 
RP-HPLC was used to determine the H1N1 HA concentration. A Phenomenex Jupiter 300 (5 
µm, C18 column) was used. 0.1%TFA in highly purified water was used as the mobile phase 
A (Eluent A), while 0.1% TFA in 75% isopropanol and 25% acetonitrile as the mobile phase 
B (Eluent B). Flow rate is 1.0 ml/min. The elution gradient is shown in Figure V-1. A 
fluorescence detector (excitation 280 nm / emission 335 nm) (DIONEX RF 2000, Idstein, 
Germany) was used, with a sensitivity that is sufficient to measure the vaccine concentration 
as low as 3.75 µg/ml. The spectrum of each sample was obtained by subtracting the signals 
from the buffer. The original vaccine with a H1N1 HA concentration of 15 µg/ml was used as 
the standard. The concentrated H1N1 HA was diluted 10 fold before used for measurement in 
case the high concentrated protein may overload the column.   
 
Figure V-1. Gradient of mobile phase A (Eluent A) and mobile phase B (Eluent B) for 
elution.  
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2.2.3 Size and zeta-potential measurements 
The details for the measurement of the sizes and zeta-potentials have been described in 
Chapter IV. Briefly, 1.0 ml of 0.2 mg/ml MSNP-NH2 in PB buffer (10 mM, pH 5.8) was used 
to mix with a specific volume (0.114 ml, 0.228 ml or 0.457 ml) of 1.75 mg/ml HA in 
KNaMgPT buffer (10 mM, pH 7.0). The mass ratios of MSNP-NH2 and HA include 1/1, 1/2 
and 1/4. The obtained mixtures were directly used for DLS measurements. To study the silica 
nanoparticles in TMD microparticles, 15 mg of microparticles was dissolved in 1 ml of 
KNaMgPT buffer (10 mM, pH 7.0) before DLS measurements.  
2.2.4 Loading of H1N1 HA on silica nanoparticles (MSNP-NH2)  
0.2 ml of 2 mg/ml MSNP-NH2 in PB buffer (10 mM, pH 5.8) and 0.2 ml of H1N1 HA in 
KNaMgPT buffer (10 mM, pH 7.0) were mixed together in a 1.5ml-EP tube by gentle hand-
shaking. HA solutions including 0.180, 0.325 and 0.548 mg/ml were used to study the loading 
under different concentrations of HA. One hour after he mixing, the EP tubes were 
centrifuged at 14 000 rpm for 10 min (Sigma 4K15 centrifuge, SIGMA Laboratory 
Centrifuges, Shropshire, UK). The HA concentration in the supernatant of each sample was 
measured by BCA assay. The loading amount was calculated as following: 
amount NH2-MSNP
amountHA t supernatan -amount HA  added
capacity  Loading =    (1) 
2.2.5 Encapsulation of H1N1 HA and silica nanoparticles in TMD microparticles by 
spray-freeze-drying 
Concentrated H1N1 HA solution was used to prepare TMD microparticles. Trehalose·2H2O, 
Mannitol, Dextran (9-10 kDa) and Dextran (150 kDa) were mixed at a mass ratio of 3:3:3:1 
and then H1N1 HA solution was added to dissolve the matrix by occasional shaking. The 
solid content of H1N1 HA in the TMD microparticles was kept to about 4 µg/mg. For the 
formulation containing silica nanoparticles, 0.010 ml of 50 mg/ml MSNP-NH2 in PB buffer 
(10 mM, pH 5.8) was added to obtain a MSNP-NH2/HA mass ratio of 1/4. The mixtures were 
then spray-freeze-dried using the same process as described in Chapter IV. Briefly, an 
ultrasonic atomizing nozzle (120 kHz, Sono-Tek, Milton, USA) was used. The power for 
spraying was set to 4.5 watts and the flow rate of the peristaltic pump to 0.6 ml/min. The 
microparticles sprayed into liquid nitrogen were collected in vials and transferred to a pre-
cooled lyophiliser at -55 ºC (Martin Christ EPSILON 2-6D, Harz, Germany). The freeze-
drying step includes 24 hours of primary drying at -10 ºC and 20 hours of secondary drying at 
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25 ºC. The chamber pressure was kept at 0.12 mbar during the whole drying process. After 
that, dry nitrogen gas was filled into the chamber fore closing the vials.   
2.2.6 SDS-PAGE and western blot of H1N1 HA 
HA was formulated in TMD microparticles by SFD. 10 mg of the microparticles were 
dissolved in 0.2 ml of KNaMgPT buffer (10 mM, pH 7.0). Concentrated HA solution was 
diluted 10 fold before used as a control. 
 
Buffers for SDS-PAGE: 
Electrophoresis running buffer was obtained by mixing 30 ml of NuPage® MES SDS Running 
Buffer (20×) and 570 ml of HPW water. Sampling (loading) buffer for non-reducing 
conditions was prepared by mixing 25 ml of 1.0 M Tris, 4 g of SDS; 23 ml of glycerol (87%) 
and 1.0 ml of bromophenol blue (0.1%), and adjusting he pH to 6.8 and total volume to 100 
ml with HPW water. Sampling buffer for reduced condition was prepared by dissolving DL-
dithiothreitol (DTT) in the non-reducing sampling buffer at a concentration of 50 µg/ml.  
 
40 µl of each sample and 60 µl of sampling buffer were mixed and then incubated at 95 ºC for 
20 min. 10 µl of each sample was added to the NuPage® 10% Bis-Tris-Gel (Invitrogen) and 
4 µl of Marker 12TM Unstained Protein Standards (Life Technologies) was added. For the gel 
used for western blot afterwards, the same amount of each sample was added and 2 µl of the 
MagicMark™ XP Western Protein Standard (Life Technologies) was added. After running 
about 1.5 hours at 80 mA, the gel for SDS-PAGE was st ined with ImperialTM Protein Stain 
(Thermo Scientific) and the other gel was used for western blot.  
 
After the SDS-PAGE step, transferring of protein from the gel to nitrocellulose membrane 
was carried out. Different layers including a nitrocellulose membrane, a fiber pad and a filter 
paper were stacked together and then placed in the chamber for electrophoretic transferring 
under a cooled condition. The transferring was done by adding a voltage of 75 V for 2h. After 
transfer, the membrane was placed into a small box with the protein side facing up. Ponceau 
red staining solution was added to check if the blotting is successful (about 1 min). The 
membrane was washed once using water and subsequently blocking buffer was added. The 
blocking was done by shaking at RT for 90 min. The membrane was washed once with TBST 
washing buffer. The primary antibody was added to the small box containing the membrane. 
The box was shaken gently overnight at a 4 ºC room. On the second day, the primary antibody 
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solution was poured into a tube for reuse next timeand the membrane was washed three times 
using TBST buffer to get rid of excessive unbound atibodies. The membrane was incubated 
in the solution of the secondary antibody in dark under shaking for 1 hour at room 
temperature (RT). The secondary antibody was recovered for reuse and the membrane was 
washed 4 times (5 min for each) at RT with PBS+0.1% Tween 20 under gentle shaking. The 
membrane was rinsed in PBS to remove residual Tween 20. Finally, the membrane was 
scanned using an odyssey imaging system (LI-COR Biosciences, Lincoln, USA). The buffers 
and antibodies used include are shown in Table V-1. 
 
Table V-1 Buffers and antibodies for western blot 
Buffer or antibody  Description  
Transferring buffer 25 mM tris-HCl, 192 mM glycine and 20% methanol, pH 8.3: 
Add 200 ml methanol in 700 ml HPW H2O. Dissolve 3.03g Tris base (Mwt. 121.2 
g/mol), 14.42g Glycine (Mwt. 75.07 g/mol) in this water-methanol solution. Adjust 
pH to 8.3 by concentrated HCl and complete the final volume to 1 L with water. 
Blocking buffer TBST + 5% skim milk (i.e. 2.5g skimmed milk in 50ml TBST) 
1X TBS buffer Tris-HCl buffer saline, pH 7.6 
2.42 g Tris base and 8 g NaCl were in 1 L of HPW H2O. Adjust pH to 7.6 (with 
concentrated HCl). 
TBST (Washing buffer): 1X TBS + 0.1% Tween 20 (i.e. 1 ml Tween 20 in 1L 1X TBS) 
Primary antibody Anti-influenza A H1N1 Hemagglutinin (HA) monoclonal antibody (MAb) (Sino 
Biological, 1.5 g/µl) 
Secondary antibody IRDye 800CW conjugated goat Anti-Mouse IgG (Licor, 1.0 g/µl) 
 
2.2.7 Hemagglutinin inhibition (HAI) assay 
Hemagglutinin inhibition (HAI) assay was firstly developed by Hirst [167]. Biologically 
active HA will bind to red blood cells, causing the formation of a lattice. Inactive HA can not 
bind the red blood cells, which will sink to the bottom and form a button. Fresh red blood 
cells (RBCs) (LABOR DR.MERK & KOLLEGEN GmbH, Ochsenhausen, Germany) were 
diluted to 0.5% (v/v) for subsequent use. A 96-well plate with round-bottom wells was used 
for the assay. 50 µl of PBS buffer was added into each well except the first column (A1-H1). 
One row of the 96-well plate is used for one sample with different dilutions. 100 µl of 
samples and controls were added into the first column (A1-H1). 50 µl solution of each well 
from the first column was transferred to the second column (A2-H2) to obtain the 1/2 diluted 
sample. After mixing in the wells (A2-H2), 50 µl solution of each well was added to the wells 
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(A3-H3) to obtain the 1/4 diluted sample. By this way, a series of dilutions from 1 to 1/2048 
for each sample was prepared. Afterwards, 50 µl suspension of RBCs (0.5%, v/v) was added 
into each well. The 96-well plate was shaken for a short time (around 1 min) (Heidolph, 
Schwabach, Germany) and then stored in an incubator (Memmert, Schwabach, Germany) at 
25 °C for 30 min. Subsequently, the microplate was put at RT for 10 min before a photo was 
taken by a camera (CASIO, Japan) to observe the red buttons formed on the bottom of the 
wells.    
3. Results and Discussion  
3.1 Influenza hemagglutinin obtained from the vaccines 
Influenza A/California/7/2009 (H1N1)v-like strain (X-179A), split-virion inactivated 
influenza vaccine Pandemrix® was used to prepare concentrated H1N1 HA by ultrafiltration. 
The concentrated H1N1 HA was diluted 10 fold and then was used for concentration 
determination by micro BCA assay. Considering the disturbance of ploysorbate 80, the 
absorption resulting from the buffer containing polys rbate 80 was subtracted. Afterwards, 
HA concentration was calculated from the standard cu ve of BSA standards. Three batches of 
concentrated H1N1 HA were prepared as shown in Table V-2.  
 
Table V-2 Concentration of concentrated H1N1 HA solution 
Sample  Batch 1 Batch 2 Batch 3 
Concentrated H1N1 HA 2.00 mg/ml 1.50 mg/ml 1.75 mg/l 
 
The HA concentration of the samples obtained in our st dy by ultrafiltration is about 1-2 
mg/ml. This concentration can be used to prepare TMD microparticles containing a HA 
content lower than 5 µg/mg, is still too low to prepare TMD microparticles with a higher 
content of HA. Ultrafiltration is good for concentra ing a small amount of HA, but is not 
convenient for scaling up. Tangential flow filtration (TFF) is more suitable for preparing a 
large batch of concentrated vaccine antigens [168]. Highly concentrated HA (up to 28 mg/ml) 
has been reported to be prepared by TFF without compr ising HA stability [168]. This 
ensures that HA concentration can be used to prepare TMD microparticles or other solid 
formulations containing a HA content up to 80 µg/mg, which is sufficient for intradermal 
immunization [169].   
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3.2 Interaction of H1N1 hemagglutinin and cationic mesoporous silica nanoparticles  
The interaction of H1N1 HA and cationic mesoporous silica nanoparticles (MSNP-NH2) was 
investigated to estimate the loading amount of HA on MSNP-NH2 and the effect of HA on 
the particle size. MSNP-NH2 nanoparticles, having a size of 130 nm and pore size of 2.5 nm, 
were prepared as described in Chapter IV. 2.0 mg/ml of MSNP-NH2 in PB buffer (10 mM, 
pH 5.8) was prepared. 0.2 ml of the MSNP-NH2 suspenion was mixed with 0.2 ml of HA 
solution having different concentrations of antigens, which were diluted from concentrated 
HA stock (1.75 mg/ml). Table V-3 shows the loading amounts determined by supernatant 
analysis at different HA concentrations. The mixtures of HA and MSNP-NH2 with mass 
ratios of 1/30, 1/15, 1/7.5 and 1/3.75 were prepared, r spectively. The load amount of HA on 
MSNP-NH2 increases with the increasing HA concentration, while the loading efficiency 
changes slightly.  
 
Table V-3 Summary of loading of HA on silica nanoparticles 
Sample 
MSNP-NH2  
(mg/ml) 
HA Con. 
(µg/ml)* 
Loading amount  
(mg/mg) 
Loading efficiency 
(%) 
HA/silica = 1/30 (w/w) 1.0 34 0.009 25.6 
HA/silica = 1/15 (w/w) 1.0 67 0.020 29.6 
HA/silica = 1/7.5 (w/w) 1.0 142 0.047 32.8 
HA/silica = 1/3.75 (w/w) 1.0 296 0.112 37.8 
*HA Con. represents the HA concentration in the mixed solution of 0.2 ml MSNP-NH2 
particles and 0.2 ml HA solution.    
 
H1N1 HA can be absorbed on the silica nanoparticles, but the effect of HA on the size and 
zeta-potential of MSNP-NH2 needs more investigation. The mixture solutions of different 
ratios of HA and MSNP-NH2 were prepared by adding different volumes of 1.75 mg/ml HA 
into 1.0 ml of 0.2 mg/ml MSNP-NH2 in PB buffer (10 mM, pH 5.8). DLS results including Z-
Ave size, PDI and zeta-potential (ZP) are shown in Table V-4. MSNP-NH2 nanoparticles 
have a positive ZP, but change to a negative ZP when H1N1 HA was added in the formulation. 
HA protein is negatively charged around neutral pH,it could be absorbed on positive surfaces 
of MSNP-NH2, leading to negative surfaces of MSNP-NH2/HA. This is similar to the case of 
ovalbumin as described in Chapter IV. The loading tests reported above confirm that HA can 
be absorbed onto MSNP-NH2 nanoparticles.  
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Table V-4 DLS results of silica nanoparticles in different con entrations of HA 
Sample Z-Ave (d.nm) PDI ZP (mv) 
H1N1 HA/MSNP-NH2 = 1/1 (w/w) 782±22 0.576±0.035 -(15.2±0.9) 
H1N1 HA/ MSNP-NH2 = 2/1 (w/w) 402±8 0.579±0.047 -(16. ±0.4) 
H1N1 HA/ MSNP-NH2 = 4/1 (w/w) 210±3 0.498±0.010 -(16.0±0.6) 
MSNP-NH2 in PB buffer (10 mM, pH 5.8) 175±2 0.161±0.024 20.5±0.5 
Concentrated HA protein (1/10× diluted) 154±4 0.414±0.055 -(16.9±0.9) 
Original vaccine 142±3 0.314±0.004 -(6.1±1.8) 
 
The PDI of MSNP-NH2 particles was increased from about 0.2 to 0.5 when HA was absorbed 
on the surface. The size and PDI of the HA from original vaccines are 142 nm and 0.314, 
indicating HA agglomerates itself. The concentrated HA has a size of 154 nm and PDI of 
0.414. HA protein not only could increase the size and PDI of MSNP-NH2, but also could 
bind MSNP-NH2 nanoparticles together, leading to the increase of particle size. As the 
relative amount of HA compared to MSNP-NH2 amount icreases, the size of MSNP-
NH2/HA decreases even though the ZP does not change. The excessive HA in the suspension 
seems to play a role in stabilising MSNP-NH2 nanoparticles. When the mass ratio of H1N1 
HA and MSNP-NH2 comes to 4/1, the MSNP-NH2 nanoparticles have a size of about 210 nm 
and a PDI of about 0.5. Thus a mass ratio of at least 4/1 for HA vs MSNP-NH2 is suggested 
when both are used together in one formulation. 
 
TMD microparticles containing H1N1 HA at a content of about 4 µg/mg (HA/TMD) and 
TMD microparticles containing 4 µg/mg of HA and 1 µg/mg of MSNP-NH2 (HA/MSNP-
NH2/TMD) were prepared. The sizes of HA protein and MSNP-NH2 nanoparticles re-
dissolved from the TMD microparticles are shown in Table V-5. The HA recovered from 
TMD microparticles has a size of 93 nm and PDI of about 0.8. The size of HA is low, but the 
PDI is very high, probably due to the TMD matrix having a PDI of about 0.6. The particle 
size and PDI of the HA/MSNP-NH2/TMD formulation are 140 nm and about 0.6. Therefore, 
cationic silica nanoparticles in the TMD microparticles containing the HA antigen do not 
produce big particles/aggregates.  
 
Table V-5 DLS of the re-dissolved microparticles containing HA and/or silica nanoparticles 
Sample Z-Ave (d.nm) PDI ZP (mV) 
H1N1 HA/TMD 93±12 0.832±0.221 -(10.7±1.2) 
H1N1 HA/MSNP-NH2/TMD 140±3 0.610±0.011 -(14.5±1.1) 
5 - 8 mg of TMD microparticles were dissolved in 1 ml of KNaMgPT buffer. 
108                          V. Formulation of H1N1 HA and Silica Nanoparticles into Microparticles 
3.3 Characterisation of H1N1 HA in TMD microparticles  
H1N1 HA was formulated in TMD microparticles by spray-freeze-drying (SFD). The HA 
content in the TMD microparticles can be calculated from the HA amount added and the 
TMD amount. Concentrated HA solutions from batch 1 (2.00 mg/ml) and batch 2 (1.50 
mg/ml) were used. 50 mg/ml MSNP-NH2 in PB buffer (10 mM, pH 5.8) was used in the 
formulations for TMD microparticles. On the other hand, HA content in the TMD 
microparticles can be directly determined by dissolving TMD microparticles and measuring 
HA concentration using RP-HPLC. As shown in Table V-6, the concentrations of all the 
samples obtained from RP-HPLC measurements are comparable to those calculated (Table 
V-2). The RP-HPLC method for determining HA concentration was considered as the 
standard. The calculated HA concentrations are obtained from the concentrated HA solutions 
whose concentrations were determined by micro BCA assay. Therefore, both RP-HPLC and 
protein micro BCA assay are suitable for the determination of HA concentration.    
 
Table V-6 Concentration of HA solution redissolved from the TMD microparticles  
Sample RP-HPLC (mg/ml) Calculated (mg/ml) 
H1N1 HA/TMD  0.190  0.175 
H1N1 HA/MSNP-NH2/TMD  0.135 0.175 
 
The HA solution recovered from TMD microparticles and the concentrated HA that was used 
to prepare TMD microparticles were studied by SDS-PAGE. As seen from the SDS-PAGE 
result in Figure V-2, there are mainly four bands including HA monomer (ca. 66 kDa), HA 
dimer (ca. 130 kDa), HA trimer (ca. 190 kDa) and subunit (HA1) protein of HA (ca. 50 kDa). 
The bands of HA monomer, HA dimer and HA trimer areconsistent with the results found in 
the literature [165]. The lane for the concentrated HA shows a distinct high concentration of 
protein.   
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Figure V-2. SDS-PAGE of concentrated HA and recovered HA from TMD microparticles. 
Lane 1 - Marker, lane 2 and lane 4 - HA from the HA/TMD formulation, lane 3 and lane 5 - 
HA from the HA/MSNP-NH2/TMD formulation, lane 6 - concentrated HA, lane 7 - 5-fold 
dilution of the concentrated HA. 
 
SDS-PAGE and western blot of H1N1 HA under non-reducing and reducing conditions were 
further studied. The SDS-PAGE and western blot results in Figure V-3 confirms that the 
three bands (ca. 66, 130, 190 kDa) belong to H1N1 HA. A very light band of the subunit HA1 
appears on the blotting membrane for the samples under reducing conditions, but the HA1 
band for the samples under non-reducing conditions s hardly observed. The HA proteins 
from the TMD microparticles have the bands as the original vaccine, except that the HA 
concentration in the original vaccine is lower than the HA reconstituted from TMD 
microparticles.  
 
Under reducing conditions, the HA monomer band becomes slightly broad and goes up a little 
bit to the higher molecular direction. According to the properties of HA protein, HA monomer 
(HA0) includes two subunits bound together by a disulfide bond [165]. The HA monomer can 
be cleaved into two parts (HA1 and HA2) under reducing conditions. HA1 appears on the 
SDS-PAGE (Figure V-3A), but HA2 is hardly seen. The subunit HA1 was observed in 
Figure V-3B, showing a molecular weight of ca. 50 kDa. The bands corresponding to HA 
dimers and trimers under reducing conditions on the SDS-PAGE gel and western blot 
membrane have less concentration than those under no-reducing conditions. It indicates that 
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HA dimers and trimers can be changed to HA monomers under reducing conditions due to the 
reversible balance between HA monomers, dimers and trimers.  
 
A  
B  
Figure V-3. Reducing and non-reducing SDS-PAGE and western blot results of H1N1 HA. 
Lane 1 - Marker, lane 2 - original vaccine, lane 3 and lane 5 - HA from the HA/TMD 
formulation, lane 4 and lane 6 - HA from the HA/MSNP-NH2/TMD formulation, lane 7 - 
reduced original vaccine, lane 8 and lane 10 - reduced HA from the HA/TMD formulation, 
lane 9 and lane 11 - reduced HA from the HA/MSNP-NH2/TMD formulation, lane 12 - 
TMD matrix.  
 
H1N1 HA protein in TMD microparticles maintains the molecular integrity and binding 
specificity in spite of the formulations containing MSNP-NH2 or not. Two conclusive aspects 
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could be drawn from the above results. One aspect is that TMD formulations and the spray-
freeze-drying process for preparing microparticles have no detriment effects on H1N1 HA. 
The other one is that silica nanoparticles in the formulation have no obvious negative effects 
on the HA antigen. Considering HA protein is sensitive o physical stresses [170], the process 
for manufacturing the nano-in-micro particle systems ade of TMD matrices and silica 
nanoparticles is useful for producing vaccine microparticles for epidermal powder 
immunisation.       
 
More experiments were carried out to obtain better quality of western blot results. The non-
reducing SDS-PAGE of HA protein is shown in Figure V-4A; the corresponding western blot 
result of each lane is shown in Figure V-4B. Compared to the conditions in the experiments 
of Figure V-3, double amount of each sample was added into the lane. It is clear that the HA 
protein recovered from TMD microparticles containing or without silica nanoparticles shows 
the same bands as the H1N1 HA control, including monomers, dimers and trimers. The 
subunit HA1 appears on the SDS-PAGE gel, but is hardly observed on the western blot 
membrane. It indicates that the bind affinity of HA1 with the primary antibody is very low. 
The bands in Figure V-4 are more clear than those in Figure V-3 because the HA amount 
added into the lane doubles. The concentration of HA monomers is distinctly larger than that 
of HA dimers, which is larger than that of trimers. TMD matrices have no protein bands on 
the gel and no binding bands on the membrane.  
 
A  B  
Figure V-4. Non-reducing SDS-PAGE (A) and western blot (B) results of H1N1 HA. Lane 1 
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- Marker, lane 2 - H1N1 HA (control), lane 3 and lane 5 - HA from the HA/TMD 
formulation, lane 4 and lane 6 - HA from the HA/MSNP-NH2/TMD formulation, lane 7 - 
TMD matrix. The right photo was imaged by ODYSSEY system using the channel of 800 nm. 
3.4 Biological activity by hemagglutinin inhibition assay 
The biological activity of H1N1 HA was determined by hemagglutinin inhibition (HAI) assay 
using chicken red blood cells (RBCs) [167]. The results are shown in Figure V-5 and 
summarized in Table V-7. The HA concentration of samples D and E is estimated to be 0.120 
mg/ml by multiplying the original vaccine concentration (0.015 mg/ml) 8 fold. The value 
0.120 mg/ml is consistent with the calculated HA protein concentration (0.118 mg/ml) 
calculated from the HA content in the microparticles. Therefore, the biological activity of HA 
in the TMD microparticles can be preserved during the spray-freeze-drying step. In addition, 
MSNP-NH2 particles have no negative effect on the activity of HA.  
 
A:  Standard HA 
(positive control) 
B: Stressed HA (negative 
control) 
C: DGV buffer 
D: HA from HA/TMD 
E: HA from HA/MSNP-
NH2/TMD 
F: HA from HA/TMD 
(repeat) 
G: HA from HA/MSNP-
NH2/TMD (repeat) 
H:  TMD matrix 
 
Figure V-5. The results of HAI assay of H1N1 HA proteins from different formulations. The 
white circle indicates the first red button appearing among the dilutions of each sample.   
 
More studies were carried out to investigate the storage effect of the concentrated HA stock 
solution and the storage effect of the reconstituted HA from TMD microparticles on the 
biological activity of HA. Concentrated freshly preared H1N1 HA and aged H1N1 HA (two 
weeks at 4 ºC) were diluted 20 fold before used for HAI assay (Table V-7). The calculated 
concentration (Con.) of HA was obtained from the concentrated HA stock concentration that 
was obtained by protein micro BCA assay, while the estimated concentration of HA was 
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calculated according to the HAI assay. Calculated HA concentrations, calculated from the 
protein content in the microparticles, were comparable to those estimated from the biological 
activity. The HA stock solutions and the freshly reconstituted HA solutions show very good 
biological activity.  
 
Table V-7 Summary of the concentrations of concentrated HA stock solutions and freshly 
reconstituted HA (unit, mg/ml) 
Sample HA 
standard 
Fresh HA stock 
(diluted) 
Aged HA stock 
(diluted) 
Fresh HA from 
HA/TMD 
Fresh HA from 
HA/silica/TMD 
Calculated HA  0.015 0.088 0.075 0.118 0.118 
Estimated HA  0.015 0.06 0.06 0.12 0.12 
Calculated HA was calculated from the HA content in the microparticles. Estimated HA was 
obtained from HAI assay.  
 
H1N1 HA solutions from TMD microparticles were prepared by reconstitution in the 
KNaMgPT buffer. The HAI assay results are summarized in Table V-8. Distinct decreased 
activities of the aged reconstituted HA samples were observed after storage at 4 ºC for one 
week. The dextran (10 kDa and 150 kDa) in TMD matrix could be detrimental to HA in 
solution by interacting with HA, resulting activity loss of the aged reconstituted HA.  
 
Table V-8 Effect of storage (4 ºC) on the reconstituted HA (unit, mg/ml) 
Sample HA 
standard 
Aged HA, 
HA/TMD 
Aged HA, 
HA/silica/TMD 
Aged HA, 
HA/TMD 
Aged HA, 
HA/silica/TMD 
Calculated HA Con.* 0.015 0.118 0.118 0.088 0.088 
Estimated HA Con.* 0.015 0.002 0.015 0.015 0.03 
*Con. = concentration.  
 
For the concentrated HA stock solution, two weeks storage in the fridge has no obvious effect 
on the activity of HA antigens. HA biological activi es of all the freshly reconstituted 
samples from TMD microparticles are as good as the original vaccine. However, the aged 
reconstituted HA (one week at 4 ºC) has much lower activity than the original vaccine. That is 
to say, the HA antigens in TMD microparticles are stable in a solid form, but not very stable 
in solution containing TMD matrices. Original HA vaccines on market are stable at 4 ºC for 
about one year, but the HA in TMD solution is not stable. Trehalose and mannitol are sugar 
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matrices that can stabilise proteins in solution, but dextran as a polysaccharide, especially the 
type with a high molecular weight (150 kDa), can destabilise vaccines such as HA.  
3.5 Stability of influenza vaccines in a solid form 
In our experiments, trehalose, manitol and dextran were used to formulate H1N1 HA into 
microparticles by SFD. Because we have already proved the suitability of these TMD 
microparticles regarding size, density and robustness for EPI delivery previously, the stability 
of HA in the formulation is the main research focus of this chapter.  
 
We have successfully prepared TMD microparticles containing biologically active HA by 
spray-freeze-drying. The H1N1 HA in the TMD microparticles shows the same molecular 
integrity as the standard. The binding affinity (Figure V-4) and the biological activity (Table 
V-7) of HA have no distinct change in the microparticles. The trehalose and mannitol act as a 
role of stabilising HA in the formulation, an approiate amount of dextran can increase the 
particle density and robustness without destabilising the vaccines in a solid form. We found 
the biological activity of HA in dry TMD microparticles is good but reconstituted HA loses 
its activity in one week at 4 ºC (Table V-8). In other studies, the stability of influenza 
vaccines in TMD microparticles has been maintained for at least 6 months at 25 °C and for 3 
months at 40 °C [169]. The conformational changes of HA can be prevented by using fast 
freezing, Hepes buffer and carbohydrates (trehalose, inulin or dextran) during freeze-drying 
[171], the HA potency in the vaccine powder keeps stable as long as at least 6 months at room 
temperature.  
 
The silica nanoparticles we used in the formulation have no negative impact on the HA 
stability. HA can be adsorbed on the cationic silica nanoparticles (MSNP-NH2) as seen from 
the above results. As the H1N1 HA stability can be pr served in TMD microparticles when 
silica nanoparticle are also included in the formulation, the nano-in-micro particle systems 
composed of MSNP-NH2, HA and TMD matrices are practic l for epidermal powder 
immunisation.    
4. Conclusion 
H1N1 hemagglutinin protein solution with a concentration of 1 - 2 mg/ml has been prepared 
from the original vaccines with a HA concentration f 15 µg/ml. The concentrated HA 
solution is stable for at least two weeks at 2 - 8 ºC. This HA solution has been used to prepare 
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TMD microparticles by spray-freeze-drying. Cationic silica nanoparticles can adsorb HA 
protein very well mainly by electrostatic interaction. HA was loading onto MSNP-NH2 
nanoparticles by absorption and then both were formulated into the TMD matrix to create 
nano-in-micro particle systems containing antigens. These nano-in-micro particles are 
pursued for the purpose of epidermal powder immunisation. The H1N1 HA reconstituted 
from the TMD microparticles maintains the integrity and shows the same binding affinity to 
the antibody as the HA standard. The biological activity of the HA from TMD microparticles 
is as good as that of concentrated HA. Silica nanoprticles encapsulated in TMD 
microparticles have no obvious negative effects on the stability of HA antigen. TMD 
microparticles containing HA and MSNP-NH2 have been successfully prepared, which could 
be used for epidermal powder injection.  
 
For now, the obtained TMD microparticles have a HA content of about 4 µg/mg. This content 
seems to be low for the application on animals or even human. As for the epidermal powder 
injection, about 1 mg of microparticles can be delivered into the epidermal layer or dermal 
up-layer. 10 - 50 µg of vaccines are needed for one shot. Therefore, it is necessary to develop 
TMD microparticles with a HA content of 10 - 50 µg/mg. These microparticles could be 
achieved by using a higher concentration of HA stock solution.  
 
 
Chapter VI. Preparation of PLGA Nanoparticles for Vaccine Delivery and 
Their Encapsulations in Sugar-based Microparticles 
 
1. Objectives 
Poly(lactic-co-glycolic acid) (PLGA) is a copolymer of lactic acid and glycolic acid linked by 
ester linkages. It has been approved for manufacturing therapeutic devices by the Food and 
Drug Administration (FDA), owning to its good biodegradability and biocompatibility [172]. 
PLGA nano/microparticles have been extensively used for drug/vaccine delivery of 
therapeutics as a sustained-release system [110, 173]. The rapid endo-lysosomal escape of 
PLGA nanoparticles after delivery into cells indicates good implications for intracellular 
delivery of genes and drugs [174]. Some products based on PLGA are on the market, e.g. 
Lupron Depot®, Sandostatin® LAR Depot, Zoladex®, Vivitrol®, etc. [175-179]. PLGA 
particles are typically prepared by emulsification methods, the encapsulation of proteins or 
peptides can be achieved [110, 180]. The controlled release of encapsulated ovalbumin from 
PLGA particles on a long term (up to 3 months) facilitates a long-term memory T cell 
response and efficacy in pathogen recall, which is very attractive for vaccine delivery [181].  
 
PLGA-based particles with different sizes can be fabric ted for multiple applications [182, 
183]. Tuskada et al. have prepared sterile PLGA nanoparticles with a mean size of 100 nm-
160 nm [182]. Protein-loaded PLGA-based particles have been investigated concerning the 
encapsulation efficiency and protein stability [173, 184, 185]. The surface charges and 
functional groups on the surface of PLGA nano/microparticles can be tailored by surface 
modification. Cationic PLGA nanoparticles have been prepared by incorporating or coating 
positively charged molecules, such as chitosan, PEICTAB, DEAE-dextran, etc. [144, 186, 
187]. Chitosan is the most popular substance for cationizing PLGA nanoparticles [146, 186, 
188-191]. PEI is another option for cationization of PLGA particles [144, 187, 192]. Coating 
methods such as PEGylation are often used for surface modification of PLGA nanoparticles 
to stabilise the dispersion and reduce unspecific interactions with cells [79, 193, 194]. There 
is an alternative method for stabilizing PLGA nanoparticles by using hydroxyethyl starch or 
pluronics [193]. PEG-PPO-PEG block polymers such as Pluronic F127, P103, P105 were 
coated on PLGA nanoparticles, thereby accelerating penetration of the particles into human 
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mucus [194]. In a word, PLGA-based nanoparticles have already been widely recognised as a 
useful drug/vaccine delivery system.  
 
PLGA-based particles have been shown in literature o be a good candidate as a vaccine 
delivery system for parenteral, nasal and oral routes of administration. Cruz et al. found that 
nano-sized PLGA particles but not microparticles can specifically deliver antigen to human 
dendritic cells [79]. Wang et al. loaded the foot and mouth disease virus (FMDV) DNA 
vaccine on chitosan-coated PLGA nanoparticles, which can induce protective immunity again 
FMDV challenge by intranasal delivery [146]. Prasad et al. optimized PLGA nanoparticles 
containing B16-tumor antigen lysate for the study of anti-tumor responses [195]. PLGA 
microparticles (3 - 5 µm) containing the immune potentiators of monophosphryl lipid A 
(MPLA) and the synthetic LPS mimetic RC529 were coated with antigens and then used for 
immune stimulation [196]. PLGA nanoparticles contaiing ovalbumin and MPLA were 
demonstrated to promote systemic and mucosal responses administered orally [148]. However, 
antigen-loaded PLGA nanoparticles have never been us d for intradermal immunisation by 
powder injection.  
 
As described in Chapter III, PLGA nanoparticles can be encapsulated into the sugar-based 
microparticles by spray-freeze-drying. PLGA nanoparticles (100 nm-1000 nm) will be further 
investigated as nanocarriers for antigens. According to the concept of nano-in-micro particle 
systems investigated in this thesis, it is reasonable to create TMD microparticles containing 
antigen-loaded PLGA nanoparticles for the purpose of epidermal powder immunisation. 
Ovalbumin (OVA) has been used as a model protein for the study of encapsulation into 
PLGA microparticles [185]. Only a few examples investigated ovalbumin-loaded PLGA 
nanoparticles [148, 181]. As an alternative to protein antigens, peptides may induce more 
direct and specific immune response. OVA 257-264 peptid  (SIINFEKL) is the natural H-
2Kb-restricted epitope of ovalbumin presented by MHC class I molecules [197, 198]. 
SIINFEKL can induce a much stronger H-2Kb-restricted response compared to OVA [197], 
but the main disadvantage of peptide antigens is that t e immunogenicity is so poor that 
adjuvants or particulate delivery systems are needed to induce effective immune response 
[198, 199]. To my knowledge, the encapsulation of SIINFEKL into PLGA nanoparticles has 
not been performed yet.    
The aim of this chapter is to use a long-term sustained release system, PLGA nanoparticles, in 
place of the fast release system, silica nanoparticles, to prepare nano-in-micro particles for the 
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purpose of epidermal powder immunisation. The objectiv s include 1) loading of ovalbumin 
into plain (anionic) and cationic PLGA nanoparticles and investigation of ovalbumin release, 
2) loading of OVA peptide (SIINFEKL) into plain and cationic PLGA nanoparticles, 3) 
encapsulation of OVA- or SIINFEKL-loaded PLGA nanoparticles into the sugar-based TMD 
microparticles. OVA and SIINFEKL will be loaded into PLGA nanoparticles by a water-in-
oil-in-water (W/O/W) double emulsion method. The antigen-loaded nanoparticles will be 
characterised including the determination of the loaded amount. The release of ovalbumin 
from PLGA nanoparticles will be determined by a protein micro BCA assay. The stability of 
PLGA nanoparticles in TMD microparticles will be investigated.      
2. Materials and Methods 
2.1 Materials 
Poly(lactic-co-glycolic acid) (PLGA) (RESOMER® RG502H) was obtained from Evonik 
Industries AG (Darmstadt, Germany. Ovalbumin (OVA), albumin from chicken egg white 
(Grade V), PEI (polyethylenimine, Mw~25.000, Branched), chitosan (low/medium molecular 
weight), and polyvinyl alcohol (PVA) (80% hydrolyzed, Mw: 9000-10000) were purchased 
from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Ethylacetate (EA) was from 
Merck kGaA (Darmstadt, Germany). Carboxyfluorescein (FAM) labeled SIINFEKL (FAM-
SIINFEKL) with a sequence of SIINFEKL was purchased from AnaSpec (Seraing, Belgium). 
The polymers used in the experiments are summarized in Table VI-1.  
 
Table VI-1 Summary of the polymers for the preparation of PLGA nanoparticles 
Product Chemical structure Description of properties 
PLGA, RESOMER® 
RG502H  
Mw: 7 000-17 000; End group: free carboxylic acid; 
Molar ration of D,L-lactide and glycolide: 50:50 
polyvinyl alcohol (PVA) 
 
80% hydrolyzed, Mw: 9 000-10 000 
Chitosan, low molecular 
weight  
 
Viscosity (1% solution in 1% acetic acid): 20-200 
cps; Deacetylation: 75-85%  
Chitosan, high molecular 
weight   
 
Viscosity (1% solution in 1% acetic acid): 200-800 
cps; Deacetylation: 75-85% 
Polyethylenimine (PEI) average Mw ~25,000 by LS, average Mn ~10,000 by 
GPC, branched 
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2.2 Methods 
2.2.1 Preparation of PLGA nanoparticles loaded with ovalbumin 
2.2.1.1 Plain PLGA nanoparticles loaded with ovalbumin 
The method for the preparation of cationic OVA-loaded PLGA nanoparticles was modified 
from Kumar, et al. [186]. 90 mg of PLGA (RG 502H) was dissolved in 3.0 ml of ethyl acetate 
(EA) in an eppendorf (EP) tube. 0.1-0.3 ml of 100 mg/ l ovalbumin in PB buffer (10 mM, 
pH 7.4) was added into the solution of PLGA in EA, and then the mixture was treated with a 
probe ultrasonicator (Bandelin UW 3200, Berlin, Germany) (Sonotrode MS 73, 20% 
amplitude) for 60 seconds in an ice bath. The obtained emulsion was quickly added into a 12 
ml solution of 1.0% (w/v) PVA in highly purified water (HPW). The solution was mixed and 
instantly ultrasonicated (Sonotrode MS 73, 20% amplitude) for 180 seconds in an ice bath. 
The obtained emulsion was then stirred at room temperature (RT) overnight to remove the 
solvent. The PLGA particles were collected by centrifugation at 14 000 rpm for 10 min at 10 
ºC (Sigma 4K15 centrifuge, SIGMA Laboratory Centrifuges, Shropshire, UK), and were 
subsequently washed twice with 12 ml of HPW. Finally, the PLGA particles encapsulating 
OVA (PLGA-OVA) were re-suspended in 1.5 ml of HPW. The suspension was ultrasonicated 
for 30 seconds to ensure that the PLGA-OVA nanoparticles were fully suspended. The 
particle concentration was determined by microbalance. 50 µl of the suspension was dried in 
an aluminium crucible and the dry amount was measured to calculate the particle 
concentration. PLGA nanoparticles loaded with different amounts of OVA were prepared by 
varying the added OVA stock volume (Table VI-2).   
 
Table VI-2 Composition of OVA-loaded PLGA nanoparticles 
Sample  PLGA (30 mg/ml) OVA stock (100 mg /ml) Theoretical OVA loading 
PLGA-OVA(10%) 3.0 ml 0.100 ml 10 wt% 
PLGA-OVA(20%) 3.0 ml 0.225 ml 20 wt% 
PLGA-OVA(25%) 3.0 ml 0.300 ml 25 wt% 
PLGA-OVA(10%)-chitosan 3.0 ml 0.100 ml 10 wt% 
PLGA-OVA(20%)-chitosan 3.0 ml 0.225 ml 20 wt% 
PLGA-OVA(25%)-chitosan 3.0 ml 0.300 ml 25 wt% 
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2.2.1.2 Cationic PLGA nanoparticles loaded with ovalbumin 
The emulsion of OVA solution dispersed in PLGA in EA was prepared using the same 
method as above. PVA and chitosan (low molecular weight) were dissolved in an acetate 
buffer (50 mM, pH 4.5) to obtain a PVA-chitosan solution containing 1.0% (w/v) of PVA and 
0.2% (w/v) of chitosan. The freshly prepared emulsion was added to 12 ml of a PVA-chitosan 
solution. The solution was mixed instantly and ultrasonicated (Sonotrode MS 73, 20% 
amplitude) for 180 seconds in an ice bath. The resulting emulsion was stirred overnight. The 
particles were collected and washed using the same procedure for PLGA-OVA nanoparticles. 
Finally, about 1.5 ml suspension of cationic PLGA-OVA nanoparticles was obtained. The 
particle concentration was determined by the microbalance method as described above. For 
the preparation of PEI-coated PLGA nanoparticles, PVA and PEI were dissolved in HPW to 
obtain a PVA-PEI solution containing 1.0% (w/v) of PVA and 0.2% (w/v) of PEI, which was 
then used for the emulsification. Cationic chitosan-coated PLGA nanoparticles loaded with 
different amounts of OVA were achieved by a similar method for PLGA-OVA nanoparticles 
(Table VI-2). Cationic PLGA-OVA(10%)-chitosan, PLGA-OVA(20%)-chitosan and PLGA-
OVA(25%)-chitosan nanoparticles were prepared.  
2.2.2 Preparation of PLGA nanoparticles loaded with SIINFEKL 
2.2.2.1 Plain PLGA nanoparticles loaded with SIINFEKL 
0.2 mg of the fluorescently labeled peptide SIINFEKL was dissolved in 100 µl of PBS 
(150mM, pH 7.4). 2 mg/ml of a fluorescently-labeled FAM-SIINFEKL solution was obtained 
after centrifugation. 50 µl of the SIINFEKL solution was added to a 1.0 ml souti n of 30 
mg/ml PLGA in EA. The mixture was ultrasonicated for 30 seconds (Sonotrode MS 72, 20% 
amplitude) in an ice bath to obtain an emulsion. For plain PLGA nanoparticles loaded with 
SIINFEKL (PLGA-SIINFEKL), the emulsion was added to 4.0 ml of 1.0% PVA aqueous 
solution, and was then ultrasonicated for 60 seconds (Sonotrode MS 72, 20% amplitude) in an 
ice bath. The emulsion was stirred overnight to remove EA. The particles were obtained by 
centrifugation and washed by HPW twice. Finally, the PLGA-SIINFEKL nanoparticles were 
re-suspended in HPW under a short ultrasonication (10 seconds). The particle concentration 
of the obtained suspension was determined by weighing the dry amount of 50 µl suspension 
using a microbalance.    
 
 
VI. Antigen-loaded PLGA Nanoparticles for Encapsulations into Microparticles 121 
2.2.2.2 Cationic PLGA nanoparticles loaded with SIINFEKL 
For cationic PLGA nanoparticles loaded with SIINFEKL, the emulsion of SIINFEKL 
dispersed in PLGA EA solution, as prepared for loading into plain PLGA nanoparticles, was 
added into 4.0 ml of a acetate buffer (50 mM, pH 4.5) containing 1.0% (w/v) PVA and 0.2% 
(w/v) chitosan. The mixed solution was then ultrasonicated for 60 seconds (Nr.72, 20% 
amplitude) in an ice bath. The resulting emulsion was stirred overnight to remove EA. The 
particles were obtained by centrifugation and washed by HPW. Finally, the cationic PLGA-
SIINFEKL-chitosan nanoparticles were re-suspended in HPW and the particle concentration 
of the obtained suspension was determined by the sam  previous method.    
2.2.3 Determination of ovalbumin loading in PLGA nanoparticles 
Sodium dodecyl sulfate (SDS) was dissolved in 0.1 M NaOH to obtain a NaOH-SDS buffer 
containing 2.0 % (w/v) SDS for dissolving PLGA nanoparticles [184]. 50 µl of OVA-loaded 
PLGA nanoparticles was dried in a 1.5-ml EP tube at 40 °C overnight. 0.2 ml of the NaOH-
SDS buffer was added to dissolve the dry particles. Three repeats for each sample were 
prepared. The EP tubes were shaken at 20 rpm for abut 60 hours at RT (GFL®-3015, 
Burgwedel, Germany). At last, the tubes were centrifuged at 14 000 rpm for 10 min, the OVA 
concentration in the supernatant was determined by a protein micro BCA assay (Thermo 
Scientific, Wilmington, USA) or Nanodrop (Thermo Scientific, Wilmington, USA). The 
encapsulation efficiency (EE) was calculated as follows: 
%100
loadingantigen  lTheoretica
loadingantigen  Measured ×=EE    (1) 
2.2.4 Determination of SIINFEKL loading in PLGA nanoparticles 
50 µl suspension of SIINFEKL-loaded PLGA nanoparticles was dried in an EP tube at 40 °C 
overnight (UL 50, Memmert, Schwabach, Germany). EA and NaOH-SDS extraction methods 
were used to recover the loaded SIINFEKL. 1) NaOH-SDS extraction: 0.2 ml of the same 
NaOH-SDS buffer as described above was added to diss lve the PLGA nanoparticles under 
gentle shaking for 60 hours at dark. Three repeats for each sample were prepared. The FAM-
SIINFEKL concentrations in the supernatants obtained from the tubes after centrifugation 
(Sigma 4K15 centrifuge, SIGMA Laboratory Centrifuges, Shropshire, UK) were measured by 
a microplate reader (Fluostar Omega, BMG LABTECH GmbH, Ortenberg, Germany). 2) EA 
extraction: Another method for extracting the SIINFEKL was carried out by dissolving 
PLGA nanoparticles in EA. PBS buffer was added to the EA solution and were then mixed 
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thoroughly. The mixture was centrifuged to separate the organic phase and aqueous phase. 
The organic phase was removed and the aqueous phasewas then used for concentration 
determination.   
 
In order to determine concentration of fluorescently-labeled SIINFEKL, a standard curve was 
needed. A series of FAM-SIINFEKL standards (1 - 20 µg/ml) were prepared. 150 µl of each 
standard or sample was added into a 96-well plate with flat-bottom wells. The emission at 520 
nm under an excitation of 488 nm was recorded using the microplate reader.  
2.2.5 Characterisation of OVA/SIINFEKL-loaded PLGA nanoparticles and the 
microparticles encapsulating the nanoparticles  
Dynamic light scattering (DLS) 
The hydrodynamic diameter and zeta-potential were dt rmined using a Zetasizer Nano ZS 
(Malvern Intruments, Herrenberg, Germany). The refractive index (RI) of all nanoparticles 
used for the size measurement was 1.59. The dispersant phase is water with RI of 1.330 and 
viscosity of 0.8872 cP. The particle concentration was kept around 0.1-0.2 mg/ml for dynamic 
light scattering (DLS) measurements. 
 
Scanning electron microscopy (SEM) 
Particles were placed on adhesive carbon Leit-Tabs (Plano GmbH, Wetzlar, Germany) and 
then coated with a thin layer of carbon before the samples were observed using a JEOL JSM-
6500F scanning electron microscope (SEM) (Joel Inc., Peabody, USA). Nanoparticles were 
viewed at a magnification of 40 000 and microparticles were viewed at a magnification of 300. 
 
Confocal Laser Scanning Microscopy (CLSM) 
Confocal Laser Scanning Microscope (LSM 510 META, Carl ZEISS, Germany) was used to 
study the microparticles with encapsulated fluorescent nanoparticles. Argon laser (488 nm) 
was used as the excitation, corresponding to the emission of BP 505-530 nm. Objectives with 
magnification of 40, 63 and 100 were used, including Plan-Neofluar 40×/1.3 Oil, Plan-
Apochromal 63×/1.4 Oil DIC and Plan-Neofluar 100×/1.3 Oil Ph3. Z-stacking mode was used 
to observe the distribution of nanoparticles in the microparticles.  
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2.2.6 Release of ovalbumin from PLGA nanoparticles 
The low loading (about 0.18 wt%) of SIINFEKL in PLGA-SIINFEKL nanoparticles can 
result in difficulties measuring the released peptide. Thus the release experiments were only 
carried out for plain and cationic PLGA-OVA nanoparticles. 1 ml of 2.0 mg/ml PLGA-OVA 
nanoparticles in PBS (150 mM, 0.02% NaN3, pH 7.4) was prepared in an EP tube, which was 
incubated at 37 °C under 2 rpm shaking. At predetermined time points, the tubes were 
centrifuged at 14 000 rpm for 10 min (Sigma 4K15 centrifuge, SIGMA Laboratory 
Centrifuges, Shropshire, UK) before sampling. 0.5 ml of the supernatant was replaced with 
0.5 ml of fresh PBS buffer. The particles were re-suspended by a short vortexing or pippetting. 
The 0.5 ml supernatant of each sample was used to determine the OVA concentration by a 
protein micro BCA assay (Thermo Scientific, Wilmington, USA). Three repeats of each 
sample were prepared.     
2.2.7 Encapsulation of OVA/SIINFEKL-loaded PLGA nanoparticles into microparticles 
Trehalose, mannitol, dextran (10 kDa) and dextran (150 kDa) (TMD) were mixed at a mass 
ratio of 3:3:3:1 in an 8-ml tube (SARSTEDT, Nuembrecht, Germany). The resulting 
suspension of the antigen-loaded PLGA nanoparticles from the previous steps was added to 
the TMD mixture. Highly purified water was added to adjust the solid concentration of the 
TMD matrix to 35% (w/w). The mixtures of TMD and PLGA nanoparticles (PLGA-NPs) 
were obtained under stirring at 500 rpm (MR 3001 K, Heidolph, Schwabach, Germany) for 
about one hour. The TMD/PLGA-NPs suspension was spray-freeze-dried (SFD) using the 
same method as described in Chapter III. Briefly, the suspensions were sprayed into a liquid 
nitrogen bath by an ultrasonic atomizing nozzle (120 kHz, Sono-Tek, Milton, USA). The 
power for spraying was set to 4.5 watts and the flow rate of a peristaltic pump (IsmaTec IPC 
78001-20, Wertheim, Germany) to 0.6 ml/min. The sprayed microparticles were collected in 
vials and transferred to a pre-cooled lyophilizer (Martin Christ EPSILON 2-6D, Harz, 
Germany). The freeze-drying sequence was carried out by 24 hours of primary drying at -10 
ºC and 20 hours of secondary drying at 25 ºC. The chamber pressure was kept at 0.12 mbar 
during the whole drying process. 
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3. Results 
3.1 Optimisation of conditions for the preparation of PLGA nanoparticles 
3.1.1 Influence of the polyvinyl alcohol (PVA) concentration on the particle size  
Emulsification is a common method for the preparation of polymer particles. PVA is a widely 
used surfactant for the preparation of stable emulsions. Thus we prepared PLGA 
nanoparticles by an emulsification method using PVA as the stabilizer. The effects of the 
PVA concentration on the particle size were studied. 0.1 ml of 100 mg/ml ovalbumin (OVA) 
in PBS (150 mM, pH 7.4) was emulsified in 1.0 ml of 30 mg/ml PLGA in ethyl acetate (EA). 
The obtained PLGA/OVA emulsion was added to 4 ml of PVA solution for a second 
emulsification. Finally, OVA-loaded PLGA nanoparticles (PLGA-OVA NPs) containing a 
theoretical OVA loading of 25% (w/w) were obtained. PVA concentrations of 0.5%, 1%, 2%, 
3%, 4% and 5.0% (w/v) were used for the preparation. As shown in Table VI-3 , the particle 
size increases from 198 nm to 708 nm when the PVA concentration increases from 1.0% 
(w/v) to 5.0% (w/v). The size becomes large when the PVA concentration decreases from 
1.0% (w/v) to 0.5% (w/v). Therefore, 1.0% (w/w) of PVA was chosen as the condition for 
preparing OVA-loaded PLGA nanoparticles with a size around 200 nm.   
 
Table VI-3 Effect of the PVA concentration on the size and PDI of PLGA-OVA 
nanoparticles  
Sample  Z-Ave (d.nm) PDI Zeta-potential (mv) 
PLGA-OVA-PVA (0.5%) nanoparticles  566±99 0.243±0.025 -(10.6±0.6) 
PLGA-OVA-PVA (1%) nanoparticles 198±3 0.256±0.009 -(32.2±2.9) 
PLGA-OVA-PVA (2%) nanoparticles 202±2 0.171±0.008 -(26.6±0.4) 
PLGA-OVA-PVA (3%) nanoparticles 240±2 0.236±0.012 -(31.3±0.7) 
PLGA-OVA-PVA (4%) nanoparticles 281±5 0.163±0.015 -(23.8±0.3) 
PLGA-OVA-PVA (5%) nanoparticles 708±45 0.685±0.046 -(21.6±0.3) 
 
3.1.2 Cationisation of PLGA-OVA nanoparticles  
Commonly, PEI and chitosan are used to prepare cationic PLGA-OVA nanoparticles [144, 
186, 187]. Water-soluble PEI was added into the PVA aqueous solution directly to obtain a 
solution containing 1.0% (w/w) of PVA and 0.2% (w/w) of PEI. The PEI modified PLGA 
nanoparticles (PLGA-PEI) PEI have a positive zeta-potential (36.2 mv) after sufficient 
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washing with HPW, which is an indication that the coating is successful. However, PEI is 
toxic for humans and this is a major drawback for the use of such systems in drug delivery 
[200]. Chitosan as a positively charged polysaccharide may be a better choice for 
cationisation.  
 
Chitosan with medium and low molecular weights as specified in the section of Materials and 
Methods were chosen to modify PLGA nanoparticles. Chitosan with a medium molecular 
weight was used to modify the surface of PLGA nanoprticles, but it was not successful. The 
obtained nanoparticles have a large hydrodynamic size and a negative zeta-potential (Table 
VI-4 ). The OVA-loaded PLGA nanoparticles were successfully coated by the chitosan with a 
low molecular weight, showing a zeta-potential of about +40 mv. The chitosan-coated PLGA-
OVA nanoparticles containing theoretical OVA loadings of 10 wt% and 20 wt% have a 
similar size around 200 nm and a narrow size distribu ion. Therefore, chitosan with a low 
molecular weight is suitable for cationisation of PLGA nanoparticles.   
 
Table VI-4 Cationic PLGA nanoparticles coated by PEI and chitosan. 
Sample Z-Ave (d.nm) PDI Zeta-potential (mv) 
PLGA-chitosan (medium) 4855±1345 0.819±0.254 -(20.7±1 ) 
PLGA-OVA-chitosan (medium) 2255±111 0.389±0.091 -(31.2±1.1) 
PLGA-PEI 368±4 0.173±0.031 36.2±1.3 
PLGA-OVA(10%)-chitosan 181±3 0.136±0.012 41.0±0.6 
PLGA-OVA(20%)-chitosan 212±3 0.164±0.011 38.7±0.7 
 
3.2 Properties of OVA/SIINFEKL-loaded PLGA nanoparticles 
3.2.1 OVA-loaded PLGA nanoparticles 
The pure PLGA nanoparticles without protein were prpared as a control. These particles 
have a Z-average (Z-Ave) size of 121 nm and a PDI of 0.071 (Table VI-5), indicating a very 
narrow size distribution. OVA was loaded into PLGA nanoparticles at theoretical OVA 
loadings of 10 wt% and 25 wt%. Cationic PLGA-OVA nanoparticles modified by chitosan 
were also prepared, showing positive zeta-potentials. PLGA nanoparticles containing 10 wt% 
OVA (PLGA-OVA(10%)) have a size of 211 nm and PLGA-OVA(25%) nanoparticles have a 
size of 159 nm. The cationic PLGA-OVA(10%) and PLGA-OVA(25%) nanoparticles show a 
size of about 250 nm and a PDI of about 0.18.    
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Table VI-5 Plain and cationic OVA-loaded PLGA nanoparticles 
Sample Z-Ave (d.nm) PDI Zeta-potential (mv) 
PLGA nanoparticles  121±2 0.071±0.034 -(24.8±0.2) 
PLGA-OVA(10%) nanoparticles  211±5 0.172±0.011 -(14.4±0.7) 
PLGA-OVA(25%) nanoparticles 159±3 0.140±0.018 -(13.7±1.0) 
PLGA-OVA(10%)-chitosan nanoparticles  235±6 0.168±0.007 31.5±1.0 
PLGA-OVA(25%)-chitosan nanoparticles 256±5 0.182±0.022 29.1±0.6 
 
In order to observe the ovalbumin loaded in PLGA nanoparticles using CLSM, fluorescently 
labeled ovalbumin (OVA-Alexa488) was used in the formulation. OVA-Alexa488 and OVA 
were mixed at a mass ratio of 1:50 and the OVA/OVA-Alexa488 mixture was encapsulated in 
PLGA nanoparticles at a theoretical loading of 10 wt%. As shown in Figure VI-1, plain and 
cationic OVA-loaded PLGA nanoparticles are spheres with diameters of about 100 nm. Their 
hydrodynamic diameters are 200 - 300 nm, which is larger than the size observed by SEM. A 
small part of large particles or aggregates exists and increases the Z-Ave size. The OVA-
loaded PLGA nanoparticles are dispersed in aqueous s lution without distinct aggregation. 
Only a few big particles were observed in suspension as seen from the CLSM micrographs 
(Figure VI-1). The sizes of big particles or aggregates of small nanoparticles (green spots) 
are smaller than 1 µm.  
  
  
Figure VI-1. Plain and cationic PLGA nanoparticles loaded with OVA/OVA-Alexa. (A) 
SEM micrograph of PLGA-OVA/OVA-Alexa488 nanoparticles; (B) SEM micrograph of 
A 
C 
B 
D 
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cationic PLGA-OVA/OVA-Alexa488 nanoparticles; (C) CLSM micrograph of PLGA-
OVA/OVA-Alexa488 nanoparticles suspended in aqueous solution; (D) CLSM micrograph of 
cationic PLGA-OVA/OVA-Alexa488 nanoparticles suspend d in aqueous solution. The scale 
bar of (A) and (B) is 100 nm, while the scale bar of (C) and (D) is 5 µm.  
3.2.2 SIINFEKL-loaded PLGA nanoparticles  
As SIINFEKL consists of only 8 amino acid units, the SIINFEKL mass is much lower than 
OVA at the same molar amount. Thus only a small amount f SIINFEKL was used for the 
encapsulation into PLGA nanoparticles. Theoretically, 0.1 mg of FAM-SIINFEKL was 
encapsulated in 30 mg of PLGA. The loading amount and efficiency will be described in the 
following section. The SIINFEKL-loaded PLGA nanoparticles (PLGA-SIINFEKL) have a 
hydrodynamic size of 114 nm and a PDI of 0.098 (Table VI-6), while the cationic ones 
(PLGA-SIINFEKL-chitosan) have a size of 261 nm and  PDI of 0.268.  
 
Table VI-6 Plain and cationic SIINFEKL-loaded PLGA nanoparticles  
Sample Name Z-Ave (d.nm) PDI ZP (mV) 
PLGA-SIINFEKL nanoparticles 114±1 0.098±0.028 -(35.0±2.2) 
PLGA-SIINFEKL-chitosan nanoparticles  261±2 0.268±0.047 50.2±1.0 
 
SEM observations of the SIINFEKL-loaded nanoparticles are shown in Figure VI-2. The 
fluorescence of PLGA-SIINFEKL nanoparticles is too weak to be observed, due to the small 
loading (less than 0.33 wt%) of SIINFEKL in the PLGA nanoparticles. The SEM sizes of all 
the PLGA-SIINFEKL nanoparticles are about 100 nm in diameter.  
 
  
Figure VI-2. Plain and cationic SIINFEKL-loaded PLGA nanoparticles. (A) SEM 
micrograph of PLGA-SIINFEKL nanoparticles; (B) SEM micrograph of cationic PLGA-
SIINFEKL nanoparticles. The scale bar is 100 nm.  
A B 
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3.3 Loading and encapsulation efficiency of OVA/SIINFEKL in PLGA nanoparticles  
3.3.1 PLGA nanoparticles encapsulating ovalbumin 
The encapsulation of OVA in PLGA nanoparticles was investigated. OVA-loaded PLGA 
nanoparticles with theoretical OVA loadings of 10 wt% and 25 wt% were prepared. The 
theoretical loadings were calculated from the amounts of OVA and PLGA used for the 
preparation. The OVA concentration (lower than 1 mg/ l) recovered from PLGA 
nanoparticles is in the low range for measurements using Nanodrop photometry. The BCA 
assay is a more precise method to detect proteins at low concentrations. As shown in Table 
VI-7 , the OVA loadings of PLGA-OVA(10%) and PLGA-OVA(25%) obtained by the BCA 
assay are 14.5 wt% and 40.1 wt%, respectively, which are very close to the results of 
Nanodrop determination. The cationic PLGA-OVA(10%)-chitosan and PLGA-OVA(25%)-
chitosan nanoparticles show OVA loadings of 9.8 wt% and 23.6 wt% from BCA results, 
while the ND results show higher OVA loadings and larger variations. The OVA loadings 
from BCA results were then used to calculate the encapsulation efficiency (EE) of OVA in 
the PLGA nanoparticles. The EE for plain PLGA-OVA nanoparticles is higher than 100%, 
which is implausible. The experiments were carefully checked and repeated to make sure that 
the right EE was obtained. In fact, the EE could be theoretically higher than 100% if the loss 
of PLGA during the preparation is higher than the loss of OVA. The EE of PLGA-
OVA(10%)-chitosan is 98% and the EE of PLGA-OVA(25%)-chitosan is 95%.  
 
Table VI-7 Encapsulation of ovalbumin in PLGA-based nanoparticles 
Sample  
Theoretical 
loading (w/w%) 
OVA loading 
(ND) (w/w%) 
OVA loading 
(BCA) (w/w%) 
Encapsulation 
efficiency (%) 
PLGA-OVA(10%) NPs 10 13.9±1.0 14.5±2.2 145±22 
PLGA-OVA(25%) NPs 25 40.6±5.2 40.1±6.0 160±24 
PLGA-OVA(10%)-chitosan NPs 10 12.3±5.2 9.8±3.5 98±35 
PLGA-OVA(25%)-chitosan NPs 25 31.7±15.0 23.6±6.4 95±26 
The data were obtained by averaging 3 repeats. All the data are shown as the mean and 
standard deviation (SD), i.e. mean±SD.  
3.3.2 PLGA nanoparticles encapsulating SIINFEKL 
Now that OVA protein has been shown to be encapsulated in PLGA nanoparticles efficiently,  
the encapsulation of SIINFEKL needs to be investigated. The concentration of SIINFEKL 
extracted from the nanoparticles was determined by fluorescence spectroscopy using a 
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microplate reader. For plain PLGA-SIINFEKL nanoparticles, the SIINFEKL loading 
extracted by the EA or NaOH-SDS method is about 0.0018 mg per l mg of PLGA-SIINFEKL 
nanoparticles. Their encapsulation efficiency (EE) is about 53.1% (Table VI-8 ). For the 
chitosan-coated PLGA-SIINFEKL nanoparticles, the SIINFEKL loading is about 1.0 µg/mg 
and the EE is 28.5%, which is distinctly lower than that of PLGA-SIINFEKL nanoparticles. 
Three independent experiments were carried out.   
 
Table VI-8 Determination of SIINFEKL loaded in PLGA-based nanoparticles 
Sample 
SIINFEKL loading 
(EA) (µg/mg) 
SIINFEKL loading 
(NaOH-SDS) 
(µg/mg) 
Theoretical 
SIINFEKL 
loading (µg/mg) 
EE (%) 
PLGA-SIINFEKL  1.79±0.09 1.77±0.31 3.33 53.1±9.2 
PLGA-SIINFEKL-chitosan  1.26±0.47 0.95±0.13 3.33 28.5±4.0 
The data were obtained by averaging 3 repeats. All the data are shown as the mean and 
standard deviation (SD), i.e. mean±SD.  
 
The true loading EEs for PLGA-SIINFEKL and PLGA-SIINFEKL-chitosan particles are 
distinctly lower than 100%. Practically, SIINFEKL (Mw, 1320 Da) may diffuse quickly from 
the organic phase to the aqueous phase during the emulsification step, causing the loss of 
SIINFEKL. PLGA-SIINFEKL-chitosan particles have a smaller EE than PLGA-SIINFEKL 
due to the effect of chitosan used during the emulsification step.    
3.4 Stability of PLGA nanoparticles during freeze-drying 
Nanoparticles in suspension are not suitable for a l ng-term storage. It is necessary to prepare 
dry particles using freeze-drying (FD), vacuum-drying, etc. FD as a promising method has 
been widely used for the preparation of dry protein formulations [201]. FD is also suitable for 
drying nanoparticles. The freezing step during FD is a process that may compromise the 
stability of PLGA nanoparticles. The suspensions of PLGA-based nanoparticles in water were 
frozen and thawed and then the sizes were measured by dynamic light scattering. It is obvious 
that one freeze-thaw circle induced PLGA nanoparticles to aggregate (Figure VI-3), 
increasing the hydrodynamic size from 120 nm to 408 nm. For cationic PLGA-chitosan 
nanoparticles, the size changed from 291 nm to 301 nm after one freeze-thaw circle and 
increased to 319 nm after the second freeze-thaw circle. The cationic PLGA-PEI 
nanoparticles are very stable during two freeze-thaw circles. Chitosan was the material chosen 
to cationise OVA-loaded PLGA nanoparticles. Chitosan-coated PLGA nanoparticles increase 
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their sizes slightly during one freeze-thaw circle. Therefore, it indicates that chitosan or PEI 
coating can improve the stability of PLGA nanoparticles.  
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Figure VI-3. Effect of freeze-thaw cycles on the stability of PLGA-based nanoparticles. (A) 
Z-Ave sizes in diameter; (B) Size distribution (PDI). 
 
In order to improve the stability of nanoparticles during freeze-drying, the addition of 
lyoprotectants such as trehalose and mannitol is necessary. Trehalose has already been used as 
a stabiliser of nanoparticles [147]. PLGA-OVA nanoparticles as shown in Table VI-5 can be 
refined to obtain a smaller size and better size distribution of particles. The suspension of 
PLGA-OVA nanoparticles was firstly centrifuged at 5000 ×g for 5 min to remove some large 
particles, the supernatant suspension was then centrifuged at 15000 ×g to collect fine PLGA-
OVA nanoparticles. Fine PLGA-OVA(10%) and cationic PLGA-OVA(10%)-chitosan 
nanparticles were used for the formulation in trehalose. The suspension of OVA-loaded 
PLGA nanoparticles and 10% (w/v) trehalose aqueous solution were mixed at a dry mass 
ration of 1/4. There is no change of sizes and zeta-po entials for the PLGA nanoparticles in 
HPW and those in trehalose solution. The freeze-drid nanoparticles were re-suspended in 
HPW for DLS measurements. The sizes, PDIs and zeta-potentials of the OVA-loaded PLGA 
nanoparticles did not change during freeze-drying when 10% (w/v) trehalose was used as the 
lyoprotectant (Table VI-9).  
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Table VI-9 Stability of OVA-loaded PLGA nanoparticles in aqueo s trehalose solution after 
freeze-drying 
Before freeze-drying After freeze-drying 
Sample Z-Ave 
(d.nm) 
PDI ZP (mv) 
Z-Ave 
(d.nm) 
PDI ZP (mv) 
PLGA-OVA(10%) NPs 126±2 0.060±0.016 -(22.9±0.5) 126±1 0.075±0.008 -25.1±0.9 
PLGA-OVA(10%)-chitosan NPs  268±1 0.194±0.004 38.1±0.8 283±3 0.167±0.008 38.6±0.5 
Trehalose/nanoparticles (NPs) = 4/1 (w/w) 
 
3.5 Sugar-based microparticles encapsulating OVA/SIINFEKL-loaded PLGA 
nanoparticles  
3.5.1 Micropartices encapsulating PLGA-OVA nanoparticles  
Plain and cationic PLGA-OVA/OVA-Alexa488 nanoparticles were added to a TMD matrix to 
obtain a loading of 25 µg/mg. As shown in Figure VI-4, most of the microparticles show a 
size range of 20-30 µm and display shrunken surfaces. There is no distinct difference between 
the microparticles encapsulating PLGA-OVA/OVA-Alexa488 and PLGA-OVA/OVA-
Alexa488-chitosan nanoparticles. The green fluorescence of OVA-Alexa488 is distributed 
over all microparticles, indicating that encapsulation has been achieved effectively. Both plain 
and cationic PLGA-OVA nanoparticles are dispersed in the microparticles as observed by 
CLSM. It is concluded that the surface properties of nanoparticles have no effect on the 
encapsulation of nanoparticles in TMD microparticles by spray-freeze-drying.  
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Figure VI-4. TMD microparticles encapsulating OVA-loaded PLGA nanoparticles. SEM 
micrograph (A), CLSM micrograph (B) and 3D view (C) of TMD/PLGA-OVA/OVA-
Alexa488 microparticles; SEM micrograph (D), CLSM micrograph (E) and 3D view (F) of 
TMD/PLGA-OVA/OVA-Alexa488-chitosan microparticles. 
3.5.2 Micropartices encapsulating PLGA-SIINFEKL nanoparticles  
In the case of peptide-loaded PLGA nanoparticles, nanoparticles were formulated in TMD 
microparticles at a concentration of 10 µg/mg. The SEM micrographs (Figure VI-5) show 
similar particles as the microparticles containing 25 µg/mg of OVA-loaded PLGA 
nanoparticles. Weak fluorescence of the microparticles encapsulating PLGA-SIINFEKL 
nanoparticles was observed. The loading of FAM-SIINFEKL in PLGA nanoparticles is very 
small (lower than 0.18 wt%), thus the fluorescence int nsity of SIINFEKL-loaded PLGA 
nanoparticles is low, which has also been demonstrated for the PLGA-SIINFEKL 
nanoparticles in suspension (Figure VI-2). However, the results obtained from CLSM 
micrographs (Figure VI-5) show that the plain and cationic PLGA-SIINFEKL nanoparticles 
have been respectively formulated into microparticles.  
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Figure VI-5. TMD microparticles encapsulating SIINFEKL-loaded PLGA nanoparticles. 
SEM micrograph (A), CLSM micrograph (B) and 3D view (C) of TMD/PLGA-SIINFEKL 
microparticles; SEM micrograph (D), CLSM micrograph (E) and 3D view (F) of 
TMD/PLGA-SIINFEKL-chitosan microparticles. 
 
As shown by CLSM observation, OVA-loaded PLGA-based nanoparticles can be 
encapsulated in the sugar-based microparticles. The stability of PLGA nanoparticles in the 
formulation is critical for the subsequent application. The sizes of the antigen-loaded PLGA 
nanoparticles before and after being formulated in TMD microparticles are shown in Table 
VI-10. The dry TMD microparticles containing PLGA-OVA nanoparticles were stored at 4 ºC 
for two months and were then dissolved in HPW for DLS measurements. The size and PDI of 
the PLGA-antigen nanoparticles in TMD microparticles do not increase after re-suspension in 
HPW compared to the formulations before spray-freeze-drying. The sizes of PLGA-OVA, 
PLGA-OVA-chitosan, PLGA-SIINFEKL and PLGA-SIINFEKL-chitosan nanoparticles 
resuspended from the microparticles are 134 nm, 303 nm, 128 nm and 213 nm, respectively, 
corresponding zeta-potentials of -19.3 mv, 34.4 mv,-23.6 mv and 19.7 mv. The PLGA-based 
nanoparticles in the microparticles after storage of tw  months at 4 ºC have almost the same 
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size and PDI of freshly prepared nanoparticles. Therefore, the formulation of the TMD matrix 
can stabilise PLGA-based nanoparticles.         
 
Table VI-10 Stability of antigen-loaded PLGA nanoparticles  
Before SFD Re-suspended 
Sample Z-Ave 
(d.nm) 
PDI ZP (mv) 
Z-Ave 
(d.nm) 
PDI ZP (mv) 
TMDD/PLGA-OVA 158±2 0.146±0.028 -(15.2±0.4) 134±1 0.135±0.026 -(19.3±1.1) 
TMDD/PLGA-OVA-
chitosan 
349±2 0.249±0.006 38.8±0.3 303±3 0.240±0.011 34.4±1.2 
TMDD/PLGA-SIINFEKL 117±2 0.154±0.009 -(25.2±1.6) 128±2 0.191±0.009 -(23.6±2.3) 
TMDD/PLGA-SIINFEKL-
chitosan 
257±2 0.318±0.028 24.9±0.6 213±7 0.280±0.020 19.7±1.3 
 
4. Discussion 
4.1 Particle size control and cationisation of PLGA-based nanoparticles 
The fabrication methods of PLGA-based nano- and microparticles include emulsification-
evaporation [185, 188], emulsification-solvent diffusion [182, 202] and nanoprecipitation 
[203, 204]. The emulsification-evaporation method was used herein because it has already 
been proved feasible for loading protein into PLGA particles [185]. The water-in-oil-in-water 
(W/O/W) double emulsion technique was used to prepare antigen-loaded PLGA nanoparticles 
[205, 206]. OVA or SIINFEKLin aqueous (water) phase was first emulsified in PLGA in 
organic phase to obtain the first (1st) emulsion (W/O). The 1st emulsion was then added to a 
surfactant aqueous (water) solution for the second (2 ) emulsification. The W/O/W double 
emulsion was finally obtained and particles were formed when the organic solvent evaporated. 
Dichloride methane is normally used as the organic solvent for dissolving PLGA, but a less 
toxic solvent, ethyl acetate, was used in this study [206].  
 
Polyvinyl alcohol (PVA) is the surfactant for stabilising the emulsion of PLGA nanoparticles. 
The particle size of PLGA-OVA(25%) nanoparticles depends on the concentration of PVA. 
The size increases when the PVA concentration increases at the range of 1% (w/w) and 5% 
(w/w). The size also increases when the PVA concentration decreases from 1% to 0.5%. Thus, 
1% of PVA is the concentration for the smallest PLGA-OVA(25%) nanoparticles. In a study 
of the preparation of pure PLGA nanoparticles by the emulsification-solvent diffusion method, 
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authors found that the use of higher PVA concentration (1% - 10%) leads to larger mean 
particles size (175 nm - 260 nm) [182]. They found that the increase of viscosity of PVA 
solution when the concentration increases is responsible for the particle size increasing [182]. 
Even though the method for the preparation of PLGA nanoparticles is different, the tendency 
of the effect of PVA concentration (no less than 1.0 %) on the particles size is similar. 
Dynamic viscosity of PVA aqueous solution increases ignificantly with increasing PVA 
concentration (0 - 10% (w/v) [207]. During the emulsification process, an emulsion with 
larger droplets may be formed for higher viscosity olution if the energy for emulsification 
stays the same. However, the emulsion will not be stable if the PVA concentration is too low, 
resulting the increasing of the particle size. This explains that the size in the case of 0.5% 
PVA is distinctly larger than that in the case of 1.0% PVA.      
 
PEI can cationise PLGA nanoparticles as proved in our experiments, but the biocompatibility 
of PEI is a big issue [200]. Chitosan is the choice for the cationisation of PLGA-based 
particles [186]. Chitosan with a low molecular weight and a medium molecular weight were 
used to coat PLGA nanoparticles. It results that the c itosan with a medium molecular weight 
did not work successfully and the chitosan with a low molecular weight has effectively 
achieved cationic PLGA nanoparticles. The reason may be explained as follows. Both 
chitosan can be dissolved in the acetate buffer (50 mM, pH 4.5). The interaction of the 
chitosan in the aqueous phase and the PLGA in the organic phase may play an important role. 
For the chitosan with a low molecular weight, the citosan dissolved in the PVA solution may 
have strong interaction with the PLGA-ethyl acetate droplets, resulting efficient coatings after 
the organic solvent is evaporated. The chitosan with a higher molecular weight may reduce 
the interaction between the chitosan and the PLGA-ethyl acetate droplets, resulting in 
insufficient coatings.     
4.2 OVA/SIINFEKL-loaded PLGA-based nanoparticles in the nano-in-micro particle 
systems 
TMD microparticles containing silica nanoparticles and ovalbumin were studied in Chapter 
IV. Compared to silica nanoparticles for loading antigens, the antigen loading amount in 
PLGA nanoparticles is significantly higher. Antigens are mainly encapsulated inside of PLGA 
nanoparticles. The OVA-loaded or SIINFEKL-loaded plain and cationic PLGA nanoparticles 
are dispersed in TMD microparticles homogeneously. This indicates that the encapsulation of 
nanoparticles in microparticles by SFD is suitable for preparing the nano-in-micro particles 
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containing PLGA-based nanoparticles. Transcutaneous delivery of antigen-loaded PLGA 
nanoparticles has also been applied on the shaved skin of mice, inducing effective immune 
responses [199]. The penetration of PLGA nanoparticles on skin is limited due to the 
biological barrier of skin. Powder injection can accelerate particles into the epidermal or even 
dermal layer of skin, but there are requirements for the particle size and density [10, 12]. It is 
very difficult to deliver PLGA nanoparticles (100-100 nm) into skin by powder injection due 
to the limitation of the device. A better solution to this problem is to formulate PLGA 
nanoparticles into microparticles as what was done in this study. Therefore, the TMD 
microparticles containing antigen-loaded PLGA nanoparticles seem to be a good candidate 
for the epidermal powder immunisation.   
 
The stability of PLGA nanoparticles is crucial for their application. Freshly prepared antigen-
loaded PLGA nanoparticles can be freeze-dried together with trehalose (disaccharide) as the 
lyoprotectant. In this study it was shown that the properties of PLGA nanoparticles can be 
preserved when the mass ratio of particles and trehalose in the formulation for freeze-drying 
is 1/4. It confirms that trehalose can stabilise PLGA nanoparticles after drying [147]. TMD 
matrix plays a similar role as trehalose for the stabilisation of PLGA nanoparticles. The sizes 
and zeta-potentials of the antigen-loaded PLGA nanop rticles in TMD microparticles are 
almost the same as those before spray-freeze-drying.  
5. Conclusion 
Ovalbumin and SIINFEKL have both been encapsulated in plain and cationic PLGA-based 
nanoparticles (150 - 300 nm in diameter) by a W/O/W double emulsion technique. Chitosan 
with a low molecular weight is suitable for cationisi g PLGA nanoparticles. Plain PLGA-
OVA nanoparticles with high OVA loadings and cationic PLGA-OVA-chitosan nanoparticles 
with OVA loadings of 10 wt% and 24 wt% were obtained. The high loading of OVA enables 
a sufficient amount of antigens for immunisation. About 0.18 wt% of SIINFEKL was loaded 
in plain PLGA nanoparticles at an encapsulation effici ncy of about 50%, while about 0.10 
wt% of SIINFEKL was loaded in cationic PLGA nanoparticles at an encapsulation efficiency 
of about 30%.     
 
OVA- and SIINFEKL-loaded PLGA nanoparticles have ben ncapsulated in the sugar-based 
TMD microparticles, respectively. Each kind of PLGA-antigen nanoparticles can be 
distributed in TMD microparticles homogeneously. Most of the TMD microparticles 
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containing PLGA-antigen nanoparticles have a size range of 20 - 30 µm, which meets the size 
requirement for epidermal powder immunisation. The stability of the antigen-loaded PLGA 
nanoparticles in TMD microparticles is sufficiently preserved. Furthermore, TMD 
microparticles containing PLGA nanoparticles enable th  delivery of PLGA nanoparticles 
into skin by ballistic powder injection. From these preliminary studies, the nano-in-micro 
systems of PLGA nanoparticles in TMD microparticles have the potential to be used for 
epidermal immunisation via ballistic delivery.  
 
 
Chapter VII. Final Summary  
 
The work of this thesis is focused on the investigation of skin models mimicking the 
mechanical properties of human skin and vaccine-loaded microparticles for the development 
and applications of epidermal powder immunisation (EPI) using a novel device. This project 
was proposed at the background that a novel, economic and effective device for EPI is being 
developed by our collaborator. There are two crucial problems that need to be addressed for 
the design and development of a novel EPI device. On  is to deliver vaccine particles into the 
viable epidermis or upper dermis of skin exactly. The vaccine cannot be efficiently presented 
to immune cells if its penetration is too small. Pain nd bleeding are expected when the 
vaccine particles penetrate deeply into lower dermis or even hypodermis. For a new 
established device for EPI, the injection on skin models or in vitro skin is a prerequisite 
before it is applied on animals or later for clinical studies. The other is to prepare appropriate 
vaccine particles for EPI. Almost all present vaccines on market are supplied in liquid 
formulations. Dry formulations of vaccines in the form of powder or particles are required for 
EPI. Appropriate size and density of vaccine particles are very important for their use in EPI. 
 
The studies in this thesis include mainly two parts. The first part is the development of a 
model skin for the evaluation and optimisation of the novel device for powder injection. This 
part is described in Chapter II . The second part is the fabrication of vaccine-loaded 
microparticles for EPI. A nanoparticles-in-microparticles (nano-in-micro) system was 
proposed to prepare vaccine microparticles for EPI.The nano-in-micro concept is described in 
Chapter III . Three embodiments of the nano-in-micro systems for EPI were further 
investigated using different nanoparticles and vaccines in the formulations. As described in 
Chapter IV , cationic mesoporous silica nanoparticles (MSNP-NH2) and ovalbumin (OVA) 
were incorporated into sugar-based microparticles that are aimed for EPI. Influenza H1N1 
hemagglutinin (HA) vaccine instead of ovalbumin and MSNP-NH2 nanoparticles formulated 
in the microparticles were described in Chapter V. Preliminary studies of OVA/SIINFEKL-
loaded PLGA nanoparticles for the formulation of TMD microparticles were described in 
Chapter VI . The detailed work of each main chapter is to be summarized further.  
 
In Chapter II , the objective was to produce a skin model simulating the mechanical 
properties of human skin for the evaluation of intradermal powder injection devices. Pig skin 
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and different films made from gelatin, silicone and agar were prepared and investigated as 
skin model candidates. The mechanical properties of the skin model candidates were 
measured with an indentation method using a texture analyser. The indentation results of the 
films and the biological skin samples suggest that gelatin films plasticised with glycerol are 
very well suitable for a skin model. The mechanical properties of gelatin-based films can be 
tailored by changing the glycerol content in the film making it even possible to simulate 
human skin with different mechanical properties. The reproducibility of the gelatin films can 
be controlled and the stability during storage is very good. In addition, fluorescently labeled 
particles in the layered structural model of gelatin at a depth of 400 µm were successfully 
visualized by CLSM. This is a major advantage for observing the penetration and distribution 
of fluorescent particles after powder injection, further supporting the feasible applications of 
the gelatin films for the evaluation of powder injection devices. 
 
Gelatin films were shown as a very good skin model simulating the mechanical properties of 
human skin, indicating them as a suitable base for powder injection.  
 
In Chapter III , the concept of nanoparticles-in-microparticles (nano-in-micro) systems for 
EPI was proposed and some examples were studied. Sugar-based microparticles (20 - 30 µm 
in diameter) consisting of trehalose, mannitol, dextran (TMD) were fabricated by spray-
freeze-drying. Nanoparticles were incorporated intothe matrix by spray-freeze-drying of the 
mixture of nanoparticles and matrix solution. Nanoparticles including PS, PLGA, gelatin, 
silica and silk were encapsulated into TMD microparticles, respectively. The sizes of PS and 
PLGA nanoparticles can be best preserved in the resusp nsion of TMD microparticles 
carrying nanoparticles. The size, tap density and velocity of microparticles determine the 
penetration into skin when the microparticles are us d for powder injection. High tap density 
is vital for the penetration of injected microparticles. The tap density of TMD microparticles 
can be enhanced by addition of CaCO3 in the formulation.  
 
In Chapter IV , MSNP-NH2 nanoparticles and ovalbumin were formulated into sugar-based 
microparticles. Loading of OVA on MSNP-NH2 was driven by electrostatic interactions. 
OVA-loaded silica nanoparticles were formulated into TMD microparticles by spray-freeze-
drying. The obtained microparticles meet the size requirement for EPI. OVA-loaded MSNP-
NH2 can be homogeneously distributed in the microparticles as demonstrated by confocal 
microscopy. Furthermore, the silica nanoparticles in the dry microparticles can be re-
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dispersed in aqueous solution without obvious aggregation. The recovered ovalbumin shows 
integrity compared to fresh ovalbumin solution. 
 
In Chapter V, concentrated H1N1 HA (1 - 2 mg/ml) and MSNP-NH2 were formulated into 
TMD microparticles using SFD. The HA content in theTMD microparticles is about 4 µg/mg. 
H1N1 HA can be adsorbed on MSNP-NH2 nanoparticles mainly by electrostatic interactions. 
The H1N1 HA reconstituted from the TMD microparticles maintains the integrity as studied 
by SDS-PAGE and shows a good binding affinity as proven by western blot. The HA 
biological activity, studied by the hemagglutinin ih bition (HAI) assay, was not affected 
during the encapsulation process of HA and MSNP-NH2 nanoparticles into TMD 
microparticles.  
 
Some preliminary results about PLGA nanoparticles for antigen loadings were described in 
Chapter VI . OVA or SIINFEKL (OVA peptide) was loaded into PLGA nanoparticles by a 
W/O/W double emulsion technique and the antigen-loaded PLGA nanoparticles were 
encapsulated into TMD microparticles. Plain PLGA-OVA nanoparticles with OVA loadings 
of 15 wt% and 40 wt% were obtained and cationic PLGA-OVA-chitosan nanoparticles with 
OVA loadings of 10 wt% and 24 wt% were obtained. For PLGA-SIINFEKL nanoparticles, 
about 0.18 wt% of SIINFEKL was loaded in plain PLGA nanoparticles and about 0.10 wt% 
of SIINFEKL was loaded in cationic PLGA nanoparticles. OVA- and SIINFEKL-loaded 
PLGA nanoparticles encapsulated in the TMD microparticles have homogeneous distributions 
and good stability for resuspension in water.    
 
In summary, the studies toward epi- and intra-dermal vaccinations by powder injection were 
carried out in the thesis. Some positive results in relation to the original objectives have been 
achieved. Major achievements include two parts: 1) gelatin-based films were found to be an 
appropriate skin model for the evaluation of epi- and intra-dermal powder injection devices; 
2) Nano-in-micro particle systems as particulate vaccines have been demonstrated feasible for 
epi- and intra-dermal powder immunisation from the formulation point of view. The skin 
models will facilitate the optimisation of a novel EPI device that is being developed by our 
collaborator. Furthermore, the applications of the nano-in-micro vaccine particles in animals 
for epidermal powder immunisation will be interesting for future studies. 
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